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Abstract
Cancer is a group of diseases that arises from irreversible genomic and epigenomic
alterations that result in unrestrained proliferation of abnormal cells. Detailed un-
derstanding of the molecular mechanisms underlying a cancer would aid the identi-
fication of most, if not all, genes responsible for its progression and the development
of molecularly targeted chemotherapy. The challenge of recurrence after treatment
shows that our understanding of cancer mechanisms is still poor. As a contribution to
overcoming this challenge, we provide an integrative multi-omic analysis on glioblas-
toma multiforme (GBM) for which large data sets on different classes of genomic and
epigenomic alterations have been made available in the Cancer Genome Atlas data
portal.
The first part of this study involves protein network analysis for the elucidation of
GBM tumourigenic molecular mechanisms, identification of driver genes, prioritisa-
tion of genes in chromosomal regions with copy number alteration, and co-expression
and transcriptional analysis. Functional modules were obtained by edge-betweenness
clustering of a protein network constructed from genes with predicted functional
impact mutations and differentially expressed genes. Pathway enrichment analysis
was performed on each module to identify statistical overrepresentation of signaling
pathways. Known and novel candidate cancer driver genes were identified in the
modules, and functionally relevant genes in chromosomal regions altered by homol-
ogous deletion or high-level amplification were prioritized with the protein network.
Co-expressed modules enriched in cancer biological processes and transcription factor
targets were identified using network genes that demonstrated high expression vari-
ance. Our findings show that GBM’s molecular mechanisms are much more complex
than those reported in previous studies.
We next identified differentially expressed miRNAs for which target genes associ-
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ated with the protein network were also differentially expressed. miRNAs and target
genes were prioritised based on the number of targeted genes and targeting miR-
NAs, respectively. miRNAs that correlated with time to progression were selected
by an elastic net-penalized Cox regression model for survival analysis. These miRNA
were combined into a signature that independently predicted adjuvant therapy-linked
progression-free survival in GBM and its subtypes and overall survival in GBM. The
results show that miRNAs play significant roles in GBM progression and patients’
survival
Finally, a prognostic mRNA signature that independently predicted progression-free
and overall survival was identified. Pathway enrichment analysis was carried on genes
with high expression variance across a cohort to identify those in chemoradioresis-
tance associated pathways. A support vector machine-based method was then used
to identify a set of genes that discriminated between rapidly- and slowly-progressing
GBM patients, with minimal 5 % cross-validation error rate. The prognostic value
of the gene set was demonstrated by its ability to predict adjuvant therapy-linked
progression-free and overall survival in GBM and its subtypes and was validated in
an independent data set.
We have identified a set of genes involved in tumourigenic mechanisms that could po-
tentially be exploited as targets in drug development for the treatment of primary and
recurrent GBM. Furthermore, given their demonstrated accuracy in this study, the
identified miRNA and mRNA signatures have strong potential to be combined and
developed into a robust clinical test for predicting prognosis and treatment response.
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Chapter 1
Introduction
Cancer is a group of multigenic diseases that arise from genomic and epigenomic
alterations, resulting in growth and proliferation of abnormal cells and is one of the
leading causes of morbidity and mortality worldwide (Bray et al., 2012). According
to the International Agency for Research on Cancer report for 2012, there were
14.1 million new cases, 8.2 million cancer deaths and 32.6 million people living with
cancer (within 5 years of diagnosis) in 2012 worldwide. 57 % (8 million) of new
cases, 65 % (5.3 million) of deaths and 48 % (15.6 million) of the 5-year prevalent
cases occured in the less developed regions (IARC, 2012; Ferlay et al., 2015). The
most commonly diagnosed cancers were lung (1.82 million), breast (1.67 million),
and colorectal (1.36 million); and the most common causes of cancer death were
lung (1.6 million deaths), liver (745, 000 deaths), and stomach (723,000 deaths)
cancers (Ferlay et al., 2015).
Cancer genes are genes, which if altered in sequence, copy number or expres-
sion level, can initiate and/or contribute to tumorigenesis, and can be categorized
into two classes: oncogenes and tumour suppressor genes (TSG). Activating alter-
ation in or over-expression of oncogenes results in the activation of cellular events
1
 
 
 
 
CHAPTER 1 Cancer gene identification in the pre-genomic era 2
that promote cell growth and proliferation and cell survival. Overexpression can
result from gene amplification and epigenetic changes. The tumour-preventive role
of TSGs is lost when they are affected by inactivating alterations, deleted, or silenced
by epigenetic changes. The search for cancer genes started long before (pre-genomics
era) and continued after (post-genomics era) the completion of the Human Genome
project in 2003 (IHGSC, 2004). This Chapter focuses on the methods and challenges
of cancer gene discovery in the two eras and the opportunities, challenges and
resources available for cancer research in the post-genomics era.
1.1 Cancer gene identification in the pre-genomic era
Slow, laborious and expensive research efforts in the pre-genomics era led the identi-
fication of cellular homologs (proto-ocogenes) of retroviral oncogenes, genes altered
by insertional mutagenesis, susceptibility genes in families with hereditary cancers,
and genes altered by promoter methylation.
1.1.1 Transforming genes of retroviruses are homologs of cellular
genes
Evidence that viruses could cause cancer came form studies conducted by Peyton
Rous in 1910, who discovered that cell-free filtrates from a spindle-cell sarcoma
arising from an infected chicken could sufficiently induce tumour in healthy chickens
(Rous, 1911). The causative agent in the filtrate was eventually identified as a
virus which was later called Rous sarcoma virus (RSV). This discovery was not
appreciated until an in vitro bioassay for RSV was developed by Temin and Rubin
(1958). Rous was awarded the Nobel prize for his discovery in 1966. Studies from
late 1950’s led to the identification of the first viral oncogene called src in RSV and
also oncogenes in other retroviruses.
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Huebner and Todaro (1969) proposed the ”Oncogene Hypothesis” which states
that the cells of most or all vertebrates have Type-C retrovirus genomes that are
transmitted vertically from parent to offspring. These viral genomes were proposed
to serve as an indigenous source of oncogenic information (oncogenes) which
transform normal cells into tumour cells. The induction of the retroviral genes by
host genetic factors or environmental factors results in production of viruses and/or
oncogene expression and tumours at some time during the lifetime of these animals
or in their cells when grown in culture. Although this hypothesis was faulted by
evidence that emerged thereafter, it however prompted investigation into whether
normal cellular DNA might contain retroviral oncogenes.
The observation that the genome of transforming RSV had a dispensable gene
not present in that of non-transforming counterpart led to the isolation of the
src (Toyoshima et al., 1970). Stehelin et al. (1976a) prepared a cDNA probe
specific for src by reverse transcription of transforming viral RNA, followed by
hybridization to the RNA of a non-transforming mutant. The cDNA was shown
by melting experiments to have sequence homology with the DNAs from several
avian species and mammals (Stehelin et al., 1976b; Spector et al., 1978). The fact
that retroviruses are species-specific and the findings that the src sequences are
conserved in evolution provided evidence that viral src is of cellular origin, which
was confirmed when it was found out to have the typical exon/intron structure of a
normal cellular gene (Takeya and Hanafusa, 1983; Shalloway et al., 1981). In 1978,
src was found to express a protein with protein kinase activity (Levinson et al, 1978;
Collett and Erikson, 1978). Similar approaches were used to identify other retroviral
oncogenes (Table 1.1). By 1983, at least 15 retroviral oncogenes had been identified
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(Bishop, 1983). They are known as v-onc (for viral oncogene), and their cellular
homologs as c-onc
Retroviral oncogenes are altered versions of cellular genes that were trans-
duced into retroviral genomes. The cellular homologs of these oncogenes are normal
genes called proto-oncogenes, which have crucial roles in the cell, and their activity is
tightly regulated. Activation of proto-oncogenes by mutation or their overexpression
can result in the transformation of a normal cell into a tumour cell.
1.1.2 Slow-transforming retroviruses causes cellular transformation
by insertional mutagenesis
Slow-transforming retroviruses are different from acute-transforming ones in that
they do not have oncogenes in their genomes. They transform a normal cell by in-
serting their genomes proximal to a cancer gene in the host genome, resulting in
altered expression of the gene. For example, c-Myc mutation by proviral insertions
leads to fusion transcripts in 80 % of avian leucosis virus-induced tumours (Rosen-
berg and Jolicoeur, 1997). Erythroleukemic virus genome integrations result in the
overexpression of mutant and inactive p53 or in a complete absence of the p53 mRNA
(Mowat et al., 1985; Ben-David et al., 1988). Genes altered by insertional mutage-
nesis were identified by cloning proviral insertion sites, followed by the screening of
these sites with probes prepared from the transforming virus under investigation.
Insertional mutagenesis has been used to identify novel oncogenes, including int-1,
int-2, pim-1, and lck (Pierotti et al., 2003).
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1.1.3 Functional assay in NIH 3T3 mouse cells
The discovery that cellular DNA carried genes are capable of causing transformation
came from three observations. (i) DNAs of chemically-transformed mouse cell lines
caused transformation of NIH 3T3 cells (Shih et al., 1979). (ii) DNA fragments of
normal cells induced transformation of NIH 3T3 cells with low efficiency (Cooper
et al., 1980). (iii) The normal DNA however induced transformation with high
efficiency in secondary transfection assays (Cooper et al., 1980). It was suggested
that dominant mutation or gene rearrangement can result in the activation of
cellular transforming genes in some cancers. The first oncogene identified by this
method was cloned from T24 human bladder carcinoma cells (Pulciani et al., 1982)
Many of the oncogenes identified by transfection of NIH 3T3 are identical or
closely related to the oncogenes transduced by the acute-transforming retroviruses.
For example, members of the ras family (HRAS, KRAS, NRAS ) were isolated
from various human tumours by this method (Der et al., 1982; Parada et al., 1982;
Hall et al., 1983), and NEU, MET, and TRK were first identified by gene transfer
(Takahashi et al., 1985; Indo , 2001; Hung et al., 1989).
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1.1.4 Pedigree analysis of familial cancers, linkage analysis and po-
sitional analysis for inherited cancer susceptibility genes
Cancers can be classified into sporadic and familial cancers based on mode of
acquisition. Sporadic cancers develop from alteration in transforming genes in
somatic cells. Familial cancers are inherited and result from germline mutations in
cancer susceptibility genes, many of which are also mutated in sporadic cancers. A
familial cancer is discerned by observing families with a high proportion of members
who have the cancer. Epidemiological studies of cancer heredity have consistently
shown that a family history of cancer is a risk factor for virtually all forms of
neoplasia in humans (Knudson, 1983).
The first inherited cancer susceptibility cancer cloned was RB1 (Friend et al.,
1986). The loss of function of both copies of this gene result in Retinoblastoma,
a rare and aggressive childhood cancer of the developing retina which can develop
as a sporadic or heritable form, and is fatal if untreated (Zhang et al., 2012a).
Knudson proposed proposed a two-hit hypothesis based on his study on 48 cases of
retinoblastoma and other published reports (Knudson, 1971). The hypothesis states
that at least two mutations are required to transform a normal cell into a cancer cell.
Most of the loss-of-function mutations that occur in tumour suppressor genes are
recessive in nature, and thus both copies of the a tumour suppressor gene must be
mutated for a particular cell to become transformed. Most tumour suppressor genes
have been discovered through studies of families with hereditary cancers (Chial,
2008). Examples of such genes are WT1, TP53, NF1, NF2, VHL, APC, BRAC1,
and BRAC2. RET was the first proto-oncogene to be implicated in an inherted
cancer susceptibility syndrome (Nagy et al., 2004).
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Pedigree analysis of families with familial cancers, genetic linkage analysis and
positional cloning are employed in identifying cancer-predisposing genes. Genes
found include tumour suppressor genes, oncogenes, and mismatch repair genes. To
map the chromosomal location of an unknown disease gene, the first step is to do a
pedigree analysis in families with high proportions of member who have the disease.
A genetic linkage analysis is carried out to identify genetic markers linked to the
disease. Linkage analysis is based on the assumption that two loci that are close to
one another co-segregate and are inherited together. The identified markers then
serve as starting points for the location of the target gene by chromosomal walking,
summarized in Figure 1.1. The two most important breast cancer susceptibility
genes, BRCA1 and BRCA2, were identified by linkage analysis and positional
cloning (Miki et al., 1994; Wooster et al., 1995).
1.1.5 Cytogenetic and molecular cytogenetic analyses, and posi-
tional cloning for identification genes in regions with chro-
mosomal abnormality
Hematological malignancies are characterized by recurring chromosomal abnormal-
ities (Dewald et al., 1985; Rubin and Beau, 1989; Rojas et al., 2000). Recurrent
chromosomal loss is also observed in solid tumours (Limon and Mitelman, 1994;
Albertson et al., 2003). High-resolution chromosomal banding techniques allowed
for detailed karyotypic analysis of cancer genomes and identification of recurrent
chromosomal abnormalities in cancer in the 1970’s (Speicher and Carter, 2005).
These abnormalities include deletion, amplification and rearrangement. Genes
in regions with chromosomal abnormalities were identified by positional cloning
following the identification of the regions using molecular cytogenetic techniques
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Figure 1.1: Chromosomal walking employed in positional cloning for disease gene
identification (Griffiths et al., 1999). End fragments of a clone are used to screen a
genomic library for overlapping clones. Restriction maps are made of the DNA of
the second set of clones, and again, outward fragments are used for new round of
selection of overlapping clones from the library. Screening for overlapping clones and
construction of restriction map are repeated until the gene of interest is identified.
(Zhao et al., 1997; Baccichet and Sinnet, 1997; Sozzi et al., 1999). Regions with
deletions are starting points of positional cloning for isolating tumour suppressor
genes that are important in the development of tumours (Figure 1.1).
Comparative genomic hybridization (CGH) is a molecular cytogenetic tech-
nique for studying DNA copy number losses and gains in one hybridization
experiments. A detailed review on the use of CGH in studying DNA amplification
is provided by Knuutila et al. (1998). This technique has been used to identify
regions containing amplified cellular oncogenes (Kallioniemi et al., 1992; Kallioniemi
et al., 1994; Isola et al., 1995). Known oncogenes that have been reported amplified
in cancers include MYC, CCDN2, REL,KRAS, ERRB2, , EGFR, CDK4, MDM2,
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and MYCN (Knuutila et al. 1998). Tumour suppressor genes (WT1, CDKN2A,
CDKN2B, PTEN, RB1, TP53, NF1 and BRCA1 ) are in regions frequently deleted
in cancers (Knuutila et al., 1999).
1.1.6 Identification of genes with aberrant promoter methylation
Epigenetic mechanisms of the regulation of gene expression involves DNA methyla-
tion and histone modifications. DNA methylation is a regulator in different biolog-
ical processes, such as embryonic development, transcription, chromatin structure,
X chromosome inactivation, genomic imprinting, genomic stability, and carcinogen-
esis (Cheung et al., 2009). Methylation of cytosine is the only known endogenous
modification of DNA in mammals and occurs by the enzymatic addition of a methyl
group to the carbon-5 position of cytosine (Law and Jacobsen, 2010; Doerfler, 1983).
Most of the 5’-methylcytosine in mammalian DNA is found in 5’CpG-3’ dinucleotides.
There are approximately 28 million CpGs in the human genome, 60 - 80 % of which
are methylated in somatic cells (Wu and Zhang, 2014a; Law and Jacobsen, 2010).
CpG islands (CGIs), 500-2000 base-pair long regions with increased CpG density,
are associated with the about 70 % of human promoters and remain predominantly
hypomethylated (Messerschmidt et al., 2014; Cheung et al., 2009). CpG islands in
the promoter regions of tumour suppressor genes are hypermethylated in almost all
tumour types (Esteller, 2002a; James et al., 2003; Jones and Baylin, 2002). Methy-
lation between normal and tumour cells can be exploited in the identification of
genes altered by promoter methylation. A common technique developed and used
in the pre-genomic era for the identification of novel genes with aberrant promoter
methylation was restriction landmark genomic scanning (RLGS), which allows for
the determination of the methylation status of up to 2000 promoters in a single run
(Dai et al., 2001). The results from RLGS is highly reproducible, making it a useful
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technique in methylation study.
1.2 Cancer gene identification in the post-genomics era
There has been tremendous progress in the field of genomics since the completion
of the Human Genome Project in 2003 by the International Human Genome
Sequencing Consortium (IHGSC) (IHGSC, 2004). The project provided the euchro-
matic sequence which represents 99 % of the human genome. Massively parallel
sequencing technologies, termed ”next-generation” sequencing (NGS), are rapidly
replacing the slow, laborious and expensive Sanger sequencing because of their
ultra-high-throughput production capacity (Naidoo et al., 2011; Guan et al., 2012;
Anderson and Schrijver, 2010). NGS technologies have been successfully applied to
whole genome, transcriptome and whole exome analyses.
NGS technologies have revolutionized cancer genomics, producing unprecedented
amounts of data that can be analysed to unravel genes driving cancer development
and progression. These technologies can provide data on all classes of genomic and
epinomic alteration (Morozova and Marra, 2008; Tuna and Amos, 2013; Meldrum
et al., 2011; Wheeler and Wang, 2013). Whole genome sequencing can be used
to identify single nucleotide variations (SNVs), indels, structural arrangements
and copy number alterations in both the coding and non-coding regions of the
genome. Whole exome sequencing identifies SNVs and indels in coding regions of
the genome. ChIP-Seq is used for the identification of transcription factor binding
sites and histone modifications on a genome-wide scale. Bisulphite DNA sequencing
(Methyl-Seq) is applied to genome-wide DNA methylation profiling. RNA-seq can
be used to quantify differential expression of genes and their spliceforms, including
chimeric transcripts that are the result of somatic structural genome rearrangements.
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Microarray technologies are a hybridization-based technique that uses a glass
slide to which probes have been attached to simultaneously estimate abundance
of nucleic acid species or genome-wide single nucleotide polymorphisms in DNA
(Morozova and Mar, 2008; Chen and Sullivan, 2003). They are applied in cancer
genomics to quantify differential gene expression (Kumar et al., 2012) and copy
number alterations (Carter, 2007), for SNP genotyping (Engle et al., 2006) and
genome-wide DNA methylation profiling (Huang et al.. 2010; Schumacher et
al.,2006). While very robust, several of these technologies are being replaced by
NGS based alternatives due to additional precision benefits (Naidoo et al., 2011).
1.2.1 Algorithms are essential to extract biological context from
data generated in the post-genomics era
Application of advanced technologies to cancer genomics has led to explosion in the
amounts of data generated. A challenge of cancer genomics in the post-genomic
era is distinguishing driver from passenger mutations, as the bulk of mutations in
cancer genomes are passengers. Driver mutations give selective growth advantage
to tumour cells, while passenger mutations do not and therefore do not contribute
to cancer development and progression. Several algorithms have been developed
for identifying driver events in the known classes of somatic alterations in cancer:
somatic mutations, copy number alterations, gene rearrangement (gene fusion), pro-
moter methylation and gene expression (mRNA and miRNA) deregulation. Some of
these algorithms are shown in Supplementary Table 1, of which several have been
designed to be used generally in genetic diseases and are therefore not cancer-specific.
For example, SIFT (Ng and Henikoff, 2001) and PolyPhen-2 are tools used to predict
the functional impact of mutation on proteins (Adzhubei et al., 2010; Ramensky et
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al., 2002). The algorithms in the supplementary table can be used for predicting
impact of somatic mutations, identifying driver cancer genes, gene and variant effect
annotation, visualization, pathway and biological process enrichment, co-expression
and transcriptional network construction, differential expression and survival analy-
ses. GenePattern (Reich et al., 2006) is a compendium of tools for almost all aspects
of cancer genomic analysis: driver gene identification, clustering analysis, classifi-
cation, survival analysis, differential expression, pathway analysis and visualization,
which can be installed locally or used online.
1.2.2 Algorithms for predicting driver genes altered by mutation or
in copy number
Most algorithms for identifying mutated or copy-number-altered driver genes can be
broadly classified into frequency- and statistics-based or protein network-based tools.
1.2.2.1 Frequency-based tools
Genes that are frequently altered in a cohort of cancer samples are candidate
drivers. Frequency-based algorithms can identify significantly altered genes in cancer
cohorts. Some of the algorithms for somatic mutation identifies the genes that have
significantly higher mutation rate than the background mutation rate (BMR). The
BMR is the probability of observing a passenger mutation in a specific region of the
genome. These algorithms differ in how they estimate the BMR and the different
mutation categories considered during its computation, and whether it is calculated
per gene and/or per sample. Examples of these algorithms are MutSiC (Dees et al.,
2012) and MutSig (Lawrence et al., 2013).
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Certain algorithms are based on the assumption that genes in a pathway or a
gene set are altered in a mutually exclusive manner. For example, Dendrix identifies
driver pathways de novo by searching for gene sets in which genes are rarely mutated
together in the same patients (Vandin et al. 2012). GISTIC (Beroukhim et al.,
2007) and JISTIC (Sanchez-Garcia et al., 2010) are used to identify chromosomal
regions of aberration that occur more often than expected by chance.
Some tools for identifying frequently altered genes combine predictions from
multiple algorithms to identify drivers. For example, oncodriveFM (Gonzalez
and Lopez-Bigas, 2012) identifies genes that are significantly biased towards the
accumulation of functional impact mutations, and uses SIFT, PolyPhen-2, and
MutationAssessor for functional impact prediction.
1.2.2.2 Protein network-based algorithms
Most gene products (proteins) do not act in isolation but are functionally or physi-
cally connected to other proteins to form biological networks. An approach used by
pathway-based methods for prediction driver genes is constructing a protein network
from known interactions between a set of altered genes in a cancer (Bashashati et
al., 2012; Cerami et al., 2010; Wu et al., 2010). The network is then clustered to
identify sets of functionally related genes called modules, which are prioritised as
candidate driver genes (Cerami et al., 2010; Wu et al., 2010).
Another approach used by pathway-based methods is to search a network
constructed from protein interaction data for genes that are in proximity to or
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have topological properties (e.g., degree, clustering coefficients and betweenness
centrality) that are similar to known cancer genes. MeMo algorithm (Ciriello et
al., 2012) searches a protein network for sub-cliques in which genes are altered in a
mutually exclusive manner, and these genes are referred to as candidate cancer genes.
O¨stlund et al., (2010) identifies a novel driver in a network based on the number of
known cancer genes or genes with cancer process annotations to which it is connected.
Both frequency-based and protein network-based methods have their strengths
and weaknesses. Frequency-based methods lack the power to identify infrequently
mutated genes and are usually employed on a single type of molecular alteration.
Protein-based methods can identify both frequently and infrequently mutated genes
but cannot identify driver genes that do not participate in signaling, e.g., genes
that encode metabolic enzymes. An example is IDH1, which encodes an isoform of
isocitrate dehydrogenase in the citric acid cycle and is a known driver identified as
significantly mutated in glioblastoma multiforme by the frequency-based methods
MutSig and InVex (Brennan et al., 2013). Combining the frequency- and protein
network-based methods would enable the identification of both frequently and
infrequently altered driver gene in a cancer.
1.2.3 Databases useful for cancer genomics research
Data and findings from many cancer genomics studies and other genomic studies
are deposited in public repositories for the use of the research communities, while
several other useful databases store data that can aid analysis in cancer genomics.
Supplementary Table 2 gives descriptions and sources of several of these databases.
The following are some of the ways the databases are being harnessed:
 
 
 
 
CHAPTER 1 Cancer gene identification in the post-genomics era 16
1. Data can be re-analysed for novel findings. For example, re-analysis
of cancer genomics data deposited in the TCGA data portal had pro-
duced more than 2,700 articles in scientific journals as of 9th March, 2015
(http://cancergenome.nih.gov/newsevents/newsannouncements). A notable
example is the expression data sets generated for glioblastoma multiforme
(GBM) (TGCA, 2008) which were used by Verhaak et al. (2010) to identify
subtypes of GBM.
2. Data can be used by scientists in the research community to validate findings
from the analysis of data sets generated in their laboratories. For example,
expression data sets deposited in TCGA, Gene Expression Omnibus and Ar-
rayExpress have been used by several studies to validate prognostic and gene
expression subtype signatures (Saintingny et al., 2011; Zhang et al., 2009).
3. Data deposited in dbSNP (Wheeler et al., 2007), COSMIC (Forbes et al., 2015)
and OMIM (Hamosh et al., 2005) have been used as training sets for develop-
ment of classifier tools for predicting the functional impact of mutations. Driver
mutations from COSMIC and common variants from dbSNP were used as train-
ing sets for a random forest classifier in CanPredict (Kaminker et al., 2007),
which predicts the functional impact of single nucleotide variants.
4. Cancer type-specific databases and COSMIC can be used to ascertain if driver
genes identified in a study are novel.
5. Co-expression databases can be queried to identify genes that are co-expressed
with a gene of interest and the transcription factors regulating some of these
genes (Van Dam, 2014).
6. Protein-protein interaction data can be used in the analysis for driver gene
identification and for studying cancer mechanisms.
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7. Gene sets stored in MSigDB can be used for pathway enrichment analysis and
transcription factor target enrichment analysis in co-expressed modules (Shi et
al., 2010)
8. Certain databases can be used to provide functional annotations for cancer
genes, for example, GeneCards (Chalifa-Caspi et al., 2003)
9. TRANSFAC (Matys et al., 2006), TRED (Zhao et al., 2005) and other tran-
scription factor databases provide transcription factor targets that can be used
in co-expression analysis.
10. The functional impact prediction scores from different algorithms for all possible
nsSNP in human genome have been deposited in dbNSFP database (Liu et al.,
2013), which can be used to determine functional effects of missense mutations
identified in driver genes.
1.2.4 Contribution to the understanding of molecular mechanisms
of cancer
The six hallmarks of cancer are self-sufficiency in growth signals, evading apoptosis,
insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative po-
tential, and tissue invasion and metastasis (Hanahan and Weinberg, 2011; Hanahan
and Weinberg, 2000; Sonnenschein and Soto, 2013). These features are largely
driven by alterations in the key cancer-related signaling pathways. Alterations can
occur at different points in these pathways and through different mechanisms, which
are somatic mutation, copy number variation, epigenetic changes, rearrangement,
and aberrant gene expression. Genes in cancer-related pathways are also not altered
to the same extent; some are frequently altered, others are rarely altered.
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Technological advancements in genomic data generation and the availability of
appropriate analytical tools have made it possible to capture multiple alterations in
individual cancer samples and in cohorts, thereby creating opportunity to identify
aberrant pathways in a given cancer. TCGA (2008) reported at least four genes
that were frequently altered in each of the three signaling pathways in GBM:
RTK/RAS/PI3K,P53, and RB pathways (Figure 1.2). Five signaling pathways have
been found to be frequently altered in colorectal cancer (TCGA, 2012): WNT,
TGF-β , PI3K and RTK-RAS and TP53 signaling pathways were altered in 92, 27,
50, 59, and 64 % of the hypermutated samples, respectively, and in 97, 87, 53, 80,
and 47 % of non-hypermutated samples, respectively. Many genes were altered in
each of the pathways.
Some genes in driver pathways show no preference for a type of alteration,
while others are preferentially altered by a single mechanism. MDM2, MDM4,
CDKN2A, CDKN2B, and CDK4 are known driver genes and are mostly altered
by amplification or deletion in GBM (TCGA, 2008; Brennan et al., 2013). MGMT
encodes O6-methylguanine-DNA methytransferase, which is involved in DNA repair,
is silenced by promoter hypermethylation in several human cancers (Shima et al.,
2011; Zhao et al., 2014; Esteller et al., 2002b; Esteller and Herman, 2004). These
findings and findings from other studies show that analyses involving a single type
of alteration may not be sufficient to capture all important driver alterations and
the genes bearing these alterations in cancer. It is advisable, therefore, to carry
out an integrative and comprehensive analysis involving all known types of genomic
and epigenomic alterations. This is the reason two large scale cancer genomic
projects, The Cancer Genome Atlas (TCGA) and the International Cancer Genome
Consortium (ICGC), were launched to provide comprehensive analyses of genomic
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and epigenomic changes and data in a number of cancers (Bell, 2010). Understanding
of the molecular mechanisms of cancer is prerequisite for target discovery and drug
development. Drug targets could be gene products frequently altered in a cancer, or
products of genes rarely altered but which is an important regulator of cancer-related
pathways. Drugs that target genes in driver pathways are already in use for cancer
treatment. BRAF is an oncogene and is mutated in about 50 % of all melanomas
as well as as several other cancer (Bollag et al., 2012). Vemurafenib was the first
drug approved for the treatment of BRAF -mutated metastatic melanoma (Bollag et
al., 2012). Erlotinib is a drug that inhibits the activity of EGFR, and is used for
the treatment of advanced non-small cell lung cancer (Dowell et al., 2005). Targeted
inhibitors of the components of RTK/RAS/PI3K, WNT, and angiogenic signaling
pathways are also in clinical trials for GBM (Wilson et al, 2014; Carlsson et al.,
2014). The challenge of treatment resistance and recurrence in cancer can be solved
by improving our understanding of its mechanisms and developing more specific
drugs.
1.2.5 Identification of predictive and prognostic biomarkers and
therapeutic targets
Biomarkers can have a predictive or prognostic function. Prognostic factors are
molecular markers whose levels or alteration predict outcome (usually survival) and
are independent of the treatment. Predictive biomarkers are molecular markers
whose expression or alterations predict the response of a patient to a particular
treatment (Shepherd and Tsao, 2006). mRNA and miRNA expression analyses are
mostly used in studies to identify prognostic or predictive gene signatures for cancers.
The general approach employed is to find the genes whose expression correlates with
clinical parameters, such as overall and disease-free survival. Prognostic signatures
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Figure 1.2: The three most frequently altered pathways in glioblastoma multiform
(TCGA, 2008).
that have been identified in cancer are either single-gene or multigene signatures
(Mehta et al., 2010). For example, expression of BRCA1 and VEGF have been
used clinically as prognostic markers for breast (James et al., 2007) and renal cell
carcinoma (Oldenhuis et al., 2008), respectively.
Oncotype, Mammostrat, and MammaPrint are multigene prognostic signatures used
in the clinic. Oncotype DX is a 21-gene qRT-PCR assay used to predict likelihood
of recurrence in women with estrogen receptor positive breast cancer (Goldstein et
al., 2008; Paik 2004 ). Mammostrat is prognostic immunohistochemical test that
uses antibodies specific for SLC7A5, p53, HTF9C, NDRG1, and CEACAM5 to
classify ER-positive, lymph node negative breast cancer cases into low-, moderate-
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or high-risk groups (Geza et al., 2013; Ring et al., 2006). Mammaprint is a 70-gene
microarray-based test for predicting risk of metastasis in breast cancer (van’tVeer
et al., 2002). BRCA1 and Her2/neu, EGFR, and MGMT are predictive biomarkers
for drug response in breast cancer (James et al., 2007), non-small cell lung cancer
(Sequist et al., 2007), and glioblastoma multiforme (Dunn et al., 2009), respectively.
Although most of the currently available clinical tests are specific for breast cancer
(Mehta et al., 2010) and Mammaprint was developed in the pre-genomic era,
transcriptomics could be exploited for the development of prognostic and predictive
signatures for other cancer types in the post-genomic era.
1.2.6 Large-scale cancer genomic projects
The Cancer Genome Atlas (TCGA) and the International Cancer Genome Con-
sortium (ICGC) are large-scale cancer genomic projects launched with the aim of
providing comprehensive analyses on the genomic and epigenomic events underlying
several cancers using high-throughput genomic analysis technologies. The data gen-
erated by these projects are catalogued in dedicated data portals and made available
at different data levels for use of the research community.
1.2.6.1 The Cancer Genomic Atlas
The Cancer Genome Atlas (TGCA) is a joint program of the National Can-
cer Institute (NCI) and the National Human Genome Research Institute
(NHGRI) launched in 2006 as a pilot project to comprehensively character-
ize the genomic and molecular features of ovarian cancer and glioblastoma
multiforme. Findings from 13 cancer types have already been published
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(http://cancergenome.nih.gov/newsevents/newsannouncements/TCGA The Next Stage).
These cancers are head and neck squamous cell carcinomas, papillary thyroid
carcinoma, chromophobe renal cell carcinoma, gastric adenocarcinoma, lung
adenocarcinoma, utethelial bladder carcinoma, glioblastoma multiforme, en-
dometrial carcinoma, adult de novo acute myeloid leukemia, breast cancer,
squamous cell lung cancer, colorectal cancer, and ovarian cancer. Results
from TCGA analyses have led to more than 2,700 articles in research journals
(http://cancergenome.nih.gov/newsevents/newsannouncements/TCGA The Next Stage).
The TCGA network has many centers that are categorized into 6 classes based on
their roles (https://wiki.nci.nih.gov/display/TCGA/The+Cancer+Genome+Atlas):
Tissue Source Sites (TSSs), Biospecimen Core Resources (BCRs), Genome Charac-
terization Centers (GCCs), Genome Sequencing Counters (GSCs), Cancer Genomics
Hub (CGHub), Genome Data Analysis Centers (GDACs). Samples and clinical
data collected by the TSSs are sent to the BCRs. The samples are then sent for
analysis by the BCRs to the GCCs and GSCs. GSCs submit trace files, sequences
and alignment mappings to the CGHub. Clinical data from BCRs and data from
the analyses carried out by GSCs and GCCs are made available to the DCC and
CGHub. The DCC and CGHub then make these data available to the research
community and the GDACs for final analysis. Analysis pipelines and data results
produced by GDACs are served to the research community via the DCC. The TCGA
pipeline is shown in Figure 1.4.
TCGA applies array-, and sequencing-based high-throughput technologies for
comprehensive analyses of cancer genome profiles (Tomczak et al., 2015). Next
generation sequencing is used for mRNA and miRNA expression measurements and
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Figure 1.3: The flow of TGCA data and biospecimen products. TSS: Tissue Source
Sites; BCR: Biospecimen Core Resources; GCC: Genome Characterization Centers;
GSC: Genome Sequencing Counters; DCC: Data Collection Center; CGHub: Cancer
Genomics Hub; GDACs: Genome Data Analysis Centers. Arrow thickness depicts
the relative volume of data transferred between TCGA centers/groups. Retrieved
from https://wiki.nci.nih.gov/display/TCGA/The+Cancer+Genome+Atlas
genome-wide structural variation determination. Array-based technologies used
are microarray platforms for mRNA, miRNA and protein expression, and for copy
number variation measurements.
Genomic data generated by the TCGA are available at four levels. Level I
data is raw data, Level II processed data, Level III is segmented/interpreted data
and Level IV data is results from analyses carried out across sample sets. Level
III and IV data can be accessed freely via TCGA data portal (https://tcga-
data.nci.nih.gov/tcga). Level I and II data that are not patient specific can also
be accessed freely through the portal, but patient-specific data requires permission
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before they can be assessed (https://tcga-data.nci.nih.gov/tcga/tcgaDataType.jsp).
1.2.6.2 International Cancer Genome Consortium
The International Cancer Genome Consortium (ICGC) is a collaborative effort with
the primary goals of generating comprehensive catalogues of genomic abnormalities
(somatic mutations, abnormal expression, epigenetic modifications) in tumours from
50 different cancer types and/or subtypes that are of clinical and societal importance
across the globe, and to make the data available to the entire research commu-
nity as rapidly as as possible with minimal restrictions, in order to accelerate re-
search into the causes and control of cancer (ICGC, 2010; https://icgc.org/#about).
The data generated by the ICGC are catalogued in a data portal available at
https://dcc.icgc.org and the consortium provides both open access and controlled
data sets (Zhang et al., 2011a). Access to controlled data sets, such as germline
variations, requires permission. The data portal Data Release 18, the most recent
release announced on 21th January, 2015, contains data from 55 cancer projects from
18 cancer primary sites and 12,807 donors. 12,942,642 simple somatic mutations in
57,517 genes are catalogued (https://dcc.icgc.org).
1.2.7 Challenges of cancer genomics research in the post-genomic
era
Despite the enormous amount of genomic data generated from cancers using advanced
high-through technologies, translation of genomic findings from these data has been
difficult. Three of the challenges responsible for the translation are highlighted below:
1. Intratumour heterogeneity complicates the development of molecu-
larly targeted therapy
It has been shown that subpopulations may exist within the same tumours, and
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that these subpopulations have marked genetic variation. A study conducted
by Gerlinger et al. (2012) using NGS reveals that more than 60 % of the known
somatic mutations were not present in all samples taken from different regions
of a tumour. Sottoriva et al. (2013) conducted a similar study on glioblas-
toma multiforme (GBM). The study carried copy number and gene expression
analyses on samples taken from different regions of GBM tumours from 11
patients. The results showed that some of the known copy number driver aber-
rations were consistently heterogeneous within the same tumour, and that most
patients displayed different known GBM subtypes (Proneural, Neural, Classi-
cal, and Mesenchymal) within the same tumour. Intratumour heterogeneity is
most likely the mechanism responsible for recurrence and treatment resistance
in cancer and poses a serious challenge to personalized medicine that is being
proposed for cancer.
2. Biomarker discovery
Lack of standardization regarding how specimens are collected, handled and
stored, and access to cohorts with well annotated clinical information are bar-
riers to the translation of biomarkers into clinical use (Vucic et al., 2012)
3. Target druggability
Many drug targets have been identified in cancer are extremely challenging to
target using small molecules (Hoelder et al., 2012). Examples of such targets
are RAS proteins, MYC, and HIF.
1.3 Glioblastoma multiforme
Glioblastoma multiforme, a World Health Organization (WHO) grade IV glioma, is
the most frequently occurring and malignant form of primary brain tumours. It is
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highly aggressive, and one of the most incurable cancers in humans (Ciafre´ et al.,
2005). The standard treatment for newly diagnosed GBM is surgical resection with
concomitant daily temozolomide and radiotherapy, followed by 6 cycles of adjuvant
for 5 days during each 28-day cycle (Stupp et al., 2005). This treatment regime has
failed to improve the median survival time (14.6 months) for patients with GBM
(Stupp et al., 2005). Small organic inhibitors and immunotherapeutic agents are
currently being considered as targeted therapy for GBM treatment; some of which
have made it to clinical trials (Wilson et al., 2014; Wick et al., 2011; Castro et al.,
2011; ).
1.4 Rationale of the thesis
Resistance to chemotherapy is responsible for treatment failure in cancer (Niero
et al., 2014; Longley and Johnston, 2005) and is complicated by the intratumour
and intertumour heterogeneity. Resistance can be acquired through additional
alterations that develop before, during, or after treatment (Yardley, 2013; Long
et al., 2011). It can also be due to subpopulations of abnormal cells within a
tumour that are not sensitive to a treatment (Fillmore and Kuperwasser, 2008;
Schulenburg et al., 2015; Bayin et al., 2014; Housman et al., 2014), and repopulate
the tumour after treatment. Intertumour heterogeneity is one of the reasons
for differential drug sensitivity in subsets of patients suffering from a cancer of
the same histological type (Wyatt et al., 2014; Menzies et al., 2014). Rational
combinatorial targeted therapy has been suggested as the solution to the challenge
of polygenic cancer drug resistance (Al-Lazikani et al., 2012). The form of therapy
would involve complete drugging of all possible targets in the genome of a cancer type.
Decreasing cost of sequencing cancer genomes and tumour heterogeneity has
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sparked a debate for personalized treatment of cancer patients. Such personalization
is however not possible without the complete understanding of the molecular
mechanisms underlying cancer processes, which would aid the development of a
number of molecularly targeted drugs for a cancer type and help make informed
decision on the drugs to administer to individual cancer patients. Treatment of
recurring tumours may also become possible because the majority of the possible
mechanisms of recurrence will have been known beforehand.
In this thesis, the computational analysis using multi-omic cancer data from
TCGA to decipher molecular molecular mechanisms of glioblastoma multiforme
(GBM), the most aggressive of brain tumours and type IV glioma, is reported. It
should be noted that while the analysis was carried out on GBM because of the
availability of multiple types of omic data, the methods reported will very likely
have strong utility in other cancers.
1.5 Thesis structure
The rest of the thesis is organized into five Chapters.
Chapter Two: A protein network constructed from mutated genes and diferen-
tially expressed genes between GBM and non-neoplastic samples was clustered into
functional modules, which were used for the identification of known and novel driver
genes. The network was also used to prioritise functionally-relevant genes from highly
amplified or homologously deleted chromosomal regions. Genes associated with the
protein network were used in co-expression and transcriptional analyses for the iden-
tification of regulatory transcription factors.
Chapter Three: miRNA-target gene regulatory networks were constructed from
differentially expressed miRNAs between GBM and non-neoplastic samples and the
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differentially expressed target genes associated with the protein network, which were
identified in chapter Two.
Chapter Four: miRNAs in the regulatory networks identified in Chapter Three that
had varied expression across the cohort of samples were used in survival analysis and
a multi-miRNA prognostic signature that predicted progression-free and overall sur-
vival was obtained.
Chapter Five: Pathway-based and SVM-based methods were used to identify a set
of genes that discriminated between rapidly-progressing and slowly-progressing GBM
patients. This gene set predicted progression-free and overall survival in GBM.
Chapter Six summarizes the all the findings and proposes potential research and
clinical applications.
 
 
 
 
Chapter 2
Network analysis for
identification of driver mutated
genes and functionally relevant
genes in altered copy number
regions in Gliobastoma
Multiforme
Abstract
Background: The aim and challenge of cancer genomics is distinguishing driver from
passenger alterations in large volumes of data generated by high-throughput tech-
nologies. We present here a network-based approach for driver gene identification,
and co-expression and transcriptional analysis in glioblastoma multiforme (GBM).
Methods: Functional modules were obtained from edge-betweenness clustering of
an intracellular gene network constructed from genes bearing functional impact mu-
tations and differentially expressed genes between normal and tumour samples. Mu-
tated driver genes in the modules were identified. Additional mutated driver genes
were obtained from samples without functional impact mutations in pathways fre-
quently altered in GBM. The network was used to prioritise functionally relevant
genes from chromosomal regions altered by homologous deletion or high-level am-
plification. Genes with variable expression values across samples in each subtype of
29
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GBM were also selected from the pooled list of network genes and their interactors.
The weighted gene correlation network analysis WGCNA tool was used for subtype-
specific co-expression analysis on variable genes. Adjacency matrix was generated
using a hard-threshold of 0.6. The matrix was then transformed into a topological
overlap matrix (TOM)-based dissimilarity matrix, which was hierarchically clustered
into modules. Transcription factor target enrichment analysis was then done on iden-
tified modules with 20 or more genes.
Results: 72 genes belonging to network modules were prioritised as candidate mu-
tated driver genes. Over 50 % of the mutations in each of the genes were deleterious,
and each gene was mutated in at least 3 samples. Previously identified driver genes
were identified, as well as novel mutated genes. These novel genes include EP300,
ACACB, ACACA, TP63, NOS1 and NOS2. TP63, member of the TP53 family, is
involved in tumour suppression. EP300 regulates transcription via chromatin remod-
elling and is involved in proliferation and differentiation. ACACA, which encodes a
rate-limiting enzyme in de novo fatty acid synthesis, is upregulated in multiple cancer
types and is being considered as a novel target for cancer therapy. Novel mutated
driver genes were also identified in samples that do have deleterious mutations in
frequently altered pathways in glioblastoma. These include DNM2, EPHB1, LPAR3,
STAT3, STAT5B, LPAR3, BARD1, GOLGA2, MYC, PTPN11, and MAX. STAT3,
STAT5B, MYC, and MAX are transcription factors with well-established oncogenic
roles in cancers. PTPN11 is a tumour suppressor gene. 89 out of 6107 genes in the
copy number altered chromosomal regions were identified as functionally relevant
genes. 5, 6, 5, and 3 co-expressed modules were identified in Proneural, Neural, Mes-
enchymal, and Classical subtypes of glioblastoma, respectively. These modules were
enriched for targets of several transcription factors, including E2F3, IRF1, NFYB,
POU2F1 and STAT5B. IRF1 and STAT5B, and NFYB are involved in the regula-
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tion of inflammatory responses, while POU2F1 encodes OCT1 whose transcription
has been shown to regulate stem cell phenotype.
Conclusion: This study identified novel GBM driver genes and pathways that were
not identified in previous frequency-based and network based studies. The detailed
underlying molecular mechanisms provided has potential to be exploited for the devel-
opment of molecularly targeted therapy and in the designing of GBM patient-specific
diagnosis and treatment programs.
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2.1 Introduction
Cancer is a disease that results from irreversible changes in the genome and the
epigenome of a cell. These changes include mutation, copy number alteration, altered
gene expression, genomic rearrangements and altered DNA methylation. They confer
on tumour cells special biological advantages, which include uncontrolled and sus-
tained proliferation, evasion of growth suppression, resistance to cell death, replica-
tive immortality, evation of immune destruction, induced angiogenesis, invasion and
metastasis (Hanahan and Weinberg, 2011; Hanahan and Weinberg, 2000). Multi-
omic studies of alterations in a cohort of cancer samples has been helping to identify
the underlying mechanisms of cancer. The studies are made possible by the advent
and application of high-throughput technologies such as whole genome and exome
sequencing, microarray analysis, genome-wide methylation analysis and whole tran-
scriptome sequencing to cancer research. As these identify alterations that are both
beneficial to cancer cells (driver alterations) and alterations that do not contribute
to cancer processes (passenger alterations), the challenge, therefore, is to reliably
identify driver alterations, which are only a small proportion.
2.1.1 Identifying frequently altered genes cancer driver genes
Several methods are available to analyse high-throughput data from cancer ge-
nomics studies to obtain causal genes bearing driver alterations. Some of them are
frequency-based and are generally used on a single type of alteration. Genomic
Identification of Significant Targets in Cancer (GISTIC) is statistical approached
used to identify significant somatic copy number alterations (Beroukhim et al., 2007).
GISTIC generates a score (called G score) for each altered chromosomal region from
amplitude (log2 signal intensity ratios) and frequency of samples with alteration in
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the region. It then does a permutation test on copy number events seen all across
the genome and generate scores for each region. A threshold score is set beyond
which a score is not due to chance alone. Regions with score above the threshold
are considered significantly altered. This tool was first applied to glioma, where it
identified 32 statistically significant regions of genomic amplification or loss. Nearly
all cancer genes previously known to be involved in glioma were identified, showing
the utility of the method. It has also been applied to glioblastoma (McLendon et
al., 2008), medulloblastoma (Northcott et al., 2009), lung and esophageal squamous
cell carcinomas (Bass et al., 2009), ovarian carcinomas (Etemadmoghadam et al.,
2009; Engler et al., 2012) and breast cancer (Staaf et al., 2010; Staaf et al., 2011)
Mutation Significance (MutSig; Lawrence et al., 2013) and Mutation Signifi-
cance in Cancer (MuSic; Dees et al., 2012) algorithms are tools used to identify
significantly mutated genes in cancer. Both algorithms rely on a background
mutation model, the probability that a base is mutated by chance. They determine
background mutation rates (BMRs) for categories of mutations: (i) transitions in
CpG dinucleotides; (ii) transversions in CpG dinucleotides; (iii) transitions in other
C’s or G’s (iv) transversions other in C’s or G’s; (v) transitions in A’s or T’s; (vi)
transversions in A’s or T’s; and (vii) small insertions/deletions, nonsense and splice
site mutations. The BMRs are then used in the calculation of p-values for genes
and rates from all the categories are combined to generate a single BMR per gene.
These tools, however, differ in the way BMRs are combined. Standard MutSig
(MutSig1.0) assume constant BMR across all genes in the genome and all patients in
a cohort. It generates a score for each gene. It then calculate a p value for the gene
by convoluting the binomial background distributions for all mutation categories
and determining the probability of meeting or exceeding this score by background
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mutation alone.
MuSiC generates subgroups of similarly mutated samples. BMRs are calcu-
lated separately for each subgroup. A score is then generated by combining p-values
from all subgroups and mutation catagories for each gene. The p-values are combined
by Fisher’s combined P -value test, Likelihood ratio test or Convolution test. The
final p-value is the probability of obtaining a value no less than the score. MutSig
has been successfully used on breast cancer (Ping et al., 2014; Sjo¨blom et al., 2006),
colorectal cancer (Sjo¨blom et al., 2006), urothelial bladder carcinoma (TCGA, 2014).
MuSic has been tested on ovarian cancer (Dees et al., 2012)
Oncodrive-FM developed by Gonzalez-Perez and Lopez-Bigas (2012) hypothe-
sized that cancer driver genes are biased towards accumulation of high functional
impact mutations. It uses Sorting Tolerant From Intolerant (SIFT), Polymorphism
Phenotyping v2 (PolyPhen2) and MutationAssessor (MA) to score the predicted
functional impact (FI) of missense mutations in genes across tumour samples.
Nonsense SNPs and frameshift indels are assigned maximum SIFT and PolyPhen2
scores and a MA score that separates medium and high FI categories. All the scores
of mutations in each gene are then averaged, and those genes with average FIs
that differ significantly from background are considered cancer driver genes, where
background is a null distribution of average FIs derived from sampling somatic
mutations obtained from a tumour or from non-synonymous mutations that are
found in human populations.
 
 
 
 
CHAPTER 2 Introduction 35
2.1.2 Identifying both frequently and infrequently altered driver
cancer genes
Proteins interact with one another and are organised into functional units called
signaling pathways. Alteration in any of the genes in a signaling tend to produce
similar phenotype. Genes encoding proteins in a pathway are not altered to the
same extent in cancer - some are altered more than the other. Frequency-based
methods of finding driver genes lack the power to find infrequently altered genes and
are usually used on a single type of genetic alteration. Some of these methods are
based on BMR which is difficult to determine, and was calculated in several different
ways in previous studies (Lawrence et al., 2013; Dees et al., 2012; Youn and Simon,
2011).
Protein network analyses depend on the interaction between proteins to iden-
tify driver genes in cancer. These analyses usually use one of these two approaches:
1. Proximity of candidate cancer genes to known cancer genes in pre-constructed
protein networks. These networks are constructed from protein-protein inter-
action data or based on evidence of functional coupling between genes, which
include protein-protein interaction, co-expression, similarity in gene ontology
terms, subcellular colocalization, shared transcription factor binding, domain
associations, and co-occurrence in pathways.
2. Analysis of a protein network constructed from altered genes in cohort of sam-
ples from a cancer for driver modules.
The first approach was used by O¨stlund et al. (2010) to identify novel cancer
genes. The authors started by retrieving known cancer genes compiled by Futreal
et al. (2004) and genes having cancer-related annotation terms from Swiss-Prot
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(UniProt Consortium, 2008). The network obtained from these genes were clustered,
and 348 genes in the major cluster were used to retrieve connected candidate
genes in the FunCoup network. The FunCoup database provides network edges
annotated with confidence scores based on different kinds of interactions: physical
interaction, protein complex member, metabolic, or signaling link (Alexeyenko and
Sonnhammer, 2009). The candidate cancer genes were then filtered for genes not
annotated for cancer-specific terms and having more links to cancer genes than to
non-cancer genes. 1891 novel candidate genes were obtained in this study, which
was not cancer-type specific and used data and evidence provided in databases and
other studies.
Core Modules Driving Dysregulation in cancer (CMDD) identified a core driver
module of 17 genes and their dysregulated genes in glioblastoma multiforme by
integrating DNA mutation, copy number, methylation, gene expression, miRNA
expression profiles, regulatory network and protein interaction network (Ping et
al., 2015). Of the 17 genes, METTL1 and CTDSP2 were identified as novel genes
and shown to be associated with shorter survival. CMDD started by generating a
binary profile of genomic alteration from DNA mutation and copy number alteration
data. A candidate gene (CG) was defined as the gene altered in at least 10 samples,
differentially expressed between samples having alteration in the gene and those
without. For each CG, a dysregulated network was built from genes that showed high
expression variability (top 70 %) across samples and were differentially expressed
between cancer and normal samples, by dividing samples into two groups: those
with alteration in the CG and those without. A regression model was constructed
for each of these genes in each group using copy number and methylation values,
combination of transcription factors and combination of miRNA targets as predictor
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variables. Genes with significant effect of predictor variables on gene expression were
used to form regulatory networks for the two groups. Regulatory interactions present
in one of the two regulatory networks were selected. To obtain dysregulated genes
for each CG, dysregulated network genes were mapped to protein-protein network,
and genes within two-distance away from the CG were selected as its dysregulated
genes. Modules of CGs were formed by estimating and clustering the functional
similarity of enriched GO biological functions between two CGs’ dysregulated gene
sets.
DriverNet algorithm developed by Bashashati et al. (2012) uses impact of ge-
nomic aberrations on transcriptional networks to identify driver mutations. It
generates a bipartite graph between each altered gene in a patient and genes with
outlying expression values in the patient, provided that the altered gene and the
outlier genes are known to interact in gene network. The outlier genes covered by
each altered gene are then determined by a greedy algorithm. To identify genes with
significant coverage of outlier genes, random permutation of the patients’ alterations
and outliers is conducted 500 times. After each permutation, the coverage is
determined. The statistical significance (p < 0.05) of each altered gene is determined
by the fraction of times that the permutated coverage is more than the observed
coverage. DriverNet identified 22 infrequently altered genes in a breast cancer
dataset, 13 in a ovarian cancer dataset, 1 in a triple negative breast cancer dataset,
and 2 in a GBM dataset.
The above two methods assumed that change gene expression was due to al-
teration in a single gene, but most cancer samples bear deleterious alterations in
more than one gene, which act concertedly to alter gene expression. The impact of
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the mutation on gene function and the nature of copy number alteration were not
taken into cognisance.
Cerami et al. (2010) employed a protein network functional module approach
to identify driver genes in GBM, the most aggressive malignant human brain cancer.
In this study, genes having either somatic mutation or DNA copy number alteration
in at least 2 samples were used to construct a protein network. The network was
then clustered using an edge betweenness algorithm to obtain functional modules. 10
modules were identified, of which two were enriched for p53/RB and PI3K signaling
pathways previously reported as the frequently altered in GBM (TCGA, 2008).
AGAP2, AVIL, KIT, TEK, FRS2, and KDR were identified as novel drivers in the
PI3K module. It is, however, possible that this study eliminated singly altered but
important driver gene with deleterious alteration, as impact of alteration on gene
product function was not considered in the selection of genes for altered protein
network construction.
2.1.3 Identifying coexpression modules and and their regulatory
transcriptional factors
Alteration in key signaling pathways that regulate cell proliferation and survival
results in aberrant regulation of the downstream transcription network. Genes whose
expression is controlled by the same transcription factor (TF) tend to be co-expressed
(Yu et al., 2003). For this reason, genes under the regulation of the same TFs are
usually obtained from the analysis of co-expression modules, groups of genes with
similar expression pattern (Shi et al., 2010; Yeung et al., 2004). The challenge with
co-expression analyses is that large numbers of modules are generated. Despite that
fact that a transcription network is regulated by upstream signaling network, most
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co-expression and transcription studies did not take upstream signaling pathways
into consideration.
In this study, we present a network-based identification of driver genes, co-
expression and transcriptional analyses in GBM. The following are the breakdown
of our analyses.
1. Missense mutations are common in cancer, but not all have significant impact
on protein function. We checked for the functional impact of each missense mu-
tation using seven algorithms and filtered out those without predicted impact.
2. Tumours are usually initiated and propagated by oncogenic mutations in genes
localized in the plasma membrane or intracellular regions. Therefore, genes
that encode protein products acting extracellularly were excluded from our
protein network construction. A network was built from genes with potentially
deleterious mutations (predicted deleterious by at least 6 algorithms if missense
mutation or belonging to one of the other types of potentially deterious mu-
tation) and from differentially expressed genes. This network was referred to
as intracellular GBM protein network. Copy number altered genes were not
used in the network construction because of the challenge of selecting func-
tionally relevant genes from large copy number altered chromosomal regions.
Given a fairly large dataset, the chance that most of the important drivers in a
cancer would be altered by somatic mutations affecting one or few nucleotides
in at least one sample is high. The International Cancer Genome Consortium
(ICGC; ICGC, 2010) determined that 500 samples would be needed per tumour
type to identify several driver genes mutated at low frequencies.
 
 
 
 
3. Clustering of the protein network for functional module identification. Enrich-
ment analysis was done on identified modules to identify relevant pathways
present in each module.
4. The network was used to prioritise functionally relevant genes in chromosomal
regions altered by homologous deletion or high-level amplification.
5. Proneural, Neural, Mesenchymal, and Classical subtypes have been identified
as glioblastoma multiforme (GBM) gene expression subtypes. Subtype-specific
co-expression modules and their enriched biological processes were determined.
Transcription factors whose targets were enriched in modules were identified.
Intracellular and extracellular proteins are expected to be under the regulation
of specific transcription factors; therefore, genes encoding extracellular proteins
and having interaction with network genes were included in co-expression anal-
ysis. Genes with variable expression across samples in a given subtype that
was in the network or had at least a gene in the network as interaction part-
ner (from protein-protein interaction data) were used in the co-expression and
transcriptional analysis.
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Figure 2.1: Flowchart for the integrated analysis of multi-omic data for the elucida-
tion of molecular mechanisms of glioblastoma multiforme. It has four parts: protein
network analysis, prioritization of functionally relevant genes in chromosomal regions
altered by homologous deletion or high level amplification, co-expression and trans-
lational analysis, and pathway enrichment analysis.
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2.2 Methods
2.2.1 Gene-centric expression data and filtering of genes
Gene expression data profiled on the HT HG-U133A Affymetrix platform for 540
GBM samples and 10 normal samples were downloaded from the data portar of
the Cancer Genome Atlas (TCGA). Each microarray platform comes with its chip
definition file (cdf), which specifies the probes that map to the same genomic unit
of interest, for example, a gene. This cdf contains locations for multiple probe
sets mapping to the same gene. Therefore, summarization with this cdf generates
more than one expression values for most genes. Since we were interested in
gene-centric expression values (one expression value for each gene), we needed to
make our customized cdf. This was achieved by first mapping probe sequences
on the HT HG-U133A platform downloaded from Affymetrix against a database
composed of RefSeq version 41 and GenBank 178 complete coding sequences using
SpliceMiner (Kahn et al., 2007). This approach was used in TCGA (2008) and
Verhaak el al., (2011) for the summarization of gbm expression profiles.
SpliceMiner is tool for interactive and batch querying Evidence Viewer Database, a
non-redundant relational database that describes all known splice variants of human
genes for which GenBank contains complete coding sequences. The parameters
for SpliceMiner were set such that only perfect match between probe sequences
and the sequences in the database were considered, and probes which mapped to
more than one gene were excluded. The output file from SpliceMiner was then
processed into a format that could be used by the perl code Makealtcdf provided
in affyprobeminer (Liu et al., 2007). Affyprobeminer is a platform-independent
tool that uses all mRNA RefSeqs and complete coding sequences in GenBank to
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regroup the individual probes into consistent probes sets and remap the probe
sets to the correct sets of mRNA transcript. It, however, generates alternative
cdf that cannot be use for gene-centric summarization of gene expression profiles.
This is why the Makealtcdf part of the tool was used to generate our alternative
cdf from the processed SpliceMiner output and the platform original cdf. The
parameters for Makealtcdf were set such that probe sets with less than five probes
were excluded from the the alternative cdf. The alternative cdf was converted to
an R package using the R package makecdfenv (Irizarry et al., 2006), which creates
cdf environments from Affymetrix chip description files. The cdf was then used in
Robust Multi-array Average (RMA) for the generation of gene-centric expression
values from the expression data, generating gene-centric expression data for 12161
genes.
2.2.2 Differential gene expression analysis
Significant Analysis of Microarray (SAM) was used to find differentially expressed
genes between non-neoplastic brain and tumor samples (Tusher et al., 2001). SAM
was chosen because it provides a means of estimating false positive rate, or false
discovery rate (FDR), in a differential expressed analysis. The principle on which
SAM is based is explained briefly.
Given the data xij, i = 1, 2, ..., p genes, j = 1, 2, ...n samples, and response
data yj = 1, 2, ..., n. A measure of relative difference called statistic di is computed
by
di =
ri
si + so
; i = 1, 2, ..., p
where ri is a core, si is a standard deviation, and so is an exchangeability factor used
to ensure the variance of di is independent of gene expression. ri can be computed in
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difference ways depending on the response type. For two-class, unpaired data used
in our study, yj = 1or2. Let Ck = j : yj = k for k = 1, 2. Let nk = # of obervations
in Ck. Let x¯i1 =
∑
j∈C1 xij/n1, x¯i2 =
∑
j∈C2 xij/n2.
ri = x¯i2 − x¯i1
si =
[
(1/n1 + 1/n2)
{ ∑
j∈C1
(xij − x¯i1)2 +
∑
j∈C2
(xij − x¯i2)2
}
/(n1 + n2 − 2)
]1/2
To find significant changes in gene expression, rank genes by magnitude of their di
values: d1 ≤ d2... ≤ dp
B sets of permutations of the response values yj are taken. For each permutation b
d∗bi and corresponding order statistics d
∗b
i ≤ d∗b2 ... ≤ d∗p are computed. The expected
relative difference, diE is then calculated for a set of B permutations,
dEi =
∑
p
dip/B
A scatter plot of the observed relative difference di versus the expected relative
difference dEi is used to identify potentially significant changes in expression.
Differentially expressed genes are represented by points displaced from the di = d
E
i
line by a distance greater than a threshold ∆ = di − dEi .
The number of falsely called genes are generated by counting the number of genes
(overexpressed) with ∆ value > threshold ∆ and genes (underexpressed) with ∆
value < threshold −∆. The number of falsely significant genes corresponding to
each permutation are computed by counting the number of genes that exceed the
threshold ∆ on both sides. The estimated number of falsely significant genes is the
median of the number genes called significant from all B permutations. The FDR
is defined as the estimated number of falsely called genes divided by the number of
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genes called significant.
Gene expression profiling of GBM samples were conducted in 16 batches. A
batch is set of microarrays processed at the same site over a short period of time
using the same platform and under approximatively identical conditions (Lazar,
2012). Using all the batches would give a number of differentially expressed genes
that were due to batch effect, not not necessarily biological variation (Leek et al.,
2010). To avoid this a single batch (Batch 8) was identified which consisted of
10 non-neoplastic brain and 25 GBM samples, which were used for differential
expression analysis. The differentially expressed genes (DEGs) between normal and
tumour samples were obtained using SAM with threshold ∆ = 6.
2.2.3 Assigning functional prediction scores to somatic mutations
A level-3 file containing somatic mutations in 282 GBM samples was downloaded
from the TCGA. The file had somatic mutations for 9505 genes. 13838 (64 %) of
the mutations were missense mutations; 5349 (25 %) were silent mutations; 550 (3)
% were frameshift deletions; 212 (1 %) were frameshift insertion; 203 (1 %) were
in-frame deletions; 27 (0.1 %) were in-frame insertions; 822 (4 %) were nonsense
mutations; 16 (0.07 %) were nonstop mutations; 368 (2 %) affected splice sites; and
70 (0.3 %) affected translation start site. All silent mutations were removed. Frame
shift, in-frame, nonsense, nonstop, splice-site and translation start site mutations
were assumed deleterious. These mutations constituted 11 % of all the mutations.
Functional predictions for all potential non-synonymous single nucleotide poly-
morphisms in the human genome from six algorithms are catalogued in the database
for Nonsynonymous SNP’s Functional Predictions (dbNSFP) version 2.0 (Liu et
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al., 2011). These algorithms are Sorting Intolerant From Tolerant (SIFT) (Ng
and Henikoff, 2003; Kumar et al., 2009), Polyphen-2, LRT (Chun and Fay, 2009),
MutationTaster (Schwarz et al., 2010), MutationAssessor (Reva et al., 2011), and
Functional Analysis Through Hidden Markov Models (FATHMM) (Shihab et al.,
2014). SIFT prediction is based on evolutionary information and physico-chemical
principles. It assigns a score between 0 and 1, and score <= 0.05 is considered
deleterious. PolyPhen-2 prediction is based on both sequence and structural
information and uses eight sequence-based and three structure-based features as
input to a naive Bayes classification. Because two pairs of datasets (HumDiv and
HumVar) were used to train and test PolyPhen-2 prediction models, PolyPhen-2
gives two predictions for each non-synonymous SNP between 0 and 1. A score
>= 0.447 is predicted damaging. Prediction by MutationAssessor is based on the
assumption that if a highly conserved residue is changed to a different residue type,
the change is presumed to have high functional impact on the function of the affected
protein. Prediction ”H” (high) and ”M” (medium) may have functional impact.
MutationTaster uses Bayes classifier built using all the features of known disease
mutations and the features of harmless SNPs and indel polymorphisms. Predictions
”A” (disease-causing automatic) and ”D” (disease-causing) are assumed deleterious.
LRT’s predictions are based on a DNA sequence evolutionary model. Prediction
”D” from LRT indicates that an SNP is deleterious. FATHMM uses hidden Markov
models representing the alignment of homologous sequences and conserved protein
domains. Prediction ”D” from FATHMM indicates that an SNP is deleterious. The
different algorithms are distinct in their principles and their predictions are therefore
not necessarily concordant. It is, therefore, expedient to combine predictions
from a combination of these algorithms when accessing functional consequences
of missense mutations. The predictions from these algorithms for all the missense
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mutations in the mutation file were extracted from dbNSFP the java program
search dbNSFP20.class provided for querying the database and downloaded from
https://sites.google.com/site/jpopgen/dbNSFP. The number of algorithms that
predicted each missense mutation deleterious was then counted and used as a
score for the mutation. Frame-shift, in-frame, nonsense, nonstop, splice-site and
translation start site mutations were given 7, which was the maximum score. Using
a cutoff of 6, 3168 genes had deleterious missense mutations and/or mutations from
mutation types assumed deleterious. These genes made up the mutated gene set.
2.2.4 Extraction of genes from homologous deleted or high-level am-
plified copy number regions
Level-3 copy number data files of 470 GBM samples were downloaded from TCGA.
Copy number profiling was carried out on HG-CGH-244A or HG-CGH-415K G4124A
platform. A level-3 TCGA copy number file contains copy number alterations for
aggregated/segmented chromosomal regions per sample, and has columns for
chromosomes, hg18 chromosomal coordinates of altered regions, and segment means
of log2 signal ratios of altered regions. Only regions whose means of log2 signal
ratios are different from those of matched normal or standard are included in the
file. A python script was written to extract chromosomal segments with log2 mean
signal ratios <= -1.2 (considered as homologous deletion) and those with log2 mean
signal ratios >= 1.2 (considered as high-level amplification), and to map these
segments to hg18 coordinates of Ref genes obtained from the UCSC Genome Browser
(http://genome.ucsc.edu/), which contains reference sequence and working draft
assemblies for a large collection of genomes . Three possibilities were considered to
map gene coordinates to chromosomal segments: (i) the gene coordinates fall within
the segment coordinates (ii) The gene coordinates enclose the segment coordinates
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(iii) at least one-quarter of one end of the gene fall within the segment coordinates.
The genes and the log2 mean signal ratios of the segments in which they
were located were extracted and used as copy number alteration (CNA) dataset.
2.2.5 Intracellular Protein Network construction and functional
module detection
The functional interaction (FI) data generated by Wu et al. (2010) was used in this
study to determine binary interactions between altered genes. The study used a
Naive Bayes classifier trained with a positive set of FIs from Reactome that met at
least one of nine types of FI evidence and with a negative set of randomised pairs
selected from proteins in the positive set. Reactome is an online curated resource
for pathway data (Vastrik et al., 2007). The performance of the classifier was tested
with FIs from other curated protein databases and used to predict and score FIs from
protein-protein interactions deposited in uncurated databases, using a threshold
of 0.5. Version 13 of these predicted FIs and annotated FIs from pathways are
deposited in Reactome database (http://www.reactome.org/pages/download-data/)
for download. This version also includes annotations on direction and nature of
interaction between protein pairs, making it suitable for building directed protein
networks. The FIs were downloaded from the database and used to construct our
protein network, selecting pairs that fulfils all FI evidence types (score = 1). 35195
unique gene pairs annotated for the word ”inhibit” or ”activate” and not having
the word ”predicted” and ”express” were extracted and used in protein network
construction. The pairs made up the gene pair dataset.
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2.2.5.1 Filtering out low-priority genes
Many tumour cells exhibit reduced requirements for growth factors compared to
normal cells. This reduced growth factor dependence of tumour cells results from
abnormal production of a growth factor by the tumour cells themselves, and/or
from abnormalities in intracellular signaling system, such as unregulated activity
of growth factor receptors or other proteins (Cooper, 2000). For this reason, we
excluded 1559 genes whose protein products are localized outside the cell based
on ”Extracellular” Gene Ontology (GO) annotations from the Human Protein
Reference Database (HPRD) (Keshava Prasad, 2009).
As genes with long coding sequences are more likely to accumulate mutations
at random during tumorigenesis genes, those with polypeptides products longer
than 4000 amino acids were excluded, using the relavant information from the
CCDS.current.txt file (Release 17) downloaded from the CCDS database (2014),
which stores a dataset of protein-coding regions annotated on mouse and human
genomes. Sex chromosome genes were also excluded as GBM is not a sex-specific
cancer.
2.2.5.2 Protein network construction and clustering
The remaining mutated genes set and differentially expressed genes that linked at
least any two of them were used for protein network construction using the R package
igraph (Csardi and Nepuszis, 2006), a collection of software packages for graph
theory and network analysis. The network was clustered using edge betweenness
clustering (Girvan and Newman, 2002). Given a network of tightly-packed and
loosely-connected clusters, all shortest paths between nodes in different clusters will
go through the few edges connecting the clusters. These edges will, therefore, have
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high edge betweenness, which is the number of number of shortest paths between
pairs of nodes that run along it.
The Girvan-Newman algorithm identifies clusters in network in four steps: (i)
Calculate the betweenness for all edges in the network; (ii) Remove the edge with
the highest betweenness (iii) Recalculate the betweennesses for all edges affected by
the removal; (iv) Repeat from step ii until no edges remain. This algorithm has been
used to cluster multiple datasets, from social networks (Girvan and Newman, 2002)
to protein interaction networks in GBM (Wu et al., 2010; Cerami et al., 2010). The
Edge-betweenness.community function in igraph was used to find functional modules
in the network. All network diagrams were drawn with Gephi (Bastian et al., 2009).
2.2.6 Identification of rare mutated driver genes and prioritization
of functionally important genes from copy number regions
Memorial Sloan Kettering Cancer Center (MSKCC), the world’s oldest and largest
private cancer center, used information from the literature and public pathway
databases to manually assemble a pathway representation of the most frequently
altered genes in GBM. The pathway representation was constructed around the
frequently altered genes identified in the pilot study conducted by TCGA on the
multidimensional analysis of genomic alterations in GBM (TCGA, 2008). The
Cytoscape file GBM.txt.xgmml containing the pathways was downloaded from
MSKCC website (http://cbio.mskcc.org/cancergenomics/gbm/pathways/). The
file was input into Cytoscape (Smoot et al., 2011), a free open-source software
application for visualizing and analysing networks, and the genes in the pathways
were extracted. Samples without deleterious mutations (score >= 3) in any of
the genes in these pathways were identified and then searched for rare deleterious
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mutations in our network modules (score >= 5).
Copy number altered regions usually involve a large number of genes, many
of which do not contribute to cancer processes. We assumed that functionally
relevant genes in these regions were either already present in the intracellular
network or interacted with genes in the the network. Two approaches were thus
used to identify driver genes in the CNV dataset obtained in Section 2.2.4.
1. Genes present in the network and had homologous deletion or high-level am-
plification in at least three samples.
2. Genes not found in the network but had at least one gene in the network as an
interaction target, and had homologous deletion or high-level amplification in
at least three samples.
2.2.7 GBM Subtype-specific Co-expression and Transcriptional
analyses
Co-expressed genes share similar expression patterns, but are not necessarily
regulated by the same transcription factor. Genes simultaneously regulated by a
transcription factors are co-regulated. To obtain sets of co-regulated genes, groups
of genes (modules) with similar expression pattern are first identified by cluster
analysis. The co-regulated genes in the modules are identified by searching for
shared transcription binding sites in their regulatory regions .
For this study, co-expression and transcriptional analysis were performed in a
subtype-specific manner and only on the intracellular network genes and their inter-
actors. The aim was to identify genes associated with the GBM network that were
under the regulation of common transcription factors. GBM subtypes were identified
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by Verhaak et al (2010) using factor analysis to integrate expression data from 200
GBM and 2 brain normal samples from three platforms into single, unified dataset.
1740 genes that were stably expressed and highly variable in expression were used
in consensus average linkage hierarchical clustering, yielding four robust subtypes.
840 signatures (210 genes per subtypes) each were identified for the four subtypes.
The subtypes were validated in a combined dataset from four different studies as a
function of the signature genes. The four subtypes were named Proneural, Neural,
Mesenchymal and Classical subtypes based on the expression of signature genes.
Proneural, Neural, Classical and Mesenchymal subtypes were characterized by
aberrations and gene expression of EFGR, NF1, and PDGFRA/IDH1, respectively.
Brennan et al. (2013) used the 840 signatures to predict the subtypes of the 342
GBM samples not included in Verhaak et al (2010) study using single-sample gene
set enrichment analysis. The GBM samples and their subtypes were provided by
Brennan et al. (2013) as supplementary data, and were downloaded and used in our
analysis.
2.2.7.1 Coexpression analysis using the weighted gene coexpression net-
work WGCNA tool
Median Absolute Deviation (MAD) was used as a measure of variability to extract
genes with varied expression across samples. Genes with MAD >= 0.5 were
selected. The variable genes interacting with the network genes were added to the
network genes to give co-expression data set. Sex chromosome genes were again
removed. For each subtype, MAD was re-calculated again for the genes in the
co-expression data set, and the ones with MAD >= 0.5 were filtered and used for
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subtype-specific co-expression analysis. Co-expression analysis was carried out using
WGCNA, an R package for weighted correlation network analysis (Langfelder and
Horvath, 2008). This package has been used in cancer co-expression studies, such as
breast cancer (Clarke et al., 2013)and endometrial cancer (Chou et al, 2014). The
Pearson correlation similarity matrix between expression values of highly variable
network genes across samples was obtained. WGCNA generates both weighted and
unweighted correlation network depending on the adjacency function used, giving
an adjacency matrix, which is a measure of connection strength between two genes.
Hard thresholding using the signum function generates unweighted network and
was used in this study. The correlation matrix was transformed into an adjacency
matrix using the signum function with hard threshold of 0.55 (strong Pearson
correlation between any two genes). In this matrix, correlation coefficient between
genes greater than the threshold was scored 1, while two genes with correlation
less than the threshold was scored 0. The adjacency matrix was transformed
into a topological overlap based dissimilarity matrix, which provides a measure of
relative connectedness between two genes. This matrix was then clustered into
modules using average linkage hierarchical clustering. To merge close modules, an
eigengene of each module was determined, which is the first principal component
of the expression values of genes in a given module and a representative expression
value for the whole module. Two modules were merged if the correlation coefficient
between their eigengenes was greater or equal to 0.75 and modules with 20 or more
genes were used for further analysis.
The co-expressed modules were analysed for enriched transcription factors that
were in the extended GBM network. To do this, gene sets for transcription factor
binding motifs were downloaded from Molecular Signatures Database (MSigDB;
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Liberzon et al., 2013). The identifiers used for these motifs were the same as
those used in the TRANSFAC database. This database provides information about
DNA-binding sites and profiles of eukaryotic transcription factors (Wingender,
2008). The transcription factors that bind to these mofits were obtained from UCSC
Genome Browser. Genes having different binding motifs that are recognised by a
common known transcription factor were combined into one gene set. The gene sets
and their transcription factors were used for transcription factor target enrichment
analysis of co-expressed modules.
2.2.8 Functional enrichment analysis of network modules and co-
expressed modules
An R script was written to compute pathway functional enrichment analysis. Given
a population of N items consisting of k type A or N-k items of type B, the probability
of obtaining x or more items of type A in a random sampling without replace of n
items from the population is calculated by
p =
n∑
i>=x
 k
x

 N − k
n− x

 N
n

For pathway enrichment of network modules and co-expression module enrichment
for transcription factor target genes and pathway enrichment of differentially
expressed genes, N was a set of genes on the microarray platform; n was a set
of module genes or differentially expressed genes; k was a pathway gene set or
transcription factor target gene set; x was an intersect between a gene set and a
module or differentially expressed genes. KEGG pathway gene sets were obtained
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from MSigDB.
The p values generated by a hypergeometric test were adjusted using the Benjamini
and Hochberg correction (Benjamini and Hochberg, 1995) to derive the False
Discovery Rates (FDRs).
Enrichment analysis of co-expressed genes for biological process was done us-
ing the enrichment tool in Database for Annotation, Visualization, and Integrated
Discovery (DAVID; Dennis et al., 2003). DAVID is web-based platform that provides
visualization of annotation and enrichment tools and results for gene set analysis. It
is available at http://david.abcc.ncifcrf.gov/
2.3 Results and Discussion
This study provides a comprehensive and integrative analysis of high throughput
multi-omic data in glioblastoma multiforme. It identified differentially expressed
genes, functional network modules, rare mutated driver genes, functionally relevant
genes in copy number altered chromosomal regions, and transcription factors that
regulate target genes in co-expression modules. It gives an insight into the underlying
mechanism that drives tumorigenic process in GBM.
2.3.1 Genes involved in neurological and cancer processes are dif-
ferentially expressed
At ∆ = 4.54, the FDR was 1.51 x 10−5 and the number of differentially expressed
genes between non-neoplastic and tumour samples was 3417. These genes were anal-
ysed for KEGG pathway enrichment identifying sixteen (16) significantly pathways
(p < 0.05) enriched for differentially expressed genes (Table 2.1). In contrast Dong
et al. (2010) identified 1,236 significantly differentially expressed genes among 243
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GBM and 11 normal samples and 30 enriched pathways, but principal component
analysis has shown that TCGA GBM expression data set had batch effect (Marko
et al., 2011), which the Dong study did not take into consideration. It is for this
reason that we restricted our analysis to a single batch containing 25 GBM and 10
non-neoplastic samples.
The significantly enriched pathways in brain processes were Long Term Potentiation
(LTP) and Long Term depression. LTP, the enhancement of postsynaptic responses
long after repetitive afferent stimulation of presynaptic afferents, is the molecular
basis for learning and memory. Progressive cognitive deficits have been reported
in patients with GBM (Sizoo et al., 2010; Oberndorfer et al., 2008). Inhibition of
endocytic removal of postsynaptic α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic
acid receptors (AMPARs; GRIA1) in freely moving rat was found to prolong LTP
(Dong et al., 2015). There was over three-fold reduction in expression of GRIA1 in
our study. GRIA1 encodes an AMPA member of the ionotropic class of glutamate
receptors which are involved in neurotransmission. AMPA and NMDA receptors
induce and sustain long term potentiation (LTP; Lynch, 2004; Lu¨scher and Malenka,
2012). NMDA receptors are multi-subunits glutamate-gated ion channels composed
of one NMDAR1 subunit and one or more of the 4 NMDAR2 subunits: NMDAR2A,
NMDAR2B, NMDAR2C, and NMDAR2A (Chaffey and Chazot, 2008; Lee et al.,
2014). NMDAR1, NMDAR2A, NMDAR2B, and NMDAR2C are encoded by GRIN1,
GRIN2A, GRIN2B, and GRIN2C, respectively. These genes were down-regulated
in our study. There were 3-, 7-, 1.52-, and 2-fold decreases in the expression of
GRIN1, GRIN2A, GRIN2B, and GRIN2C, respectively. These results suggest that
down-regulation of AMPA and NMDA receptors is one of mechanisms of reduced
LTP and of memory deficit in glioblastoma multiforme (GBM) patients.
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Pathways previously implicated in cancer were also deregulated (Table 2.1),
including the MAPK pathway, cell cycle and ErbB pathway, which were previously
identified as frequently altered pathways in GBM (TCGA, 2008). Fibroblast growth
factor (FGF) signaling pathway is a MAPK pathway and has a role in cellular
proliferation, migration, and differentiation, and survival (Turner and Grose, 2010).
It has been shown that the FGF pathway promotes or inhibits tumorigenesis
depending on tumour type. FGFR2 expression was reduced in transitional cell
bladder carcinomas (Diez de Medina et al., 1997), prostate cancer (Naimi et al.,
2002), hepatocellular carcinoma (Amann et al., 2010) and salivary adenocarcinoma
(Zhang et al., 2001). FGF13, FGF9, FGF12, FGF14 and FGFR2 activate this
pathway and were significantly underexpressed in this study (p < 1 x 10−5; Table
2.2). Inhibitors of this pathway, SPRY1, SPRY2 and SPRY4, were overexpressed (p
< 1 x 10−5; Table 2.2). These findings indicate that the FGF pathway is targeted
for downregulation in GBM.
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Table 2.1: KEGG pathway Enrichment of differentially expressed
Genes in GBM
Pathway # of Genes raw p adj. p
Long term potentiation 43 7.84e-10 1.45e-07
Oocyte meiosis 44 6.03e-05 0.0056
Lysosome 49 9.04e-05 0.0056
Long term depression 32 0.0002 0.0062
Gap junction 38 0.0002 0.0062
Antigen processing and presentation 32 0.0007 0.0203
Epithelial cell signaling in helicobacter pylori infection 29 0.0001 0.0230
Focal adhesion 73 0.0010 0.0230
DNA replication 18 0.0012 0.0230
Glycosaminoglycan degradation 13 0.0012 0.0230
Vibrio cholerae infection 24 0.0015 0.0256
MAPK signaling pathway 89 0.0025 0.0385
Axon guidance 45 0.0031 0.0407
Endocytosis 61 0.0031 0.0407
Cell cycle 43 0.0037 0.0456
ErbB signaling pathway 35 0.0040 0.0464
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Table 2.2: Genes in MAPK pathways differentially
expressed in GBM
Pathway Gene Fold Change
FGFR Pathway
FGF13 0.039
FGF9 0.133
FGF12 0.185
FGFR2 0. 627
SPRY1 4.834
SPRY2 1.969
SPRY4 4.23
Calicum ion transport
CACNA1D 0.433
CACNA1B 0.727
CACNA1A 0.377
CACNA2D2 0.246
CACNA2D3 0.064
CACNB1 0.414
CACNB2 0.119
CACNB3 0.227
CACNB4 0.172
CACNG2 0.352
CACNG3 0.026
PRKCB 0.042
PPP3CA 0.254
PPP3CB 0.319
JNK pathway
DAXX 1.492
MAPK10 0.197
MAPK8 0.696
MAPK8IP1 0.430
MAPK8IP2 0.230
MAPK8IP3 0.740
MAPK9 0.324
MAP2K4 0.216
Receptor Tyrosine Kinase pathway
NRAS 2.646
RAF1 1.766
AKT1 1.677
EGFR 6.593
Inhibitors of MAPK pathways
DUSP8 0.160
DUSP3 0.607
DUSP7 0.590
DUSP2 0.291
DUSP6 2.518
All genes were significantly differentially expressed with SAM FDR <= 0.00001
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EGFR
ABI2
ATM
ABL1
EPHA3
EPHA5
EPHB1
EPHB2
EPHB4
EPHB6
PLCG1
SRC
TP53
ACACB
MAX
MYC
ACVRL1
SMAD7
ADAM10
PRKCB
PRKCD
S1PR1
ADCY10
ADCY2
ADCY6
ADCY8
ADCY9
KCNQ1
ADCYAP1R1
GRM3
ADRBK2
NTRK1
AGAP2
DAB1
GNAO1
HSP90AB1
INPPL1
ITGB4
JAK1
MDM2MLST8
MTOR
PIK3CA
PIK3CB
PIK3R1
PIK3R2
PPP2R3A
PTEN
PTPN11
STAT1
STAT5B
STRN
TRAF6
AMPH
ANKLE2
AP2A2
AXIN1
CSNK2A1
CSNK2B
CUL1 DVL2
APH1A
KDR PAK1
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Figure 2.2: The intracellular GBM network. The network was constructed from
genes with missense mutations predicted deleterious by at least six algorithms and/or
with mutations belonging to other classes of potentially deleterious mutations, and
differentially expressed genes that linked at least two of these mutated genes. Genes
in yellow were mutated genes, and genes in green were non-mutated differentially
expressed genes.
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Figure 2.3: Modules identified in the GBM network. Genes with the same color are
in the same module. Only modules with at least 5 genes are shown.
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Figure 2.4: Frequencies of alterations by mutation or copy-number alteration (high-
level amplifications and homozygous deletions) of genes in signaling pathways that
are altered in glioblastoma. Amplifications and activating mutations are shown
in shades of red and homozygous deletions and inactivating mutations are shown
in shades of blue, based on 91 samples with sequencing and copy-number data
(http://cbio.mskcc.org/cancergenomics/gbm/pathways/).
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Table 2.3: Description, alteration and KEGG pathways enriched for GBM
network modules
Module # genes # samples1 # samples2 Enriched pathway # of genes
(mutation) (cnv) mapped in
n=282 n=470 the pathway
1 9 7 4 Regulation of actin cytoskeleton 7
2 149 251 299 ErbB signaling pathway 35
Neurotrophin signaling pathway 37
MAPK signaling pathway 44
Chemokine signaling pathway 34
Focal adhesion 38
Glioma 25
Insulin signaling pathway 27
Regulation of actin cytoskeleton 28
VEGF signaling pathway 20
JAK/STAT signaling pathway 23
Adipocytokine signaling pathway 17
MTOR signaling pathway 15
Tight junction 18
Gap junction 14
Apoptosis 13
NOD-like receptor signaling pathway 11
Phosphatidylinositol signaling system 12
Inositol phosphate metabolism 9
WNT signaling pathway 11
3 15 38 3 Homologous recombination 4
4 11 13 1 Cell cycle 8
5 60 111 303 Cell cycle 17
WNT signaling pathway 13
NOTCH signaling pathway 7
TGF-β signaling pathway 8
p53 signaling pathway 5
Ubiquitin mediated proteolysis
9 7 21 3 Adipocytokine signaling pathway 6
Insulin signaling pathway 6
Pyruvate metabolism 3
10 13 33 19 Tight junction 6
15 17 43 6 Calcium signaling pathway 11
GnRH signaling pathway 9
Neurotrophin signaling pathway 8
Glioma 5
Phosphatidylinositol signaling system 5
Gap junction 4
16 89 119 29 Chemokine signaling pathway 21
Calcium signaling pathway 16
Gap junction 12
MAPK signaling pathway 16
GnRH signaling pathway 10
WNT signaling pathway 10
Tight junction 9
23 21 34 45 DNA replication 13
Mismatch repair 7
Cell cycle 6
Base excision repair 4
27 14 18 6 WNT signaling pathway 10
Pathways in cancer 9
NOTCH signaling pathway 4
All pathways had p-values < 0.05
1The number of samples with mutated genes in the module.
2The number of samples with copy number altered genes in the module.
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Table 2.4: Mutated genes∗ identified in GBM network modules
Module # of Genes # of Genes with Genes
in module score ≥ 3 in 3
or more samples
2 149 53
PTEN TP53 EGFR NF1 PIK3CA PIK3R1
PDGFRA KDR MAP3K1 BRAF PTPN11
PLCG1 IL4R MTOR FGFR3 AMPH ZAP70
VAV1 TSC2 TLR2 TEK PRKCD PRKCB
PLCG2 PIK3R2 PIK3CB PDGFRB PAK4
MLLT4 MAP3K7 LPAR3 IRS1 IL18RAP
IGF1R EPHB2 EPHA3 RXRA PTK2B
PGR MAP2K3 ITGB4 ITGB2 INSRR ESR2
EPHB1 TYK2 PTPRR PTPN6 NTRK1
MPL IFNGR2 DNM2 CTTN
3 15 5 SMC3 CHEK2 MDC1 RBBP8 BRCA1
4 11 1 CDC27
5 60 20
RB1 CHD9 TP63 CREBBP CLOCK ZFHX3
NFIB NCOA2 FOXG1 CDKN2C TLE4
PAX3 HIRA HDAC2 CARM1 TERT RBPJL
EP300 EHMT2 CUL1
9 7 4 ACACB ACACA SLC2A1 PCK1
10 13 5 MYH8 MYH13 MYH15 MYH6 MYH4
15 7 17
NOS1 ITPR3 ITPR1 SCN5A SLC6A3
ITPR2 GRM5
16 89 22
GRM3 CACNA1S GRM8 SCN1A CHRM2
CACNA2D1 CACNA1D CACNA1C ADCY9
RGS9 NOS3 MAP4K1 GNAT3 GABBR2
CACNG3 ADCY2 ADCY1 CHEK1 CACNB3
CACNA2D2 CACNA1A ADCY6
23 21 4 TEX15 MCM7 PPM1D MCM6
27 14 3 FZD10 DVL2 AXIN1
39 12 3 DCC SPTAN1 GZMB
41 9 3 MAP4K3 MAP4K2 CYLD
63 5 1 CPSF1
∗ Genes with mutations predicted deleterious by at least 3 algorithms, in at least 3 samples and in over 50
% of the samples with mutations in the genes.
Genes in red were identified as mutated drivers by both frequency-based and network-based approaches.
Genes in blue were identified as mutated drivers by frequency-based approach alone.
Genes in purple were identified as mutated drivers by network-based approach alone.
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Table 2.5: Candidate mutated driver genes in samples without dele-
terious mutations in frequently altered GBM signaling pathways
Module # of genes Genes
2 19
ABL1 DNM2 EPHB1 ESR2 ITGB4 LPAR3 MTOR
NCOR2 PGR PLCG1 PLCG2 PTPN11 PTPRR
RAPGEF2 RPS6KA2 STAT3 STAT5B TEK TYK2
3 4 BARD1 CHEK2 RBBP8 SMC3
4 2 CDC27 GOLGA2
5 7 CHD9 MAX MYC POU2F1 PSMC1 SMURF1 TLE4
9 1 ACACB
10 4 MYH6 MYH8 MYH13 MYH15
15 3 CAMK4 ITPR1 NOS1
16 5 GRM3 GRM8 MAP4K1 SCN1A YWHAH
27 1 DVL2
39 2 PARP1 RFC1
41 1 MAP4K2
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Table 2.6: Genes in GBM network modules with alteration in copy number
Genea Approved Symbol # of samples
with alteration
CDKN2A Cyclin-dependent kinase inhibitor 2A 228
CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 224
EGFR Epidermal growth factor receptor 210
CDK4 Cyclin-dependent kinase 4 61
AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 61
PDGFRA Platelet-derived growth factor receptor, alpha polypeptide 48
MDM2 MDM2 proto-oncogene, E3 ubiquitin protein ligase 39
PTEN Phosphatase and tensin homolog 38
PIK3C2B Phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta 27
KDR Kinase insert domain receptor 21
TEK TEK tyrosine kinase, endothelial 17
RAP1B RAP1B, member of RAS oncogene family 17
CLOCK Clock circadian regulator 17
EXOC1 Exocyst complex component 1 15
RB1 Retinoblastoma 1 12
CDKN2C Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 11
FAF1 Fas (TNFRSF6) associated factor 1 11
SKP1 S-phase kinase-associated protein 1 10
MET MET proto-oncogene, receptor tyrosine kinase 10
PTPRR Protein tyrosine phosphatase, receptor type, R 9
HLA-DRB1 Major histocompatibility complex, class II, DR beta 1 8
CCND2 Cyclin D2 7
PTPRB Protein tyrosine phosphatase, receptor type, B 7
IRAK3 Interleukin-1 receptor-associated kinase 3 7
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 6
TP53 Tumor protein p53 5
EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 5
DVL3 Dishevelled segment polarity protein 3 5
ACTL6A Actin-like 6A 5
PER3 Period circadian clock 3 4
VAMP3 Vesicle-associated membrane protein 3 4
NFIB Nuclear factor I/B 4
EPHA3 EPH receptor A3 4
STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor) 3
NF1 Neurofibromin 1 3
IRS2 Insulin receptor substrate 2 3
CACNA1C Calcium channel, voltage-dependent, L type, alpha 1C subunit 3
AKT1 v-Akt murine thymoma viral oncogene homolog 1 3
ADCYAP1R1 Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I 3
Genes in red were amplified and genes in blue were deleted.
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Table 2.7: Genes with alteration in copy number and having genes in the
GBM network as interaction targets
Gene Approved Symbol # of samples
with alteration
KIT v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 35
PHKG1 phosphorylase kinase, gamma 1 (muscle) 33
DDIT3 DNA-damage-inducible transcript 3 33
NUP107 Nucleoporin 107kDa 27
MDM4 MDM4, p53 regulator 27
PRKG1 Protein kinase, cGMP-dependent, type I 12
FRS2 Fibroblast growth factor receptor substrate 2 12
NAIP NLR family, apoptosis inhibitory protein 10
FAS Fas cell surface death receptor 10
CDK6 Cyclin-dependent kinase 6 10
GRB10 Growth factor receptor-bound protein 10 8
DYRK2 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 6
CTNNA3 Catenin (cadherin-associated protein), alpha 3 6
CREB5 cAMP responsive element binding protein 5 6
AKT3 v-Akt murine thymoma viral oncogene homolog 3 6
EIF2B5 Eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa 5
WNK1 WNK lysine deficient protein kinase 1 5
EPHB3 EPH receptor B3 5
AP2M1 Adaptor-related protein complex 2, mu 1 subunit 5
TIMELESS Timeless circadian clock 4 ADIPOR1 adiponectin receptor 1 4
TFDP1 Transcription factor Dp-1 3
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 3
PIK3CD Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta 3
MAGI2 Membrane associated guanylate kinase, WW and PDZ domain containing 2 3
ITPKB Inositol-trisphosphate 3-kinase B 3
GNGT1 Guanine nucleotide binding protein (G protein), gamma transducing 3
activity polypeptide 1
GNG11 Guanine nucleotide binding protein (G protein), gamma 11 3
GCK Glucokinase (hexokinase 4) 3
DUSP22 Dual specificity phosphatase 22 3
CTNNA2 Catenin (cadherin-associated protein), alpha 2 3
CREB3L1 cAMP responsive element binding protein 3-like 1 3
CHRM4 Cholinergic receptor, muscarinic 4 3
CCNE1 Cyclin E1 3
BLNK B-cell linker 3
Genes in red were amplified and genes in blue were deleted.
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Figure 2.5: Altered GBM subnetwork. The red stars presents AKT1 and AKT3 that
appear to separate the network into two parts. Some of the pathways represented in
the subnetwork are shown. Green circles represent genes altered in copy number only
in at least 3 samples; yellow circles represent genes altered by mutation only in at
least 3 samples, or genes with deleterious mutation and linking genes mutated in at
least 3 samples; red circles represent genes altered by mutation and in copy number.
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Table 2.8: Subtype-specific co-expressed modules and regulatory transcription factors
Subtype Module # genes Enriched TF∗ for enriched
biological process targets in module
Proneural
1 120
Cell cycle, DNA replication, DNA repair,cell pro-
liferation, DNA damage checkpoint
E2F3(14), NFYB(10)
2 100
Immune response, inflammatory response,
chemotaxis,reponse to hypoxia, response to heat,
response to drug,apoptosis, hemopoiesis
RELA(14), NFKB1(15)
3 100
Regulation of neurogenesis, regulation of neu-
ronal differentiation, regulation of cell prolif-
eration, positive regulation of macromolecule
metabolic process
FOXO1(11), POU2F1(19)
CEBPA(19), EGR2(6)
4 25 - SRF(5)
5 21
Neurotransmitter transport, axonogene-
sis,neurone development
-
Neural
1 76
Immune response, chemotaxis, hemopoiesis,
calcium ion homestasis, apoptosis, positive
JAK/STAT cascade
IRF1(7), RELA(8)
STAT5B
2 69
Cell cycle, DNA repair, cellular response to
stress, cell cycle checkpoint, cell proliferation
E2F3(12), NFYB(7)
3 57 Apoptosis, cellular response to stress -
4 55 Neurotransmitter transport POU2F1(11), FOS(7)
5 50
Neuronal differentiation, regulation of neurogen-
esis, regulation of axonogenesis, cell fate commit-
ment
POU2F1(10)
6 38
Extracellular organization, cell migration, angio-
genesis, regulation of epithelial proliferation, in-
flammatory response
SRF(7)
Mesenchymal
1 115
Regulation of neurogenesis, cell adhesion, regula-
tion of neuron differentiation, axonogenesis, cell
migration, response to insulin stimulus, cell fate
commitment, response to organic molecule, posi-
tive regulation of apoptosis
-
2 82
Immune response, inflammatory response,
hemopoiesis, chemotaxis, clacium ion homeosta-
sis, response to drug, apoptosis, response to
radiation, response to hypoxia, integrin-mediated
signaling pathway
RELA(9), STAT5B(7)
3 74
Cell cycle, cell cycle checkpoint, DNA replica-
tion, DNA repair, cell proliferation, cellular re-
sponse to stress
E2F3(10), NFYB (10)
4 25
Extracellular matrix organization, cell adhesion,
cell migration, angiogenesis
-
5 21
Chemotaxis, immune response, inflammatory re-
sponse, response to glucocorticoid stimulus, re-
sponse to corticosteroid stimulus, negative regu-
lation of cell proliferation
NFKB1(6), IRF1(6)
RELA(5)
Classical
1 64 Protein kinase cascade -
2 53
Immune response, hemopoiesis, inflammatory re-
sponse, chemotaxis, calcium ion homeostasis,
apoptosis, response to hormone stimulus
-
3 51
Cell cycle, DNA repair, cell cycle checkpoint, cell
proliferation, cellular response to stress
E2F3(11), NFYB(6)
∗ Transcription factor
Genes in red are subtype-specific transcription factors
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2.3.1.1 Genes encoding calcium channels were deregulated was GBM
Ca2+ is a second messenger that regulates the activity of some cellular signaling path-
way, including MAPK pathway. It is involved cancer processes, including apoptosis
(Monteith et al., 2007; Berridge et al., 2003), malignancy (Hanahan and Weinberg,
2000), proliferation (Becchetti, 2011), cell motility (Huang et al., 2004) and angio-
genesis (Patton et al., 2003). The intracellular calcium levels are regulated by voltage
gated calcium channels in the plasma membrane and by ligand-gated channels in the
endoplasmic reticulum. Calcium influx through voltate gated channels leads to ac-
tivation of key proteins in the MAPK signaling pathway (Rosen et al., 1994; Rosen
et al., 1996; Ferchmin et al., 2003). All the fourteen genes in the enriched MAPK
signaling pathway category (Table 2.1) that regulate intracellular calcium levels were
significantly underexpressed (p < 1 x 10−5; Table 2.2). Eleven of these genes are
voltage-gated calcium channels. The voltage-gated calcium channel α2δ2 subunit
consists of 4 genes, two (CACNA2D2, CACNA2D3 ) of which were significantly un-
derexpressed in this study. Overexpression of CACNA2D2 in nonsmall cell lung
cancer cell lines deficient in CACNA2D2 gene induced apoptosis by disruption mi-
tochondrial membrane integrity, the release of cyt c, and the activation of caspases
(Carboni et al., 2003). CACNA2D2 was in the homozygously deleted region of chro-
mosome 3p21.3 in lung and breast cancers (Lerman and Minna, 2000; Gao et al.,
2000). Promoter methylation of CACNA2D3 in advanced gastric cancer was found
to result in poor prognosis, and exogenous expression of CACNA2D3 inhibited cell
growth and adhesion in HEK-293T and NUGC4 cells (Wanajo et al., 2008).
2.3.1.2 JNK signaling pathway was deregulated in GBM
Key genes in JNK signaling pathway were significantly underexpressed in this study
(p < 1 x 10−5; Table 2.2). These genes are MAPK8 (JNK1 ), MAPK9 (JNK2 ) and
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MAPK10 (JNK3 ). JNK signaling pathway regulates proliferation, differentiation,
survival and migration (Wagner and Nebreda, 2009). It is activated by environ-
mental and genotoxic stresses. The action of this pathway is cell context-specific
and cell-type specific. Sustained activation of JNK in Iκκβ∆hep mice increased sus-
ceptibility to diethylnitrosamine-induced hepatocarcinogenesis (Sakurai et al., 2006).
Apoptosis in cerebellar granule neurons and developing neurons was mediated by
JNK or JUN (Mei et al., 2008; Barone et al., 2008). Downregulation of JNK genes
in this study shows that JNK pathway has a tumour inhibitory role in glioblastoma.
The apoptotic function of JNK in GBM is supported by the findings that JNK is
involved is the mechanism of action of certain anti-tumour agents. For example,
the anti-tumour activity of BBMD3, a synthetic derivative from the natural product
Berbamine, was shown to involve the JNK signaling pathway and the downstream
target AP-1 transcription factor (Yang et al., 2014).
2.3.1.3 The classical MAPK signaling pathway was up-regulated in GBM
The extracellular-signal-regulated kinase (ERK) pathway is a classical MAPK path-
way regulated by cell surface receptors, such as receptor tyrosine kinases (RTK),
G-protein-coupled receptors (GPCRs) and integrins (Morrison, 2012). It is deregu-
lated in one-third of all human cancers (Dhillon et al., 2007). NRAS, RAF1, AKT1,
and EGFR are known oncogenes in this pathway, and were overexpressed in this
study (p < 1 x 10−5; Table 2.2). Dual-specificity protein phosphatases (DUSPs) are
negative regulators of the MAPK pathways in mammalian cells, and they belong to
the dual-specificity MAP kinase phosphatase family (Dhillon et al., 2007). There
are 10 members in this family (Theodosiou and Ashworth, 2002), five of which were
differentially expressed in this study (p < 1 x 10−5; Table 2.2). DUSP8, DUSP3,
DUSP7, and DUSP2 were underexpressed, and DUSP6 was overexpressed, indicating
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that the classical MAPK pathway is upregulated in GBM.
2.3.1.4 Focal adhesion is altered in GBM
The results show that genes involved in focal adhesion were differentially expressed
(p < 0.05; Table 2.1). 9 genes encoding integrins and ILK were overexpressed, and
PTK2 was underexpressed. Attachment of cells to extracellular matrix components
results in the clustering of integrins on the cell surface. Integrins are transmembrane
proteins and cytoplasmic parts of clustered integrins recruit cellular proteins such as
adaptor and signaling proteins to the inner surface of the plasma membrane to form
structures called focal adhesions (FAs) (Nagano et al., 2012). The formation and
disassembly of these structures controls migration, proliferation and survival (Mitra
et al., 2005; McDonald et al., 2008). PTK2 encodes Focal Adhesion Kinase (FAK),
which has been shown to have a greater effect on disassembly than on formation
of FAs (Webb et al., 2004; Llıc´ et al., 2002). ILK encodes Integrin-Linked Kinase
(ILK), an intracellular effector of cell-matrix interactions (McDonald et al., 2008).
Strong ILK expression correlates with poor prognosis in prostate cancer (Graff et
al., 2001), non-small cell lung cancer (Okamura et al, 2007; Takanami, 2005) and
pancreatic cancer (Yau et al., 2005). Alteration in focal adhesion, gap junction and
glycosaminoglycan synthesis have been implicated in the modulation of interaction
of glioma cell with extracellular matrix, proliferation and migration of glioma cells
(Mendes de Aguiar et al., 2005).
These findings suggest that JNK pathway, ERK pathway, calcium channels,
and focal adhesion may be useful targets for therapeutic intervention and chemopre-
vention of GBM.
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2.3.2 The derived intracellular GBM network contains functionally
relevant modules
15137 non-silent mutations were found in 282 GBM samples. 12985 of these
were missense, and the remaining 2359 belonged to other categories of non-silent
mutations. The predictions from six algorithms for each of missense mutations
were obtained from the dbNSFP and the number of algorithms that that predicted
a missense mutation deleterious was taken as the score for the mutation. 2359
missense mutations had a score equal or greater than six and mutations in the
other categories were assigned the maximum score, which was 7, resulting in 4511
high impact mutations in 3168 genes. 2654 genes remained after discarding sex-
chromosome genes and those either encoding proteins with more than 5000 amino
acids or extracellular proteins. 199 differentially expressed genes not in the mutated
set and which connected at least two those were added to give 2853 genes for network
construction. The largest component of the constructed intracellular network had
624 genes (nodes) and 3918 edges. Edge-betweenness clustering of this network
produced 14 modules with at least 5 genes each and 133 genes appeared as singletons.
Enrichment analysis on the modules shows that 11 of the 14 modules were
significantly enriched for pathways implicated in cancer (p <= 0.05; Table 2.3).
All the modules except module 1 were altered in at least 5 % of the 282 mutated
samples. Modules 2, 5 and 16 were mutated in 89 %, 39 % and 42 % of the samples,
respectively. Modules 2, 5, and 23 were the top three modules with alterations in
copy number. MTOR pathway, phosphatidylinositol signaling system and inositol
phosphate metabolism form the PIK3/AKT pathway. PIK3/AKT, RB1, p53
pathways, and receptor tyrosine kinase (RTK) pathways were identified as frequently
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altered pathways in GBM (TCGA, 2008). CDK2, CCND3, CCND2, CDKN2B,
CDKN2A, CDK4, RB1 and CDKN2C are in the RB1 pathway but are included
under cell cycle in KEGG. All these genes were found in cell cycle and Module 5
(Table 2.3). Our results are in agreement with those of previous studies on protein
network analysis of altered genes in GBM (Cerami et al., 2010; Wu et al., 2010).
PIK3/AKT and RB1 modules were reported as altered by mutation and in copy
number in GBM by Cerami et al. (2010). Wu et al. (2010) identified alterations
focal adhesion, cell cycle, RTK, and p53 pathways in GBM.
2.3.2.1 Novel signaling pathways were overrepresented in network mod-
ules
Traditional molecular biology experiments involving few genes have identified WNT,
NOTCH, TGF-β and JAK/STAT pathways as having important roles in GBM.
These pathways have, however, not been identified in the computational analyses of
high-throughput data from GBM. Module 2, 5, 16 and 27 were significantly enriched
(p < 0.05; Table 2.3) for WNT pathway. WNT pathway is involved in embryonic
development. Defective WNT pathway is a causative factor in human diseases,
including cancers (Anastas and Moon, 2013; Komiya and Habas, 2008). Expression
of positive regulators and targets of WNT pathways is altered in glioma and GBM
(Wang et al., 2010a). Silencing of β-catenin, Wnt-2, and Pygo-2 in WNT pathway
inhibited the proliferation of GBM U251 cells (Wang et al., 2010a; Pu et al., 2009).
Module 5 and 27 were significantly enriched for the NOTCH signaling path-
way (p < 0.05), which plays a crucial role in proliferation, stem cell maintenance,
embryonic and adult development and self-renewing organs (Lino et al., 2010).
Inhibition of Notch signaling was shown to block growth of GBM cell lines and
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GBM stem cells obtained from a patient (Chen et al., 2010). Module 5 was also
significantly enriched for the TGF-β pathway (p < 0.05; Table 2.3) .The TGF-β
pathway acts a tumour-suppressor or tumour-promoting pathway in cancer. It
suppresses proliferation by inhibiting cell cycle progression, causing apoptosis, and
by maintaining genomic stability (Katz et al., 2013). Augmented expression of
TGF-β in tumours, mostly malignant ones, that have escaped the suppressive effect
of TGF-β pathway can result in tumour progression and metastasis. The mechanism
of tumour promotion are epithelial-to-mesenchymal transition, immune system
evasion and modulation of the tumour microenvironment (Derynck and Akhurst,
2007; Wakefield and Roberts, 2002). Enhanced TGF-β pathway activity promotes
oncogenic capacity (Eichhorn et al., 2012) and increases the self-renewal capacity of
patient-derived glioma-initiating cells (Pen`uelas et al., 2009).
Module 2 was significantly enriched for the JAK/STAT pathway (p < 0.05;
Table 2.3). The JAK/STAT pathway is another important pathway that plays
essential roles in inflammation, proliferation, and invasion/migration (Aggarwal et
al., 2009). STAT-3, a transcription factor and regulator of the JAK/STAT pathway,
is known to be aberrantly activated in GBM (Bowman et al., 2000).
2.3.3 Multiple genes in the GBM network modules accumulated
deleterious mutations
We looked at the occurrence of overall mutations and deleterious mutations in
module genes. Mutations with the scores ≥ 3 (considered deleterious) and found
in any of the module genes were filtered from each mutated sample. Then, the
number of samples bearing these mutations were counted for each module gene.
Table 2.4 shows genes that had these mutations in at least 3 samples. The genes in
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red were previously identified by both frequency-based (TCGA, 2008; Brennan et
al., 2013) and network-based (Cerami et al., 2010) approaches. NF1 and IL18RAP
(in blue) were identified by frequency-based approach alone, and genes were also
identified in this study as mutated driver genes. Genes in purple were identified by
network-based approach alone.
All the previously identified mutated driver genes except RB1 are in module
2. PTEN, TP53, EGFR, NF1, PIK3CA, PIK3R1, RB1, and PDGFRA had the
highest occurrence of overall mutations and deleterious mutations. Nearly 100 % of
the mutations in the genes were deleterious. Module 2 also contained other genes
that have been implicated in cancer, but functional impact mutations were not
found in these. TEK and KDR were identified as likely novel driver genes targeted
by copy number alteration (Cerami et al., 2010), but this study has shown that
the genes could also be targets of functional impact mutations. These two genes
encode cell surface receptors for angiopoietin-1 and Vascular Endothelial Growth
Factor (VEGF), respectively, which are involved in angiogenesis. TEK activation
contributes to angiogenesis and growth in astrocytoma (Zadeh et al., 2004); Slattery
et al. (2014) identified 3 SNPs that are associated with survival after diagnosis with
rectal cancer. The other genes in module 2 that have been implicated in cancer
include MTOR (Guertin et al., 2007; Matsubara et al., 2013), PAK4 (Wong et al.,
2013a; Minden, 2012; Tabusa et al., 2013), TYK2 (Zhang et al., 2011b; Sanda et
al., 2013; U¨bel et al., 2013), and PTPN11 (Chan et al., 2008).
Other modules also contain genes that have been implicated in cancer. These
include checkpoint kinases (CHEK1 and CHEK2 ; Nevanlinna and Bartek, 2006;
Bartek and Lukas, 2003), TP63 (Flores, 2007; Costanzo et al., 2014; Wei et al.,
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2011), TERT (Heidenreich et al., 2014; Vinagre et al., 2013), EP300 (Gayther et al.,
2000; Kim et al., 2013). EP300 regulates transcription via chromatin remodelling
and is involved in proliferation and differentiation (Wallberg et al., 2003; Spin et
al., 2010). TP63, a member of the TP53 family, is involved in tumour suppression
(Flores, 2007; Graziano and De Laurenzi, 2011; Nekulova et al., 2011). Two genes
(NOS2 and NOS1 ) encoding enzymes involved in nitric oxide synthesis were found
to be mutated. Nitric oxide is a free radical involved in both physiological and
pathological processes depending on its concentrations (Alderton et al., 2001).
Studies involving inhibition or genetic deletion of NOSs have shown that NO has
tumour-promoting functions, including proliferation and angiogenesis (Fukumura et
al., 2006; Williams and Djamgoz, 2005).
2.3.3.1 Non-muscle myosin and metabolic genes are mutated in GBMs
Module 10 contains myosin genes that were deleteriously mutated in at least 3 sam-
ples. These genes are MYH8, MYH13, MYH15, MYH6, and MYH4. Myosins are
ATPases that move along actin filaments by coupling ATP hydrolysis to conforma-
tional changes Lodish et al., 2000). Non-muscle myosins are involved in vital cancer
processes, including proliferation and avoidance of growth suppression, replicative
immortality, apoptosis, angiogenesis, inflammation, immune response evasion, and
invasion and metastasis (Ouderkirk and Krendel, 2014). Genes encoding proteins
involved in glucose and lipid metabolism are found in module 9. ACACB and
ACACA encode two isoforms of acetyl-CoA carboxylase. Acetyl-CoA carboxylase
catalyses the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in
fatty acid synthesis. PCK1 encodes phosphoenolpyruvate carboxykinase, the enzyme
that catalyses the conversion of oxaloacetate to phosphoenolpyruvate. This is a rate-
limiting step in gluconeogenesis. SLC2A1 encodes GLUT1, a facilitative glucose
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transporter responsible for the constitutive glucose uptake. Tumour cells have been
shown to reprogram metabolic pathways to their need during tumour progression
(Cairns et al., 2011). A shift from ATP synthesis through oxidative phosphorylation
to ATP synthesis through glycolysis is the best characterized metabolic adaptation
in tumour cells, and a shift is called Warburg effect (Warburg, 1956). Our results
therefore suggest that glucose and lipid metabolic pathways could be therapeutic
targets for GBM.
2.3.4 Rare mutated genes in modules drive GBM without functional
impact mutations in frequently altered GBM pathways
Genes in RTK, PIK3/AKT, cell cycle (RB1) and p53 pathways are frequently
mutated in GBM (TCGA, 2008). To search for mutated driver genes not in these
pathways, all genes in these pathways were extracted from a Cytoscape network file
provided by MSKCC. Each mutation give a score equal to the number of algorithms
that predicted it deleterious if missense or maximum score (7) if it belongs to other
categories of potentially deleterious mutations. Samples having mutations with
scores ≥ 3 in any of the genes in the pathways were removed. We then search
the remaining mutated samples for genes altered by mutations with scores ≥ 5
and found in any of the identified network modules. A score ≥ 5 were predicted
deleterious by 5 or more algorithms. 49 genes were identified and listed in Table
2.5 with the modules containing them. Only ABL1 has been reported as mutated
driver gene in GBM. ABL1 is protooncogene which encodes a non-receptor tyrosine
kinase. This kinase has been implicated in cell differentiation, cell division, cell
adhesion and stress response. ABL1 was first identified as an oncogene required
for the development of leukaemias (Greuber et al., 2013). ABL1 had two missense
mutations, one of them was predicted deleterious by all the algorithms. Mutations
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in this gene was reported in gliomas by Kesari et al. (2014). Most of these
genes have been implicated in cancer, but detected in this study as new candidate
mutated drivers in GBM. They were not detected by frequency-based significance
test methods or previous pathway-based analysis. These genes include DNM2,
EPHB1, LPAR3, STAT3, STAT5B, LPAR3, BARD1, GOLGA2, MYC, PTPN11,
and MAX. DNM2 is a regulator of endocytosis, and its levels are decrease during
hypoxia (Joshi et al., 2014). EPHB1 encodes protein which belongs to the family
of Eph receptors and is a tyrosine kinase receptor. Overexpression of this gene
negatively regulates glioma cell invasion (Teng et al., 2013). LPAR3 encodes a G
protein-coupled receptor for Lysophosphatidic acid (LPA). LPAR3 participates in
proliferation, growth, survival, invasion, and promotion of angiogenesis (Gardell et
al, 2006; Rivera and Chun, 2008). LPA stimulates migration of oral carcinoma cells
through LPAR3 (Brusevold et al., 2014). STAT3 is an oncogene and transcription
factor in the JAK/STAT pathway. Activating mutations in this gene have been
shown to be rare in cancers (Lui et al., 2014). One sample in our study had
mutation in STAT3 predicted deleterious by all the algorithms. STAT5B was
altered in one sample by frameshift deletion. Depletion of STAT5B expression with
siRNA in GBM cells shows that STAT5B is involved in GBM cell growth, cell cycle
progression, invasion and migration (Liang et al., 2009). BRCA1 Associated RING
Domain 1 (BARD1 ) gene encodes a protein which interacts with the N-terminal
region of BRCA1. BRCA1-BARD1 complex, a tumour suppressor in breast and
ovarian cancers, plays a role in the control cell cycle in response to DNA damage
(Baer and Ludwig, 2002; Ratajska et al., 2012). A sample was identified in this
study with deleterious mutation in BARD1 but with no other deleterious mutations
in frequently altered GBM pathways. Golgin A2 (GOLGA2 ) gene encodes a protein
that is involved in glycosylation and transport of proteins and lipids in the secretory
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pathway. GOLGA2 plays an important role in angiogenesis, invasion and tumour
progression in lung cancer animal model and cell line (Chang et al., 2012). V-Myc
Avian Myelocytomatosis Viral Oncogene Homolog (MYC ) is a transcription factor
and known oncogenes in most cancer (Vita and Henriksson, 2006). MYC inhibi-
tion reduces proliferation and increases apoptosis in gioma cells (Annibali et al., 2014)
PSMC1, CAMK4, and ACACB have not been previously implicated in can-
cer. ACACB and ACACA encode acetyl-CoA carboxylase, a metabolic enzyme
which catalyses the rate-limiting step in fatty acid synthesis. The gene was mutated
in 8 samples, 5 of which had mutations predicted deleterious by 5 or more algorithms.
ACACA is upregulated in multiple cancer types, and is being considered as a novel
target for cancer therapy (Wang et al., 2010b). IDH1 and IDH2 that encode
isoforms of the metabolic enzyme isocitrate dehydrogenase have been identified as
driver genes and are mutated in more than 50 % of GBMs (Yan et al., 2009; Dunn,
2013, Brennan et al., 2013). This suggests that additional metabolic enzyme genes
may be drivers in GBM. PSMC1 encodes one of the ATPase subunits of the 26S
proteasome, which is involved in the ATP-dependent degradation of ubiquitinated
proteins (Tsvetkov et al., 2014).
These results suggest that infrequently mutated genes are as important as the
frequently mutated ones in tumorigenesis and should, therefore, not be discarded.
Algorithms for assessing functional impact of mutations should be used in the
selection of both rarely and frequently mutated genes for network-based driver gene
detection analysis.
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2.3.5 Network selected functionally relevant genes in copy number
altered chromosomal regions
Copy number alteration is a common event in human cancer and altered regions
could be a focal or broad event, depending on the length and number of genes in the
regions (Beroukhim et al., 2007). A focal copy number event affects few genes, and
in broad copy number events, regions near the size of a chromosome arm are deleted
or amplified. The challenge with frequency-based significance methods for copy
number alteration is the identification of functionally important genes from hundreds
of genes in broad altered regions. In this study, a gene in a copy number altered
region had to satisfy one of two conditions to be regarded as functionally important
in cancer. First, the gene must be in homologous deleted or high-level amplification
region. Second, the gene had to be found in our intracellular network or have any
of the network genes as an interacting partner in the functional interaction data
set. Functionally relevant genes were also limited to those encoding intracellular
products alone.
Chromosomal regions with mean log2 signal ratios ≥ 1.2 (high-level amplifica-
tion) or ≤ -1.2 (homologous deletion) were filtered from GBM samples with copy
number data. log2 signal ≥ ratio means that there 4 or more copies of an altered
region, and log2 ratio ≤ means that both copies of the region are deleted. Ref
genes that fell within the filtered regions were extracted for each sample. The genes
that were found in the network or having any of the network genes as targets were
filtered. The number of samples in which a gene was altered was counted and a total
of 6107 genes were in the altered regions. 89 genes altered in at least 3 samples were
identified as functionally relevant: 49 were found in the intracellular network (Table
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2.6), and 35 had network genes as interaction targets (Table 2.7). The genes shown
in red were amplified, and those in blue were deleted.
The amplified genes identified by the frequency-based method (TCGA, 2008;
Brennan et al., 2013) and in this study are EGFR, CDK4, PDGFRA, MDM2,
MDM4, MET, CDK6, PIK3CA, MET, and AKT3. The deleted genes are CDKN2A,
CDKN2B, PTEN, CDKN2C, RB1, CCND2, TP53, PIK3C2B, and NF1. AGAP2,
TEX, and KIT were first identified as novel copy number altered genes in GBM by
a network-based analysis (Cerami et al., 2010).
Novel copy number altered candidate genes were discovered in this study.
Those amplified include SKP1, PTPRB, PTPRR, IRAK3, EIF4G1, DVL3, STAT3,
and NAIP. NAIP encodes a member of the inhibitor of apoptosis proteins and
is located in 5p13.2. High-level amplification of NAIP occurred in 11 samples.
NAIP is overexpressed in breast cancer patients that showed unfavourable clinical
features (Choi et al., 2007) and in prostate cancer cell line (Nachmias et al., 2004).
DVL3 is located in 3q27 and encode Dishevelled protein which plays essential
role in WNT signaling. DVL3 is upregulated and correlates with Wnt/β-catenin
activity in cervical cancer (Kwan et al., 2013). SKP1, amplified in 10 samples,
encodes an essential component of the SCF (SKP1-CUL1-F-box protein) ubiquitin
ligate complex, which mediates the ubiquitination of proteins involved in cell cycle
progression, signal transduction and transcription. It has been shown that SCF
complex is involved in the regulation of Glioma stem cell fate by NUMB (Jiang
et al., 2012). There was high-level amplification of PTPRB and PTPRR in 7 and
9 samples, respectively. Both genes are located in 12q15. Epigenetic silencing
of PTPRR shows that it inhibits MAPK signaling and has an important role in
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metastasis in cervival cancer (Su et al., 2013). The roles of PTPRB and PTPRR
amplification should be further investigated in GBM.
Homologous deletion of PRKG1 and CTNNA3 in 12 and 6 samples, respec-
tively, were detected as novel copy number altered genes in GBM. PRKG1 is located
in 10q11.2 and encodes type I cGMP-dependent protein kinase (PKG-1). Gain-
of-function mutation in PRKG1 is identified as a cause of thoracic aortic disease
(Guo et al., 2013a), but it is yet to be implicated in cancer. CTNNA3, located in
10q22.2, encodes α-catenin, a protein that plays role in cell-cell adhesion in muscle
cells. CTNNA3 is a frequently mutated gene and has been identified as a potential
tumour suppressor in Laryngeal squamous cell carcinoma (Fanjul-Ferna´ndez et al.,
2013).
2.3.6 Altered subnetwork represents vital cancer signaling pathways
All altered genes Tables 2.4, 2.5, 2.6 and 2.7 were pooled. The genes in each table were
altered in at least three samples. Genes mutated in 2 or less than samples, having
mutations predicted deleterious by at least 6 algorithms, and linking two or more
genes in the pooled list were added to the list. The subnetwork of these altered genes
is shown in Figure 2.5, consisting of 238 genes and 1085 interactions (edges). The
subnetwork consists of major cancer-related pathways, of which MAPK, p53, WNT,
RB1, apoptotic and G protein-couple receptor signaling pathways and calcium ion
metabolism are shown in the Figure. V-Akt Thymoma Viral Oncogene Homologs
1 (AKT) and 3 (AKT3) , known oncogenes, appear to separate the subnetwork
into two halves. Activated AKTs promote cell cycle progression and proliferation,
increase nutrient status of the cells, inhibit apoptosis, and play a significant role in
progression to more advanced aggressive tumours (Madhunapantula and Robertson,
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2009). AKT’s positions in the network suggests that they play a critical role in GBM
progression and pathogenicity.
2.3.7 Biologically important co-expressed modules were enriched
for transcription factor targets
Co-expression and transcription factor target enrichment analyses were done in
subtype-specific manner. Verhaak et al. (2010) classified 200 GBM samples into four
subtypes based their gene expression profiles. The subtypes are Proneural, Neural,
Mesenchymal and Classical. The 840 signature genes for these subtypes were used
to classify additional 342 GBM samples into one of the subtypes using single-sample
gene set enrichment analysis (Brennan et al., 2013). Samples and their subtypes
obtained from (Brennan et al., 2013) was used for this analysis. 144, 155, 83,
and 137 samples were in Classical, Mesenchymal, Neural and Proneural subtypes,
respectively. We started by selecting genes for co-expression analysis. Intracellular
GBM network genes and genes having interaction with the network genes were
pooled. Genes with variable expression values (MAD ≥ 0.5) across samples in
each subtype were used for subtype-specific co-expression analysis. 533, 881, 625,
693 genes met the MAD cut-off in Classical, Mesenchymal, Neural and Proneural
subtypes, respectively. Co-expression modules with 20 or more genes were considered.
Modules in each subtype were significantly enriched for biological processes (p
< 0.05), except for module 4 in Proneural (Table 2.8). Cell cycle, DNA repair, cell
proliferation, DNA damage checkpoint, immune response, inflammatory response
and chemotaxis (cell migration) were common biological process in all subtypes.
Neurogenesis and neuronal differentiation were found in all subtypes, except the
Classical subype. Neural precursor and stem cell marker NES and developmental
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genes in Notch (NOTCH3, JAG1, LFNG) and in Sonic hedgehog (SMO, GAS1,
GLI2 ) signaling pathways were highly expressed in the Classical subtype (Verhaak
et al., 2010). This suggests that tumours in the Classical subtype arise from undiffer-
entiated cells and does not involve the reversal of differentiation for its development.
Neurotransmitter transport was enriched in the Proneural and Neural subtypes,
suggesting that this process is retained during tumour progression from cells of origin.
Transcription factor target enrichment analysis was performed on every mod-
ule in each subtype. The transcription factors for the significantly enriched targets
(p < 0.05) are shown in Table 2.8. E2F3 and NFYB targets were found in all
subtypes and in modules enriched for cell cycle. E2F3 encodes a protein that
interacts directly with the retinoblastoma protein to regulates the expression of
genes involved in the cell cycle. It is overexpressed in cancer (Foster et al., 2004;
Vimala et al., 2012; Feber et al., 2003). Module 3 in the Proneural subtype
were enriched in the targets for FOXO1, POU2F1, CEBPA and EGR2. Only
POU2F1 had targets in Module 5 in the Neural subtype. Modules 3 in Proneural
and 5 in Neural contained genes that are involved in neurogenesis and neuronal
differentiation. FOXO1 encodes a member of the forkhead family of transcription
factors. Forkhead box O genes are involve in cell fate determination and regulation
of apoptosis (Fu and Tindall, 2008; Zhang et al., 2011c). POU2F1 encodes the
OCT1 transcription factor, member of the POU transcription factor family. OCT1
has been shown to regulate the stem cell phenotype (Maddox et al., 2012) and the
expression of the developmental genes HOXD10 and HOXD11 in Head and Neck
cancer (Sharpe et al., 2014). CEBPA is downregulated in Acute Promyelocytic
Leukamia (Santana-Lemos et al., 2011) and mutated in approximately 5-14 % of
acute myeloid patients (Mueller and Pabst, 2006). EGR2 is encode a transcription
 
 
 
 
CHAPTER 2 Conclusion 86
factor with three zinc finger domains, which EGR2 induces apoptosis in various cell
lines by transactivating the expression of its target anti-apoptotic proteins, BNIP3L
and BAX (Unoki and Nakamura, 2003). Module 2 in the Proneural, Module 1 in the
Neural, and Modules 2 and 5 in the Mesenchymal subtypes were enriched in targets
for transcription factors that participate in immune and inflammatory responses.
These transcription factors are RELA, NFKB1, IRF1 and STAT5B (Oeckinghaus
and Ghosh, 2009; Caaman˜o and Hunter, 2002; Grivennikov et al., 2010; Yu et al.,
2009; Eckhardt et al., 2014).
2.4 Conclusion
Network-based methods for cancer driver gene identification in high-throughput
data has the advantage of identifying both frequently and infrequently altered
genes. Genes that, however, do not interact physically or functionally with other
genes cannot be identified. Integrating network-based and frequency-based sta-
tistical approaches would improve the identification of relevant genes that drive
tumorigenesis. The accuracy of network-based methods depends on the quality of
the protein-protein interaction data used. The interaction data used in this study
was derived from annotated signaling pathways that satisfied a number of criteria,
including known interactions between orthologs of human genes. We believe the
data is suitable for the purpose of biological network construction.
This study identified novel driver genes as well as pathways that were not identified
in previous frequency-based and network based studies. The identified pathways
have previously been implicated by traditional molecular biology experiments as
having a crucial role in GBM and other cancers. They include WNT, NOTCH
and TGF-β signaling pathways. We also introduced a novel method to lessen the
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burden of identifying functionally important genes in copy number altered regions of
chromosomes. Our network-based gene selection considerably reduced the number
of genes used in co-expression and transcription factor target enrichment analyses.
Identified transcription factors regulating the cell cycle, neuronal differentiation, and
immune and inflammatory response in the four subtypes of GBM could potentially
be exploited in designing subtype-specific drugs .
Detailed molecular mechanisms driving glioblastoma multiforme have been
proposed, which can be exploited for the development of molecularly targeted
therapy and in the designing of GBM patient-specific diagnosis and treatment
programs.
Deregulated miRNAs that target genes in the GBM network identified here
are reported and discussed in the next Chapter.
 
 
 
 
Chapter 3
Identification of differentially
expressed miRNAs and their
target genes in the altered
glioblastoma multiforme
network
Abstract
Background: miRNAs are small non-coding RNAs of 18-25 nucleotides that
interact with mRNAs, inducing their degradation and translational repression.
Expression of specific oncogenic and tumour suppressing miRNAs targeting cancer-
related pathways are deregulated in cancer. We aimed to identify deregulated
miRNAs that target genes in our constructed altered glioblastoma multiforme
(GBM) network that we found to be significantly differentially expressed.
Methods: Differential miRNA expression analysis was carried out on 10 non-
neoplastic brain and 25 GBM samples profiled at the same time in a single
experimental batch. To obtain miRNA targets among the differentially expressed
genes associated with the intracellular GBM network obtained in Chapter Two,
consensus miRNA-target gene interactions predicted by both TargetScan and
miRanda algorithms were compiled. The targets for each deregulated miRNA were
identified and underexpressed miRNA-overexpressed target gene and overexpressed
88
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miRNA-underexpressed target gene networks were constructed. The miRNAs tar-
geting each differentially expressed genes were also counted. Multivariate regression
was used to assess the combined effect of miRNAs on the expression of their target
genes. Enrichment analysis was performed to identify pathways statistically enriched
with miRNA targets in the networks, and the number of miRNAs that targeted each
pathway were counted.
Results: 94 miRNAs were differentially expressed with fold change ≥ 1.5 or ≤ -1.5
between GBM and non-neoplastic brain samples (p < 0.0001). 70 of these targeted
261 of 649 differentially expressed genes associated with the altered GBM network.
18 miRNAs were not previously identified as differentially expressed in GBM. The
underexpressed miRNA-overexpressed target gene network had 231 edges formed
from 32 miRNAs and 147 target genes. The overexpressed miRNA-underexpressed
target gene network had 556 edges formed from 38 miRNAs and 147 target genes.
hsa-miR-23-3p was significantly underexpressed (p < 0.0001) in GBM compared
to non-neoplastic brain samples and had the highest number of targets (21). 85
significantly underexpressed and 35 significantly overexpressed genes (p < 0.00001)
had at least 5 and 3 targeting miRNAs each, respectively. hsa-miR-30a-5p and
hsa-miR-23b-3p targeted the highest numbers (37 and 21). ANK3 and PHLPP2
were the most targeted underexpressed genes, and NFIX and VEGFA were the most
targeted overexpressed genes. Over 10 % of the variance in expression of CDK2R1,
WASF1 and PPMID was due to their targeting miRNAs. MAPK signaling pathway
was the most targeted of the 53 pathways enriched with miRNA targets from the
networks. WNT, NOTCH, ErbB, and mTOR signaling pathways were also targeted.
Conclusion: The findings show that miRNA deregulation are as important in the
development and progression of GBM as mutation and copy number alteration. The
miRNAs in the regulatory networks that target multiple pathways are also strong
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candidates for targeting in the therapeutic intervention in GBM.
3.1 Introduction
MicroRNAs (miRNAs) are small non-coding RNAs of 18-25 nucleotides that interfere
with mRNA translation. The position 2-8 (called the seed region) from 5’ the end
of an miRNA base pairs with the 3’ untranslated regions of its target mRNAs,
inducing their destabilisation and translation inhibition (Filipowicz et al., 2008).
There is also evidence that miRNAs can bind to sites within the coding regions or
5’ untranslated regions of mRNAs, and target sites have been found in the coding
regions (Hausser et al., 2013; Ott et al., 2011; Qin et al., 2010) and 5’ untranslated
regions (Lytle et al., 2007; Xu et al., 2014a; Hsu et al., 2011) of mammalian mRNAs.
Several miRNAs are involved in the processes that characterise cancer. These
include self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion
of apoptosis, limitless replicative potential, angiogenesis, invasion and metastasis
(Hanahan and Weinberg, 2011; Lages et al., 2012). Genes in the pathways that
regulate these processes are miRNA targets. miR-7-3, miR-34a, miR-181d, and
miR-193b were found to be associated with MAP2K, a protein kinase in MAPK
signaling pathway, in human pancreatic cancer (Ikeda et al., 2012). miR-524-5p
targets MAPK /ERK pathway by suppressing the expression of BRAF and ERK2
(Liu et al., 2014a). The regulators of the cell cycle are also targets for several
miRNAs. mir-15a-16-1 cluster may induce cell cycle arrest by targeting CDK1,
CDK2 and CDK6 as well as cyclins. CDC25A, which encodes phosphatase that
removes inactivating phosphates from CDKs, is targeted by let-7 family members,
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miR-125b, miR-322/424, miR-503 and miR-499a/449b in cancers including breast,
prostate, lung, glioblastoma and ovarian cancers (Bueno and Malumbres, 2011).
When miRNAs are deregulated in cancer, their oncogenic-like features are ei-
ther elevated or their tumour suppressor-like function are repressed. Overexpression
resulting from amplification and loss of normal repressive epigenetic marks result
in up-regulation of oncogenic miRNAs (Jansson and Lund, 2012). let-7a-3 was
up-regulated in a lung cancer cell line from which both DNA (Cytosine-5-)-
Methyltransferase 1 (DNMT1) and DNA (Cytosine-5-)-Methyltransferase 3 Beta
(DNMT3B) had been knocked out compared to wild type and in lung (Brueckner et
al., 2007) samples from adenocarcinoma patients compared to normal lung tissues
with hypomethylation of the miRNA from the same patients. Overexpression of
let-7a-3 by transfection resulted in up-regulation of oncogenic genes, suggesting
that this miRNA functions as oncogene in lung cancer (Brueckner et al., 2007).
Mechanisms of down-regulation of tumour suppressor miRNAs include loss of
acetylation, aberrant DNA hypermethylation, repression by transcription factors,
and loss of tumour suppressor transcription factors (Jansson and Lund, 2012).
MYC, a known oncogenic transcription factor, represses miRNAs with documented
tumour suppressor activity, including let-7 family members, miR-15a/16-1, miR-26a,
miR-29 family members, and miR-34a (Bui and Mendell, 2010). TP53, a tumour
suppressor inactivated in many cancers, regulates the expression of miR-34 family
members, which are known to promote apoptosis, cell cycle arrest and senescence
(Chang et al., 2007; Corney et al., 2007; Raver-Shapira et al., 2007).
In this Chapter, we identified differentially expressed miRNAs between GBM
and non-neoplastic brain tissue. Using miRNA-target gene interaction data pre-
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dicted by TargetScan and Miranda, the differentially expressed genes associated
with the altered intracellular GBM network obtained in Chapter Two targeted by
the differentially expressed miRNAs were obtained. These were used to construct
underexpressed miRNA-underexpressed target gene and overexpressed miRNA-
overexpressed target gene networks. Finally, enrichment analysis was done to
identify pathways enriched with the miRNA target genes in the two networks.
3.2 Methods
3.2.1 Generation of consistent names for miRNAs
Ambiguity in the identifiers used for miRNAs in publications has led to inconsistent
names for miRNAs in different databases. Different names could refer to the same
miRNA, some names are old and obsolete (Vergoulis et al., 2015; Van Peer et al.,
2014). For example, human mature hsa-miR-34b was called microRNA-34b in Corney
et al. (2007) and miRNA-34b in Balc¸a-Silva et al. (2012). To avoid loss of data and
irregularity in analyses due to this, consistent identifiers were generated for human
mature miRNA sequences. A Fasta file containing all mature miRNAs deposited
in the mirBase database was downloaded from http://www.mirbase.org/ftp.shtml.
miRBase, established in 2002, is the public repository for all published miRNA se-
quences and their annotations (Kozomara and Griffiths-Jones, 2014). The file con-
tained 35828 miRNA sequences and their annotations. All human mature miRNA
sequences in the file were selected. miRNA profiling of samples used in this study
was done on H-miTNA 8x15K and the required probe sequences were downloaded
from TCGA. To map probe names to a mature miRNA miRBase identifier, a python
script was written. The reverse complements of these probe sequences were generated
and transcribed. The identifier of an miRNA sequence to which the transcribed
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Figure 3.1: Flowchart for miRNA analysis in glioblastoma multiforme
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sequence perfectly matched and the corresponding miRNA were obtained. Probe
names that mapped to more than one miRNA identifier were removed and a single
identifier used.
3.2.2 Differential miRNA expression analysis
Level 2 miRNA files for 566 GBM samples and 10 non-neoplastic brain samples were
downloaded from the TCGA data portal. A level 2 dataset for miRNA contains
quantile normalized log2 signal ratio (summarized expression value) per probe for
each participant’s tumour sample. The files were combined into a matrix containing
probe names as rows and sample barcodes as columns. The probe names in the matrix
were changed to our miRNA identifiers. When two or more probes mapped to the
same miRNA, the median miRNA expression value was used. Expression analysis was
performed on the 25 GBM and 10 normal samples in Batch 8 to avoid the batch effect.
Differentially expressed miRNAs between tumour and non-neoplastic brain samples
(control) were identified using Significant Analysis of Microarray (SAM; Tusher et
al., 2001) and a threshold ∆ of 3.
3.2.3 Compilation of predicted miRNA targets
Predicted miRNA targets were generated by combining two predicted miRNA
target data sets from TargetScan (Friedman et al., 2009; Grimson et al., 2007) and
microRNA.org (Betel et al., 2008; John et al., 2004). These sources were chosen
because they provided miRNA sequences in their data sets, which made it possible
to generate common identifiers for the sequences provided. These databases used
different algorithms to predict the miRNA targets in their data sets. TargetScan
used the TargetScan software developed by Lewis et al. (2005), which uses a
conserved miRNA seed (2-8 bases, numbered from the 5’ end) in multiple organisms
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to search for perfect Watson-Crick complementarity for the seed in a set of 3’ UTR
sequences from these organisms. It does the search on a set of 3’ UTRs from one
organism at a time and then assigns a folding free energy to all miRNA-target site
interactions in each UTR. A score is generated that combines all the free energies for
each UTR. A gene is predicted as a target is it score is above a pre-chosen threshold.
microRNA.org uses the miranda algorithm developed by Enright et al. (2004), which
scans all available miRNA sequences for a given genome against 3’ UTR sequences
of that genome. It scores based on complementarity of nucleotides between miRNA
and UTR. It then generates a duplex by using a linker to join the miRNA and 3’
UTR sequences from the hybridization alignment. The strength of the duplex is then
estimated thermodynamically using a secondary structure programming library. A
candidate target must have a complementarity score greater than 90 and minimum
free energy lower than -17 kcal/mol (John et al., 2004). Since the approaches used
by the sources of the data sets are different, we intersected these data sets to reduce
the number of false positives.
Files containing predicted targets of human conserved and non-conserved miR-
NAs were downloaded from http://www.microrna.org/microrna/getDownloads.do
and combined into a single file. There were 717 unique miRNA sequences
and 17647 predicted targets in the combined file. The target gene symbol,
miRNA sequence columns in the file were extracted. TargetScan file of predicted
targets of conserved miRNAs was obtained from http://www.targetscan.org/cgi-
bin/targetscan/data download.cgi?db=vert 61. This file contained 687 unique
miRNA sequences and 12200 predicted target genes. The target gene symbol,
miRNA sequence columns in the file were extracted. The file obtained in Section
3.2.1, filtered TargetScan file and filtered microRNA.org file were merged on the
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miRNA sequence column common to the three files and used to obtain targets of
differentially expressed miRNAs in this present study.
3.2.4 Target genes of differentially expressed miRNAs
The intracellular GBM network genes and 3417 differentially expressed genes in Chap-
ter Two were used in this analysis. Two sets of differentially expressed genes were
generated. One set contained differentially expressed genes in the intracellular GBM
network. The other set contained differentially expressed genes that interacted with
at least one gene in the intracellular GBM network. The two sets were combined into
a single set of unique genes. The following conditions were used to extract differen-
tially expressed miRNAs targeting these genes from the merged file of miRNA-target
gene interactions:
1. miRNA-target gene interaction in which both miRNA and gene were statisti-
cally differentially expressed with a fold change equal or greater than 2 (overex-
pressed) and a fold change equal or less than 0.5 (underexpressed), respectively.
2. miRNA-target gene interaction in which miRNA and gene were statistically
differentially expressed with a fold change equal or less than -2 (underexpressed)
and a fold change equal or greater than 2 (overexpressed), respectively.
The genes targeted by each differentially expressed miRNA in the extracted
miRNA-target gene interactions were counted. Pathway enrichment analysis on was
done on the target genes using KEGG pathway gene sets and 12161 genes with
gene-centric expression data generated in Chapter Two. The detailed explanation
for pathway enrichment analysis is provided in Chapter Two. The number of
miRNAs targeting each significantly enriched pathway was also counted. Gephi
(Bastian et al., 2009) was used to draw two miRNA regulatory networks: one for
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underexpressed miRNA and overexpressed genes, and the other for overexpressed
miRNA and underexpressed genes.
The miRNAs targeting DE genes were counted. The multivariate linear re-
gression was used to determine the effect of the expression of multiple targeting
miRNAs on target gene expression. In the multivariate regression model, the
dependent variable is described as a linear function of the independent variables xi,
as follows:
y = a+ β1 ∗ x1 + β2 ∗ x2 + ...+ βn ∗ xn,
where βi is the regression coefficient of each independent variable xi, and a is the
y-intersect of the regression line. y in the equation was mRNA expression and xi was
a targeting miRNA expression.
3.3 Results and Discussion
In this Chapter, differentially expressed miRNA between normal (control) and 25
tumour samples are reported. The target mRNAs of these miRNA and pathways
significantly enriched in these mRNAs were identified. Finally, miRNA regulatory
networks were constructed for underexpressed miRNAs and overexpressed mRNAs,
and for overexpressed miRNAs and underexpressed mRNAs.
3.3.1 Differentially expressed miRNAs had GBM altered network-
associated genes as predicted targets
Expression values for 387 human mature miRNAs were generated from summariza-
tion of Level 2 miRNA expression data. Since batch effect confound differential
expression analysis and is difficult to remove completely (Buhule et al., 2014), we
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limited the analysis to Batch 8 containing 10 non-neoplastic brain and 25 tumour
samples. Also, only this batch had non-neoplastic brain samples, which could be used
as reference. At ∆ = 3, the FDR was 3.54 x 10−4 and the number of significantly
differentially expressed miRNAs was 154. 94 of these miRNAs had fold changes ≥
1.5 or ≤ 0.67. 51 miRNAs were underexpressed and 43 were overexpressed.
3.3.1.1 Differentially expressed miRNAs and numbers of targeted genes
9889 genes were predicted as targets for 248 miRNAs by both TargetScan and
miRanda predictions tools. The predicted target genes and their targeting miRNAs
gave 83197 miRNA-target gene interactions. In this study, a gene was said be a
predicted target of an miRNA if the gene was predicted as target for the miRNA
by both TargetScan and miRanda, found in or directly interacted with any of
the intracellular network genes, and was significantly differentially expressed (p <
0.00001) with a fold change ≥ 1.5 or ≤ 1.5.
Table 3.1 shows the DE miRNAs that had at least one target gene associated
with the altered GBM network. The miRNAs in red were first identified as differen-
tially expressed in our study. Four underexpressed miRNAs had at least 10 target
genes each, with hsa-miR-23b-3p having the highest number of predicted target
genes. 21 overexpressed miRNAs had at least 10 target genes each. Four (hsa-miR-
20b-5p, hsa-miR-424-5p, hsa-miR-195-5p, hsa-miR-19b-3p) of the miRNAs were not
identified as DE miRNAs in previous studies. hsa-miR-20b-5p, hsa-miR-424-5p,
hsa-miR-195-5p, hsa-miR-19b-3p had 28, 21, 21, and 19 target genes, respectively.
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Table 3.1: Differentially expressed miRNAs that targeted at least one pre-
dicted gene associated with the GBM altered network
miRNA1 Fold Change # of Targets2 miRNA1 Fold Change # of Targets
Underexpressed Overexpressed
hsa-miR-23b-3p -1.53 21 hsa-miR-30a-5p 2.15 37
hsa-miR-29a-3p -1.73 19 hsa-miR-106b-5p 3.78 33
hsa-miR-29b-3p -3.19 19 hsa-miR-93-5p 2.93 31
hsa-miR-29c-3p -3.37 17 hsa-miR-20a-5p 2.76 29
hsa-miR-381-3p -2.05 16 hsa-miR-20b-5p 1.87 28
hsa-miR-137 -13.02 12 hsa-miR-27a-3p 6.42 27
hsa-miR-410-3p -4.82 10 hsa-miR-23a-3p 5 24
hsa-miR-129-5p -9.25 10 hsa-miR-15b-5p 3.43 23
hsa-miR-758-3p -1.86 9 hsa-miR-497-5p 1.89 22
hsa-miR-433-3p -2.07 8 hsa-miR-16-5p 2.45 21
hsa-miR-218-5p -9.99 8 hsa-miR-424-5p 2.43 21
hsa-miR-132-3p -4.28 7 hsa-miR-195-5p 2.48 21
hsa-miR-138-5p -5.3 7 hsa-miR-92a-3p 2.56 20
hsa-miR-133b -1.57 6 hsa-miR-92b-3p 2.25 20
hsa-miR-103a-3p -1.99 6 hsa-miR-25-3p 3.96 20
hsa-miR-107 -2.02 6 hsa-miR-19a-3p 2.01 19
hsa-miR-221-3p -1.75 5 hsa-miR-19b-3p 2.11 19
hsa-miR-125a-5p -1.59 5 hsa-miR-130b-3p 2.7 19
hsa-miR-219a-5p -10.15 5 hsa-miR-15a-5p 2.84 17
hsa-miR-7-5p -10.6 5 hsa-miR-130a-3p 1.98 16
hsa-miR-328-3p -1.49 4 hsa-miR-148a-3p 2.99 13
hsa-miR-377-3p -2.85 4 hsa-miR-24-3p 1.73 8
hsa-miR-33a-5p -2.12 4 hsa-miR-21-5p 26.62 8
hsa-miR-149-5p -3.89 4 hsa-miR-590-5p 1.59 7
hsa-miR-490-3p -1.5 4 hsa-miR-193a-3p 2.18 7
hsa-miR-504-5p -1.76 2 hsa-let-7i-5p 2.39 7
hsa-miR-154-5p -1.57 2 hsa-miR-10b-5p 4.42 6
hsa-miR-329-3p -2.05 2 hsa-miR-10a-5p 1.74 5
hsa-miR-411-5p -1.92 1 hsa-miR-196b-5p 2.03 4
hsa-miR-379-5p -3.55 1 hsa-miR-18a-5p 1.73 4
hsa-miR-485-5p -1.56 1 hsa-miR-142-3p 3.43 4
hsa-miR-383-5p -2.55 1 hsa-miR-155-5p 3.6 4
hsa-miR-196a-5p 1.99 3
hsa-miR-146b-5p 1.8 3
hsa-miR-28-5p 1.53 2
hsa-miR-339-5p 2.03 2
hsa-miR-100-5p 1.73 1
hsa-miR-210-3p 4.09 1
miRNAs are arranged according to the numbers of target genes they had in the altered GBM network.
1 Significantly differential expressed miRNAs with p < 0.0001 and fold change ≥ 1.5 or ≤ 1.5.
2 Targets were significantly differentially expressed genes p < 0.00001 and had fold change ≥ 1.5 or ≤ -1.5.
miRNAs in red were first identified in this study as significantly differentially expressed miRNAs in GBM.
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Table 3.2: Top altered GBM network-associated genes targeted by DE
miRNAs
Gene1 # of miRNAs2 p∗ R2∗ Gene1 # of miRNAs2 p∗ R2∗
Underexpressed genes3 targeted by Overexpressed genes targeted4 by
overexpressed miRNAs underexpressed miRNAs
ANK3 14 9.74E-13 0.158 NFIX 7 1.65E-07 0.084
PHLPP2 12 2.74E-06 0.091 VEGFA 6 1.68E-12 0.122
PAFAH1B1 11 7.06E-02 0.036 SPRY1 6 4.17E-01 0.012
NLK 10 1.35E-15 0.166 NOTCH2 6 8.27E-01 0.006
KALRN 10 2.27E-09 0.113 PPM1D 5 2.20E-16 0.179
BMPR2 10 3.84E-08 0.101 COL5A1 5 3.08E-07 0.072
WWP1 9 3.06E-05 0.069 COL1A2 5 2.00E-05 0.056
SYNJ1 9 3.59E-14 0.150 YES1 4 2.46E-01 0.011
RAPGEF2 9 2.73E-04 0.059 TOP1 4 8.10E-07 0.064
ERBB3 9 3.23E-09 0.107 TGFB2 4 7.72E-01 0.004
EGR3 9 2.19E-07 0.090 STAT3 4 6.42E-04 0.037
TSC1 8 5.50E-06 0.073 LPP 4 1.69E-10 0.096
TIAM1 8 1.77E-08 0.097 GNG12 4 7.50E-03 0.027
NEDD4L 8 1.91E-10 0.114 COL5A2 4 8.36E-05 0.046
MYO5A 8 1.70E-07 0.087 COL4A1 4 5.67E-02 0.018
CLOCK 8 3.32E-04 0.055 ZYX 3 4.36E-03 0.026
ATP2B2 8 8.67E-02 0.027 WEE1 3 2.91E-11 0.096
SYT1 7 1.02E-10 0.112 VCL 3 9.76E-10 0.084
SATB1 7 2.20E-16 0.213 TNFRSF1A 3 6.64E-16 0.134
RPS6KA2 7 4.76E-02 0.028 TCF7L1 3 1.64E-03 0.030
PAK7 7 2.20E-16 0.185 SP3 3 6.55E-10 0.085
EPS15 7 1.32E-13 0.136 RHOQ 3 4.19E-01 0.006
DRD1 7 1.22E-03 0.046 PTBP1 3 2.46E-06 0.055
CDK5R1 7 2.20E-16 0.260 PRKD3 3 2.65E-05 0.046
CALM1 7 6.39E-08 0.087 MAML1 3 2.51E-01 0.008
STX1A 6 7.67E-06 0.064 LAMA2 3 4.42E-04 0.035
SEH1L 6 3.36E-09 0.094 FZD7 3 4.45E-11 0.095
RELN 6 2.42E-03 0.039 EIF4EBP1 3 2.87E-08 0.071
PRKCE 6 3.07E-02 0.027 CTNND1 3 7.23E-05 0.042
PPP3R1 6 2.63E-10 0.104 COL6A2 3 1.02E-03 0.031
MAP2K1 6 2.27E-05 0.059 COL4A2 3 1.34E-02 0.021
HTR2A 6 8.98E-05 0.054 COL3A1 3 6.96E-06 0.051
GRM7 6 5.21E-03 0.036 CDC23 3 5.40E-05 0.043
BDNF 6 1.65E-03 0.041 CASP7 3 1.13E-03 0.031
YWHAH 5 1.20E-07 0.076 ADAM12 3 2.23E-07 0.064
WASF3 5 1.14E-04 0.049
WASF1 5 2.20E-16 0.264
SH3GL2 5 2.663e-09 0.090
SCN1A 5 4.17E-05 0.053
RPS6KA5 5 2.20E-16 0.190
PTPRM 5 1.40E-05 0.057
PLCB1 5 2.02E-11 0.108
NTRK3 5 7.47E-03 0.031
ITPR1 5 6.80E-13 0.121
HSPA8 5 1.72E-02 0.027
FBXW7 5 3.20E-08 0.081
EPHA4 5 1.55E-06 0.066
CDC40 5 7.53E-05 0.050
ANK2 5 1.46E-02 0.028
Genes are arranged according to the number of targeting miRNAs
1Targets were significantly differentially expressed genes p < 0.00001 and had fold change ≥ 1.5 or ≤ -1.5.
2 miRNAs with p < 0.0001 and fold change ≥ 1.5 or ≤ 1.5.
∗ Obtained from multivariate linear regression models
3Underexpressed genes targeted by at least 5 miRNAs are shown.
4Overexpressed genes targeted by at least 3 miRNAs are shown.
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Figure 3.2: Underexpressed miRNAs-overexpressed gene network. Yellow circles rep-
resent significantly overexpressed expressed genes (p < 0.00001; fold change ≥ 1.5),
and green circles represent significantly underexpressed miRNAs (p < 0.0001; fold
change ≤ –1.5).
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Figure 3.3: Overexpressed miRNAs-underexpressed gene network. Yellow circles
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fold change ≥ 1.5).
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Figure 3.4: Pathways enriched with miRNA target genes. Red bars represent -log10
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Table 3.1 shows the DE miRNAs that had at least one target gene associated with
the altered GBM network. The miRNAs in red were first identified as differentially
expressed in our study. Four underexpressed miRNAs had at least 10 target genes
each, with hsa-miR-23b-3p having the highest number of predicted target genes. 21
overexpressed miRNAs had at least 10 target genes each. Four (hsa-miR-20b-5p, hsa-
miR-424-5p, hsa-miR-195-5p, hsa-miR-19b-3p) of the miRNAs were not identified as
DE miRNAs in previous studies. hsa-miR-20b-5p, hsa-miR-424-5p, hsa-miR-195-5p,
hsa-miR-19b-3p had 28, 21, 21, and 19 target genes, respectively.
3.3.1.2 miRNA-target gene regulatory networks
miRNA-target gene (mRNA) pairs from DE miRNAs and mRNA were used to
construct two miRNA-mRNA regulatory networks: one for underexpressed miRNAs
and overexpressed genes (Figure 3.2); the other for overexpressed miRNAs and
underexpressed genes (Figure 3.3). Figure 3.2 shows 231 edges formed from
32 miRNAs and 114 target genes. Figure 3.3 shows 556 edges formed from 38
miRNAs and 147 genes. Many of the miRNAs in Figure 3.3 are network huns.
hsa-miR-30a-5p, has-mIR-106b-5p, hsa-miR-93-5p, and hsa-miR-20a-5p targeted
37, 33, 31, and 29 genes, respectively. These miRNAs have the potential to regulate
and alter single or multiple pathways at different points. For example, ERBB3,
DUSP2, PHLPP2, PFKP, CLOCK, DRD1, EPHA4, ERBB3, GABBR2, HSPA8,
MAPK9,NTRK3, PAK7, PHLPP2, BMPR2 and CLOCK are DE predicted targets
for has-miR-106b. ERBB3, EPHA4,NEDD4L, NTRK3, MAPK9, and DUSP2 are
in the MAPK signaling pathway; GABBR2 and DRD1 are involved in G-coupled
receptor signaling; CLOCK and HSPA8 are involved in transcription regulation;
PHLPP2 regulates AKT in the PIK3/AKT pathway; PAK7 is involved in focal
adhesion; NEDD4L is involved in ubiquitination and protein degradation; BMPR2
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is in TGF-β signaling; and PFKP, is in the glycolytic pathway. hsa-miR-106b-5p
promotes cell proliferation in glioma tumour cells (Liu et al., 2014b) and contributes
to metastasis and invasion through the inhibition of RECK (Xie et al., 2014).
Down-regulation of RECK, an inhibitor of matrix metalloproteinases, promotes
metastasis in cancer (Sakurai et al., 2014; Alexius-Lindgren et al., 2014). These hub
miRNAs may be useful targets for therapeutic intervention in GBM as many cancer
related pathways would be hit simultaneously.
Expression of an mIRNA is reciprocally related to that of its targets. An un-
derexpressed tumour suppressor miRNA would therefore be expected to have an
oncogenic gene’s mRNA as target. This pattern was observed in the two miRNA
regulatory networks. For example, in the underexpressed miRNA-overexpressed
target network, hsa-miR-125a-5p and hsa-miR-7-5p targeted RAF1, and hsa-miR-
7-5p targeted EGFR, a know driver gene in cancers including GBM, regulates
proliferation, survival and differentiation (Yewale et al., 2013; Voldborg et al., 1997).
RAF1 is an oncogene in the MAPK signaling pathway (Roberts and Der, 2007;
McCubrey et al., 2007). hsa-miR-125a-5p and hsa-miR-7-5p are tumour suppressor
miRNAs (Sun et al., 2013; Chen et al., 2014; Giles et al., 2013; Shi et al., 2015).
In the overexpressed miRNA-underexpressed mRNA network, hsa-miR-142-3a was
overexpressed and targets the adenomatous polyposis coli (APC ) gene, which is
a well known tumour suppressor gene in the Wnt-β signaling pathway (Aoki and
Taketo, 2007; Goss and Groden, 2000). hsa-miR-142-3a has also previously been
reported as an oncogenic miRNA (Lv et al., 2012; Saito et al., 2012)
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3.3.1.3 Deregulated miRNAs have roles in cancer
Møller et al., (2013) did a systemic review on miRNA in GBM in 2013 and identified
15 miRNAs as the most studied. hsa-miR-10b-5p, hsa-miR-15b-5p, hsa-miR-21-5p,
hsa-miR-25-3p, and hsa-miR-195-5p were up-regulated and had 6, 23, 8, 20, and
21 predicted target genes, respectively. hsa-miR-21-5p has been identified as an
oncogenic miRNA and highly expressed in GBM. It has been shown to promote
proliferation and suppress apoptosis in GBM cell lines by down-regulating the
expression of oncogenes (Gaur et al., 2011; Lei et al., 2014) and also suppresses
chemosensitivity to the anti-cancer drug taxol and cisplatin (Ren et al., 2010; Lei et
al., 2014). miR-21 silencing increased the efficacy of the tyrosine kinase inhibitor
sunitinib (Costa et al., 2013). Up-regulation of hsa-miR-25-3p and hsa-miR-195-5p
in this study suggest these miRNAs could have oncogenic function in GBM. However,
these miRNAs have been suggested have tumour-suppressive effect in GBM cell lines
by promoting cell cycle arrest through down-regulation of some cell cycle oncogenes
(Zhang et al., 2012b; Suh et al., 2012).
hsa-miR-7-5p, hsa-miR-132-3p, hsa-miR-137, and hsa-miR-221-3p are among
the most studied miRNAs in GBM and had 5, 7, 12 and 5 predicted targets in
the underexpressed miRNA-overexpressed gene network (Figure 3.2), respectively.
hsa-miR-7-5p is a potential tumour suppressor and have been shown to suppress
EGFR expression and inhibit AKT pathway by targeting upstream regulators in
GBM (Kefas et al., 2008). miR-7-5p had anti-angiogenic and growth-suppressive
effects in a human GBM xenograft model (Babae et al., 2014). EGFR was one of
the significantly overexpressed predicted targets for hsa-miR-7-5p. hsa-miR-132-3p
suppressed cell proliferation, apoptosis and migration by targeting vital oncogenes,
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including KIT, AKT2 and CDK6, and regulated expression of genes involved
in neuronal differentiation in GBM cells (Tamim et al., 2014). The predicted
down-regulated targets for this miRNA included BRCA1, PRKD1 and TTK. TTK
has been identified as a potential therapeutic target in Triple-Negative Breast Cancer
(Maire et al., 2013) and in hepatocellular carcinoma (Liang et al., 2014). BRCA1 is
a tumour suppressor mutated in 1-2 % of breast cancer cases and approximately all
of the familial breast-ovary tumours (Karami and Mehdipour, 2013).
3.3.1.4 Differentially expressed miRNAs not found in previous studies
have roles in cancer
All miRNAs in Table 3.1 except the ones in red were reported in previous studies
as differentially expressed (Dong et al., 2010; Skalsky et al., 2011; Ciafre` et al.,
2005; Godlewski et al.. 2008; Silber et al., 2008). Three down-regulated and
fifteen up-regulated miRNAs were identified as such for the first time in this study.
hsa-miR-125a-5p, hsa-miR-23b-3p, and hsa-miR-328-3p were up-regulated and
had 5, 21 and 4 predicted targets in the overexpressed miRNA-underexpresssed
gene network (Figure 3.3), respectively. hsa-miR-125a-5p and hsa-miR-125a-5p
are mature products of hsa-mir-125a and have opposing functions in invasion and
metastasis in non-small cell lung cancer cells (Jiang et al., 2010). hsa-miR-125a-5p
suppresses ERBB2 and phosphorylated AKT, and is an independent prognostic
factor in gastric cancer (Nishida et al., 2011). A similar result was reported in
a breast cancer cell line in which motility and invasion were suppressed through
down-regulation of ERBB2 and ERBB3 by hsa-miR-125a-5p (Scott et al., 2007).
The barrier function of the brain endothelium and eﬄux of immune cells through
the brain cell barrier is regulated by hsa-miR-125a-5p (Reijerkerk et al., 2013).
CASP6, EIF4EBP1, ITGA7, RAF1, and RHOQ were up-regulated predicted target
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genes for hsa-miR-125a-5p. Down-regulation of ABCG2 by hsa-miR-328 in a breast
cell line suggests the involvement of its mature miRNA products in the regulation
of drug disposition. hsa-miR-328-3p is one of the products of hsa-miR-328 precursor
(Li et al., 2011).
Of the 15 up-regulated miRNAs first identified in this study, hsa-miR-19b-3p,
hsa-miR-195-3p, hsa-miR-20b-5p, hsa-miR-497-5p, hsa-miR-424-5p, and hsa-miR-
424-5p targeted at least 10 down-regulated genes each in the underexpressed
miRNA-overexpresssed gene network (Figure 3.2). hsa-miR-195-5p was down-
regulated and shown to have tumour suppressive function in colorectal cancer (Wang
et al., 2014a), breast cancer (Luo et al., 2014), and hepatocellular carcinoma (Amer
et al., 2014). These findings are in contrast with our ours, as hsa-miR-192-5p was
up-regulated. PPP2R1A, PTPRM and PTPRR were down-regulated and predicted
by TargetScan and miRanda as targets of hsa-miR-192-5p. These genes encode
protein-tyrosine phosphates that may act as tumour suppressors (Ostman et al.,
2006; Labbe´ et al, 2012; Nunes-Xavier et al., 2013). Further studies are therefore
required to ascertain the role of hsa-miR-192-5p in GBM. hsa-miR-424-5p was
up-regulated and suppressed the expression of SOCS6 in pancreatic cancer, and it
increased the proliferation, migration and invasion of pancreatic cancer cells (Wu et
al., 2013). JAK/STAT signaling, one of the cancer pathways, induces the expression
of SOCS proteins, which in turn inhibits this pathway via a classical feedback loop
(Inagaki-Ohara et al., 2013). hsa-miR-19b-3p was up-regulated in patients who had
poor prognosis compared to those who had good prognosis in diffuse large B-cell
lymphoma (Shepshelovich et al., 2015).
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3.3.1.5 Several altered GBM network-associated genes were targeted by
several differentially expressed miRNAs
Overexpressed and underexpressed genes targeted by at least 5 and 3 miRNAs,
respectively, are given in Table 3.2. miRNAs regulate gene expression at the
post-transcriptional level by inducing the degradation or translational repression of
target mRNAs. Some mRNAs are targeted by two or more miRNAs. It is reasonable
to assume that deregulated miRNAs can act in concert to inhibit the translation
of a common mRNA target. We used the multivariate regression model to assess
the combined effect of the expression of miRNAs (independent variables) on the
expression of their target gene (dependent variable). The p value for significance
between expression of miRNAs and that of their target gene as well as the coefficient
of determination are provided in Table 3.2. Coefficient of determination (R2) gives
the proportion of variance of the dependent variable due to an independent variable.
ANK3 had the highest number of targeting overexpressed miRNAs, followed by
PHLPP2. ANK3 encodes an ankyrin G protein that functions as a scaffold protein
and adapter molecue between various membrane proteins and the inner membrane
cytoskeleton. It has been implicated in neurogenesis, synaptic transmission, protein
trafficking and intracellular signaling (Leussis et al., 2012). PHLPP2 encodes a
phosphatase that remove activating phosphate group on Thr308 of Akt (Brognard
et al., 2007). Activation of Akt promotes cell growth and proliferation, and cell
survival. PHLPP2 is a novel tumour suppressor whose aberrant expression has been
shown to correlates with poor prognostic outcomes in hypopharyngeal squamous cell
carcinoma (Zhou et al., 2015).
Multivariate regression analysis showed that the expression of WASF1, SATB1,
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CDK5R1 and PAK7 appeared to be the underexpressed genes most affected by
miRNAs. Target miRNAs accounted 26.4 %, 21.3 %, 26.0 %, and 18.5 of the
variance of the expression WASF1, SATB1, CDK5R1 and PAK7, respectively.
WASF1 encodes a protein that is involved in regulating the actin cytoskeleton
reguired for membrane ruﬄing. WASF1 deletion was found to occur more frequently
with PTEN in metastatic lethal than in primary prostate cancer (Sowalsky et al.,
2015). SATB1 is a matrix protein that participates in the regulation of chromatin
remodeling and gene expression. SATB1 was demonstrated to alter gene expression
in breast cancer cells by reprogramming chromatin organization, leading to the
promotion of growth and metastasis (Han et al., 2008). SATB1 was found to
be overexpressed in metastatic prostate cancer and to promote cell growth and
invasion (Mao et al., 2013a). CDK5R1 is an activator of cyclin-dependent kinase 5
(CDK5). CDK5 is a neurone-specific kinase that and has been shown to promote
cell migration in cancer (Liang et al, 2013; Feldmann et al., 2010). PAK encodes
p21-activated kinase. Gu et al. (2013) demonstrated that PAK7 promoted cell
proliferation in gastric cancer by up-regulating cell cycle regulators.
NFIX and VEGFRA were overexpressed genes with highest number of target-
ing mIRNAs (Table 3.2). NFIX is a a member of NFI protein family, which bind
the palindromic consensus sequence 5-PyTGGCA-N3-TGCCAPu-3’ as homo- and
heterodimers. Their role in cancer is yet unknown. VEGFRA encodes a growth
factor that act on endothelial cells and has various functions, including inducing
angiogenesis, vasculogenesis, and endothelial cell growth, promoting cell migration,
and inhibiting apoptosis (Takahashi et al., 2005; Kerbel et al., 2008; Rahimi et
al., 2006). 17.9, 13.4, and 12.2 % of the variance in the expression of PPMID,
TNFRSF1A and VEGFA, respectively, were due to their targeting miRNAs.
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PPMID encodes a member of the PP2C family of Ser/Thr protein phophatases
and it negatively regulates proteins in the cell stress response pathways such as p53
and Chk1 (Lu et al., 2005; Kleiblova et al., 2013). TNFRSF1A encodes a tumour
necrosis factor receptor that can activate NF-κB, mediated apoptosis, and functions
as a regulator of inflammation (Verstrepen et al., 2008; D’Osualdo et al., 2006).
3.3.2 miRNA differentially-expressed predicted target genes were
enriched for cancer-related pathways
Significantly differentially expressed intracellular GBM network-associated genes that
were targets for differentially expressed miRNAs were analysed for KEGG pathway
enrichment. A total of 53 pathways were targeted by 70 miRNAs (Figure 3.4). The
red bars in Figure 3.4 represent -log10 of FDR corrected p values, and the blue bars
represent the number of miRNAs targeting each pathway. 52 of these pathways were
targeted by at least 10 miRNAs are shown in Figure 3.4. The mammalian circadian
rhythm pathway was targeted by 4 miRNAs. MAPK, calcium, ErbB, Wnt, Notch,
phosphatidylinositol and VEGF signaling pathways, cell cycle, and focal adhesion are
well-established cancer pathways, and are shown to be targets for differentially ex-
pressed miRNAs. MAPK signaling pathway was the most targeted pathway (targeted
by 105 miRNAs), followed by calcium signaling pathway (targeted by 89 miRNAs).
3.4 Conclusion
Several genes in the altered GBM network that have previously been established
as cancer genes and this study shows that several of those that regulate important
cellular processes are targets of miRNAs with deregulated expression. The results
show that miRNA deregulation are as important in the development and progression
of GBM as mutation and copy number alteration. The miRNAs that target genes in
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multiple pathways are attractive potential targets for GBM drug development as they
have the potential to simultaneously cripple multiple drivers of tumourigenesis as well
as the tumour’s adaptative mechanisms and resistance to chemo and radiotherapy.
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Identification of prognostic
miRNAs for adjuvant
therapy-linked progression-free
survival prediction in
Glioblastoma Multiforme
patients
Abstract
Background: miRNAs are a class of small non-coding RNAs that regulate gene
expression at the post-transcriptional level by inducing degradation of target mRNAs
or by inhibiting its translation. The involvement of miRNAs in processes that are
deregulated in cancer has necessitated studies into their role in cancer prognosis.
This study aimed to an identify miRNA signature in the miRNA-mRNA regulatory
networks obtained in Chapter Three that could predict progression-free survival of
GBM patients who received adjuvant chemo- and radiotherapy.
Methods: Clinical information on GBM patients provided by TCGA was used to
select those who received adjuvant chemo- and radiotherapy. The selected patients
were randomly assigned into training and testing groups with equal numbers in
each set. The miRNAs in the networks which had varied expression (MAD ≥ 0.5)
across 556 samples were used in the selection of miRNAs that were correlated with
113
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progression-free survival of training set samples using the elastic net-penalized Cox
regression model. miRNAs with non-zero regression coefficients were selected and
combined into a signature, and the coefficients and expression levels of the signature
miRNAs were then used to compute prognostic index (PI) for each patient in the
training and testing sets. Patients in each set were assigned into low- and high-risk
groups based on the PI. Progression-free and overall survival of the risk groups was
estimated by Kaplan-Meier method, the statistical difference between the groups
were computed by log-rank test. Hazard ratios of the high-risk to low-risk groups
were calculated using Cox proportional hazards regression model, and prognostic
value of the signature was evaluated in the four known subtypes of GBM. A
multivariate Cox regression involving the miRNA signature, age at diagnosis, sex,
and MGMT promoter methylation status was carried out on 70 training patients to
evaluate the independence of the signature in predicting survival.
Results: Eight miRNAs which had non-zero elastic net-penalized regression
coefficients were combined into a signature. Two of these miRNAs were protective
(β < 0); others were risk-conferring (β > 0). The differences in progression-free
survival between risk groups in both training and testing sets were statistically
significant (p < 0.05). The patients in high-risk group had 2.33 and 1.84 times more
rapid progression in the training and testing sets than those in low-risk groups,
respectively. The differences in overall survival between the two risk groups in both
training and testing sets were also statistically significant (p < 0.05). There were
significant differences (p < 0.05) between the two risk groups in progression-free
survival in all four subtypes. Multivariate analysis showed that our miRNA signature
is an independent predictor of progression-free survival.
Conclusion We have identified eight-miRNA signature in the miRNA-mRNA
networks that can predict progression-free survival of GBM patients, irrespective
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of the subtypes to which they belong. The miRNAs in the signature are therefore
attractive targets for the development of subtype-unspecific predictive diagnostics
for GBM.
4.1 Introduction
Searching for prognostic factors has been one of the aims of cancer research. Prog-
nostic factors are patient or tumour characteristics that predict outcome (usually
survival) and are independent of the treatment (Shepherd and Tsao, 2006). Most
research prognostic factors are biomarkers which include biological, pathological,
imaging, clinical, and physiological variables (Riley et al., 2013). Biological variables
of prognostic importance most studied in cancer are mRNA and recently miRNA
expression.
miRNAs are small non-coding RNAs of 18-25 nucleotides that interfere with
mRNA translation. They are involved in post-transcriptional regulation of gene
expression by interacting with and causing degradation or inhibition of translation
of target mRNAs. All mature miRNAs are products of processed pre-miRNAs
produced through transcription by RNA polymerase II and which have hairpin
secondary structure (Zhang et al., 2007). They have been shown to be differentially
expressed between tumour and non-neoplastic samples from the same tissue, suggest-
ing that they play a crucial role in tumour development and progression. Functional
assays involving exogenous expression or inhibition of miRNAs have shown that
they are regulators of cell proliferation, apoptosis, angiogenesis, migration, invasion,
and metastasis (Lages et al., 2012; Di Leva et al., 2014). miRNAs have also been
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implicated in cancer susceptibility. For example, the C allele of SNP rs2910164 is
associated with significantly decreased risk of bladder cancer and GC/CC genotypes
confer a significantly reduced risk of occurrence, compared with the GC genotype.
Shen et al. (2009) observed 7 novel variants in 7 prinmary or precursor miRNA
genes predicted to regulate key breast cancer genes in the screen of 42 patients
with familial breast cancer (Wang et al., 2012). One rare variant in the precursor
of miR-30c-1 and one rare variant in the primary precursor of miR-17 were only
observed in noncarriers of BRCA1/2 (breast cancer susceptibility protein-coding
genes) mutations. miRNAs are known to regulate protein-coding oncogenes and
tumour suppressor genes such as MYC, RAS, and p53 (Kent and Mendell, 2006) .
Oncogenic and tumour suppressor miRNAs target tumour suppressor and oncogenic
proteins respectively.
The common approach to the identification of prognostic factors in cancer in-
volves the use of Cox proportional hazard regression model or penalized Cox
regression model to select factors which correlate with survival. The review carried
out by Burton and Altman (2004) shows that 100 articles published in 2002 on
survival analysis to access potential prognostic factors used Cox modelling. Similarly,
Mallett et al. (2010) reported that almost all of 47 articles on prediction of patient
outcome used Cox modelling. The independence of a selected prognostic factor
in predicting survival is determined in a multivariate Cox model involving other
potential factors. Most cancer studies that identified prognostic miRNAs used
univariate Cox models for feature selection and a multivariate Cox model to as-
sess whether selected features could predict survival independent of clinical variables.
Several studies have reported miRNAs whose expression were correlated with
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overall survival (OS) or progression-free survival (PFS) in GBM. Qiu et al. (2013)
identified two sets of prognostic miRNAs: one for OS and the other for PFS. High
levels of miR-326/miR-130a and low levels of miR-323/miR-329/miR-155/miR-210
were significantly associated with long OS. High-levels of miR-326/miR-130a and
low levels of miR-155/miR-210 were associated with long PFS. The study also
showed that multi-miRNA signatures were better predictors of OS and PFS than
individual miRNAs. Srinivasan et al. (2011) used a signature of 10 miRNAs that
were significantly correlated with OS to classify GBM patients into low-risk and
high-risk groups. The study reported a significant difference in OS between the
groups. Zhao et al. (2013a) showed that patients with levels of miR-106a below the
median expression had shorter OS than those with levels of the miRNA above the
median. miR-148a was the only miRNA in the integrated mRNA and miRNA ex-
pression signature identified as negatively correlated with OS in GBM (Xiong, 2014 ).
In this study, we aimed to identify miRNAs in the miRNA-mRNA regulatory
networks from Chapter Three that could predict progression-free survival in the
TCGA GBM sample cohort. We started by identifying miRNAs with non-zero
elastic net-penalized regression coefficients in a training set using times to GBM
progression. The expression levels of the identified miRNAs and their coefficients
were used to compute a prognostic index for each patient in both the training and
testing set. The patients in each set were then classified based on prognostic index
into low- and high-risk groups. The statistical differences in PFS and OS between
the groups were determined in the training and testing sets. Finally, we carried out
multivariate Cox modelling with other potential factors to determine if our signature
could independently predict PFS.
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4.2 Methods
4.2.1 Sample selection
A clinical follow-up file (nationwidechildrens.org clinical follow up v1.0 gbm.txt) for
558 GBM patients was downloaded from TCGA data portal. This file contained
information on days to death from initial treatment, days to last contact from initial
treatment, and treatment received. Standard treatment for GBM was established
in a clinical trial conducted 2005, in which paients with newly diagnosed and
histologically confirmed GBM were given radiotherapy plus continuous daily doses
of temozolomide (7 days per week from the first to the last day of radiotherapy),
followed by six cycles of adjuvant temozolomide (Stupp et al., 2005). This treatment
regime starts a few weeks after surgery (Cohen et al., 2011). Figure 4.1 illustrates
how samples used in this study were selected. 415 patients received adjuvant
radiation and chemotherapy and had complete clinical information. Gene and
miRNA expression profiles of 376 of these patients were available in the TCGA data
portal. The expression and clinical data from these patients were used in this study.
The file (nationwidechildrens.org clinical follow up v1.0 nte gbm.txt) contain-
ing information on new tumour events in 378 patients was downloaded from TCGA.
For GBM, tumour recurrence is the re-appearance of tumour, usually within 2 cm
from the original site, after a complete surgical removal of the visible mass. Tumour
progression refers to as an increase in tumour size after a subtotal excision (Iacob
and Dinca, 2009). Only the patients who experienced progression were considered.
262 patients had uncensored data on days to progression (progression-free survival
time.) and 200 received adjuvant radiation and chemotherapy and also had both
gene and miRNA expression data available in the TGCA repository.
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556 had clinical
data
415 received both ajuvant
chemotherapy and radiation
376 had both Gene and
miRNA expression data
200 had both progression-free
and overall survival time data
Training set
(100 samples)
Testing set
(100 samples)
70 had MGMT
methylation status data
Figure 4.1: Sample selection for the identification of prognostic miRNAs
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4.2.2 Survival Analysis
4.2.2.1 Elastic net-penalized Cox regression model
Cox proportional hazards regression model is a common approach for assessing the
effect of variables (independent) on time to event (dependent variable). Mathemati-
cally, Cox model is defined as
h(t|xi) = ho(t)exp(xTi β), (4.1)
where h(t|xi) is the hazard function for patient i, which is the probability that a
patient will experience an event with a small interval time, given that the individual
has survived up to the beginning of the interval. ho(t) is the baseline hazard function
where all independent variables in the model are zero. xTi = (xi1, ..., xip) represents
the expression levels of p genes. β = (β1, ..., βp) is a vector of regression parameters.
estimated by maximizing Cox log partial likelihood as follow:
l(β) =
n∑
i=1
δi
[
xTi β − log
{ ∑
rR(tr)
exp(xTr β)
}]
, (4.2)
where δi equals 1 if the patient experienced an event (e.g death), or 0 if a patient
did not experience an event. R(ti) denotes the set of indices of individuals at risk
for the event at time tr.
In Cox proportional hazards model, it is assumed that all independent vari-
ables change linearly with the logarithm of the hazard. This assumption is known as
proportionality hazard. The other assumption is that the ratio of hazard functions
of different observations does not depend on time.
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There are two challenges associated with using microarray data for survival
analysis. First, large numbers of genes make the prediction model very high
dimensional and create difficulty of computing. Second, the expression levels of
some genes are highly correlated. These challenges are solved by using penalized
regression methods. L1- and L2-penalized regression methods control over-fitting by
adding a regularization term in the Cox partial likelihood function. L1-penalized
regression, also known as the least absolute shrinkage and selection operator (lasso)
estimation was proposed by Tibshirani (1996). This method employs constraints to
convert some coefficients to zero and to build interpretable models. L1-penalized log
partial likelihood is given by
l(β, λ1) = l(β)−
p∑
r=1
λ1
∣∣βr∣∣. (4.3)
L2-penalized regression, also known as ridge regression, conserves all parameters to
construct prediction models. L2-penalized log partial likelihood is given by
l(β, λ2) = l(β)−
p∑
r=1
λ2β
2
r . (4.4)
λ1 and λ2 are tuning (shrinkage) parameters for L1- and L2-penalized regression,
respectively. The performance of L1-penalized regression is not very satisfactory when
then number of predictors (variables) is much larger than the number of observations
samples. Elastic net penalized method improves on the performance of L1-penalized
regression by adding L1 and L1 penalties together to create a new regularization term
(Zou and Hastie, 2005). Elastic net-penalized log partial likelihood is given by
l(β, (λ1, λ2)) = l(β)−
p∑
r=1
(
λ1
∣∣βr∣∣+ λ2β2r). (4.5)
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Elastic net penalty is employed by the R package glmnet, which was used in this
study to select miRNAs with non-zero coefficient (β).
The effect of an independent variable on survival is assessed and represented
by hazard ratio (HR), which is computed as the exponential of β for the the variable.
For survival prediction using microarray data, equation (4.1) shows that hazard
function of a patient is dependent on expression of genes in the Cox model. xTi β is
therefore a measure of risk and is known as prognostic index or risk score. Prognostic
index of a patient is given by
PI = β1 ∗ gene1 + β2 ∗ gene2...+ βg ∗ geneg, (4.6)
where geneg is the expression value of gene g in the patient. Prognostic index is a
weighted sum of the variables in the model, where the weights are the regression
coefficients. High values of PI indicate poor prognosis.
If the assumption of proportional hazards holds, the hazard for any individual
in a group (for example, treated group) at any given time is proportional to the
hazard for any individual in another group (for example, untreated group). Then,
the ratio of the slope of a survival curve for one group to that of the other group is
called hazard ratio. HR greater than 1 signifies poor survival, and HR lower than 1
signifies good survival. Risk groups can be created by splitting ordered PI by the
median to give two equal number of samples. Meier-Kaplan curves are drawn for
the two groups. A statistical significance test called log-rank test is performed and
HR is calculated.
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4.2.3 miRNAs associated with Glioblastoma multiforme patient
survival
200 glioblastoma multiforme (GBM) patients with time to progression and time
to death data were randomly assigned into two equally sized training and testing
groups. 70 differentially expressed miRNAs were identified in the miRNA regulatory
networks (Figures 3.2 and 3.3) reported in Chapter 3. For any of these miRNAs
to predict progression-free survival, its expression must vary across samples. 53
miRNAs had Median Absolute Deviation (MAD) ≥ 0.5 across 556 GBM samples.
These miRNAs and the 100 samples in the training set were used for in the selection
of miRNAs which correlated with progression-free survival. glmnet package was
used for the selection with 10-fold cross validation and 100,000 iterations. miRNAs
with non-zero elastic net-penalized regression coefficients were selected for inclusion
in the prognostic miRNA signature. Significance of correlation with progression-free
survival and HR were determined by univariate Cox proportional hazards regression
analysis.
The prognostic value of the miRNA signature was accessed in the training
and testing dataset. Equation (4.6) was used to compute the prognostic index for
patients in each set. The PI values in each set were standardised by subtracting
mean PI from each PI and dividing by the standard deviation of the PIs. The
patients in each set were grouped into low-risk and high-risk groups by choosing
a value between the largest and the lowest prognostic indices that ensured proper
sample distribution into the two groups. The Kaplan-Meier method was used to
estimate progression-free and overall survival for the two groups and differences
in survival were determined using log-rank test. Hazard ratios (HR) between the
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groups were analysed using Cox proportional hazards regression model. These
analyses were done with the R package survival.
4.2.3.1 Assessing the prognostic value of miRNA signature in GBM sub-
types
The prognostic value of the miRNA signature was also accessed in each GBM
subtype. A GBM sample belongs to one of the four gene expression subtypes
identified by Verhaak e al. (2000). The subtypes are Proneural, Neural, Classical
and Classical. All the 200 samples were assigned to their subtypes based on the
clinical information provided by Brennan et al., (2013) for these samples. The
samples in each subtype were assigned to low- and high-risk groups based on
prognostic index. Progression-free and Overall survival for the groups was estimated
by the Kaplan-Meier method, and differences in survival again determined by the
log-rank test.
All measurements were associated with 95 % confidence intervals (95 % CI)
and statistical tests were considered significant if p < 0.05.
4.2.3.2 Multivariate Cox survival analysis
Other factors affect prognosis in cancer besides to expression of prognostic genes,
including type and subtype of cancer, location of the cancer, tumour stage and
grade, age, and treatment response. Therefore, there was a need to ascertain that
our miRNA signature could predict progression-free and overall survival independent
of other covariates. multivariate Cox model involving the miRNA signature, age and
O-6-methylguanine-DNA methytransferase (MGMT) promoter methylation status
was developed for progression-free and overall survival in the training set. MGMT
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encodes O-6-methylguanine-DNA methyltransferase, a DNA-repair enzyme that
removes alkylating groups at the O6 of guanine residues. Epigenetic silencing of this
gene by promoter methylation results in the loss MGMT expression and defective
DNA repair (Watts et al., 1997 and Esteller et al., 1999). Epigenetic silencing of
MGMT is a common event in human cancers (Esteller et al., 1999), and has been
associated with longer overall survival in patients with glioblastoma who received
temozolomide (Hegi et al., 2005; Esteller et al., 2000; Hegi et al, 2004), an akylating
prodrug which at physiological pH is converted to monomethyl triazeno imidazole
carboxamide that methylates purine bases of DNA (Sharma et al., 2009; Zhang et
al., 2012c). MGMT promoter methylation is a known marker for treatment response
in GBM (Hegi et al., 2005). Brennan et al. (2013) however reported that MGMT
promoter methylation was only correlated with overall survival in the GBM Classical
subtype but not in other subtypes (Proneural, Neural, and Mesenchymal).
Ages of patients at diagnosis were obtained from the clinical file (clini-
cal patient gbm.txt) provided by TCGA and MGMT promoter methylation
status data were obtained from the clinical file provided by Brennan et al., (2013).
70 (35 females and 35 males) of the patients in the training set had data for the
three covariates. The univariate Cox analysis was first carried out on each variable
followed by multivariate Cox analysis on all the variables. coxph function in R
survival package was used for the analysis. The median prognostic index (PI ) was
used to assign the patients into high- or low-risk groups. The patients with PI less
than the median were assigned to the low-risk group, and those with PI greater
that or equal to the median to the high-risk group. The low-risk group was used as
reference. Female patients were used as reference for the sex variable. The MGMT
promoter was methylated in 37 of the patients, and these patients were used as
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reference. All measurements were associated with 95 % confidence intervals (95 %
CI) and statistical tests were considered significant if p(Wald) < 0.05.
4.3 Results and Discussion
Table 4.1: Clinical characteristics of GBM patients in training and testing
sets
Characteristic Entire set Training set Testing set p
n=200 n=100 n=100
Age (Mean ± SD) 54.45 ± 13.52 54.70 ± 13.86 54.19 ± 13.24 0.79a
Sex
Female 75 45 30 0.04b
Male 125 55 70
Neoadjuvant treatment
Treated primary GBM 13 6 7 1b
Untreated primary GBM 187 94 93
aT-test for difference between ages in training and testing set
bChi-squared test for sex and neoadjuvant treatment distribution between training
and testing sets
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Table 4.2: 8 miRNAs correlated with progression-free survival in the training
set
miRNA βa HRb (CI) Effect Expressionc # pb
targetsc
hsa-miR-132-3p 0.1124 1.54 (1.11-2.15) Risk- Underexpressed 7 1.00E-2
associated
hsa-miR-155-5p 0.0078 1.46 (1.16-1.86) Risk- Overexpressed 4 1.63E-3
associated
hsa-miR-25-3p -0.0997 0.62 (0.45-0.87) Protective Overexpressed 20 6.16E-3
associated
hsa-miR-92a-3p -0.0321 0.68 (0.53-0.88) Protective Overexpressed 20 2.90E-3
associated
hsa-miR-142-3p 0.0599 1.40 (1.14-1.71) Risk- Overexpressed 4 1.10E-3
associated
hsa-miR-193a-3p 0.1616 1.83 (1.34-2.49) Risk- Overexpressed 7 1.48E-4
associated
hsa-miR-221-3p 0.0175 1.32 (1.09-1.61) Risk- Underexpressed 5 4.90E-3
associated
hsa-miR-146b-5p 0.1451 1.70 (1.30-2.22) Risk- Overexpressed 3 1.04E-4
associated
a Elastic net-penalized regression coefficient
b Obtained from univariate Cox regression model
c Results obtained in Chapter 3
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In this study, we proposed a eight-miRNA signature for predicting progression-free
and overall survival in GBM patients. The predictive value of the signature was
subtype-unspecific, as it predicted GBM patient survival irrespective of the subtype
to which the tumour sample from the patient belongs. The signature was validated in
an internal testing dataset as independent GBM miRNA datasets are not yet available
in the public repositories. However, the findings still demonstrate the significant
potential of miRNA expression profiles in predicting the prognosis of GBM patients.
4.3.1 Clinical characteristics of patients in the GBM cohort
All the patients in the training and testing groups had experienced progression before
the last day of follow-up and 79 in the former and 81 in the latter set had died
before that then. The rest were either alive on the last follow-up day or lost to
follow up. Table 4.1 shows the clinical characteristics of the entire training and
testing data sets. There was no significant difference between the ages of samples
in the training and testing set (p > 0.05). The mean ages in the training and
testing sets were 54.70 ± 13.86 and 54.19 ± 13.24, respectively. There was a bias
in the distribution of sex between the two sets (p < 0.05), but a previous study
showed that sex was not statistically correlated with survival (Xiong et al., 2014).
Samples were uniformly distributed in terms of neoadjuvant treatment between the
sets (p > 0.05). Collectively, these results show that the random grouping of the
samples was appropriate for the study.
4.3.2 Eight miRNAs were correlated with progression-free survival
in the training set
Elastic net-penalized Cox regression model was used for the estimation of regression
coefficient parameters and for the selection of non-zero coefficients. The training set
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and 53 differentially expressed and variable miRNAs were used to select miRNAs
that were correlated with progression-free survival. Table 4.2 shows the eight (8)
miRNAs that had non-zero elastic net-penalized regression coefficients, their HRs
and significance of correlation with progression-free survival. All the eight miRNAs
were significantly correlated with survival (p < 0.05). hsa-miR-25-3p and hsa-miR-
92a-3p were protective and negatively correlated with hazard (β < 0 and HR < 1).
hsa-miR-132-3p, hsa-miR-155-5p, hsa-miR-142-3p, hsa-miR-193a-3p, hsa-miR-221-
3p, and hsa-miR-146b-5p were risk-associated and positively correlated with hazard
(β > 0 and HR > 1). The eight miRNAs were combined into a prognostic signature.
4.3.3 The eight-miRNA signature predicted progression-free (PFS)
and overall survival (OS) in the training and the testing sets
4.3.3.1 The eight-miRNA predicted PFS and OS in the training set
Prognostic index (PI )was calculated for each patient in the training and the testing
sets by substituting the regression coefficient parameters for the eight miRNAs into
the equation (4.6). This resulting equation was
PI = (1.1124 ∗ hsa−miR− 132− 3p) + (0.0078 ∗ hsa−miR− 155− 5p)
+(0.0599 ∗ hsa−miR− 142− 3p) + (0.1616 ∗ hsa−miR− 193a− 3p)
+(0.0175 ∗ hsa−miR− 221− 3p) + (0.1451 ∗ hsa−miR− 146b− 5p)
−(0.0997 ∗ hsa−miR− 25− 3p)− (0.0321 ∗ hsa−miR− 92a− 3p).
(4.7)
A value was chosen between the highest and lowest PIs in each set that properly
distributed samples into low-risk and high-risk groups. The lowest and highest PIs
in the training set were -2.73 and 1.91 (Standardized), respectively. The value 0.071
was used to split the training set into 45 low-risk and 55 high-risk samples. Figure
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4.2 A is a heat map showing the correlation between PI and expression of each of
the miRNAs in the signature. The column represent samples ranked according to
their PIs, from the lowest the highest. The row represents miRNAs hierarchically
clustered by Pearson correlation distance. Figure 4.2 B shows the PIs of samples
in the training set. The samples in the low- and high-risk groups were ranked by
PIs. Figure 4.2 C shows the days to progression of patients in the two risk groups.
Again, the samples were ranked by PI. Figure 4.2 D shows the Kaplan-Meier plot
of progression-free survival curves of the two risk groups. The red and blue curves
represent survival curves for low-risk and high-risk groups, respectively. The patients
in the high-risk group had shorter median progression-free survival (158 days; 95 %
CI = 131-214 days) than those in the low-risk group (299 days; 95 % CI = 210-
394 days). The difference between progression-free survival between the groups was
statistically significant (p < 0.05) (Figure 4.2 D). The patients in the high-risk group
experienced progression 2.33 times (HR) as fast as those in the low-risk group. The
two groups also differed significantly in the overall survival (p < 0.05). The median
overall survival in the high-risk group (441 days; 95 % CI = 393-546) was lower
than that of the low-risk group (630 days; 95 %CI = 489-812). The patients in the
high-risk group died twice as fast as those in the low-risk group (HR = 2).
4.3.3.2 The eight-miRNA signature predicted PFS and OS in the vali-
dation testing set
The prognostic value of the eight-miRNA signature was internally validated in the
testing set. PI was calculated for 97 patients in the testing set with days to pro-
gression ≤ 1400. The lowest and highest PIs in the testing set were -1.94 and 2.31
(Standardized), respectively. The value 0.142 was used to split testing set into 55
low-risk and 42 low-risk samples. Figures 4.3 C and D shows the Kaplan-Meier plots
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for progression-free and overall survival in the testing set respectively. Patients with
survival times ≤ 2000 days were considered for overall survival analysis. The median
progression-free survival in the high-risk group was 166 days (95 % CI = 136-224),
and that of the low-risk group was 217 days (% CI = 186-311). Progression-free
survival in the two groups was statistically different (p < 0.05), and the HR was 1.84
(95 % CI = 1.2-2.8). The medians of overall survival in the high- and low-risk groups
were 430 days (95 % CI = 345-482) and 486 days (95 % CI = 424-684), respectively.
The two groups differed significantly in the overall survival (p < 0.05), and the HR
was 1.68 (95 % CI = 1.04-2.71).
4.3.3.3 The eight-miRNA signature had prognostic value in the four sub-
types of GBM
Figure 4.3 shows that the miRNA signature could predict progression-free survival
in all the Proneural, Neural, Classical and Mesenchymal subtypes of GBM. The
difference in the progression-free survival between high-risk and low-risk group in each
subtype was statistically significant (p < 0.05). The HRs for Classical, Proneural,
Neural, and Mesenchymal subtypes were 1.88 (95 % CI = 1.06-3.34), 2.72 (95 % CI
= 1.33-5.55), 2.34 (95 % CI 1.09-5.02), and 2.17 ( 95 % CI = 1.23-3.84), respectively.
The median progression-free survival in high-risk was lower than that of the low-risk
group in each subtype. In the Classical subtype, the median survival in the high-risk
group was 167 days (95 % CI = 125-253), and that of the low-risk group was 257
days (95 % CI = 238-374). In the Mesenchymal subtype, the median survival in the
high-risk group was 152 days (95 % CI = 127-219), and that of the low-risk group
was 233 days (95 % CI = 145-488). In the Proneural subtype, the median survival in
the high-risk group was 174 days (95 % CI = 154-239), and that of the low-risk group
was 311 days (95 % CI = 164-1315). In the Neural subtype, the median survival in
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the high-risk group was 180 days (95 % CI = 93-369), and that of the low-risk group
was 358 days (95 % CI = 192-711).
4.3.3.4 The eight-miRNA prognostic signature was an independent
progression-free survival predictor
A multivariate Cox analysis involving the eight-miRNA prognostic signature, age,
sex and MGMT promoter methylation status was carried out. Table 4.3 shows the
results of univariate and multivariate Cox analyses on the prognostic signature, age,
sex, and MGMT promoter status. The analyses were carried on progression-free and
overall survival of 70 training set samples with data for the 4 covariates. All the 70
patients had progression before their last follow-up day. The prognostic signature
and age were significantly correlated with progression-free survival in the univariate
analysis (p < 0.05). 50 of these patients had died during the follow-up period. The
remaining 20 were alive on the last days of follow-up or were lost to follow-up. Only
the prognostic signature had significant correlation with progression-free survival.
Age and our prognostic miRNA signature were significantly correlated with overall
survival in both univariate and multivariate Cox analysis. MGMT promoter was
methylated in 37 patients and unmethylated in 33 patients. There was no statisti-
cally significant difference (p > 0.05) in progression-free and overall survival between
the promoter methylated and unmethylated groups both univariate and multivariate
analyses. The 70 patients were equally distributed in terms of sex (35 females and 35
males). Progression-free and overall survival between the sex groups was not signif-
icantly different (p > 0.05) in the Cox analyses. These results clearly show that the
miRNAs in the prognostic signature are involved in tumour progression in GBM. Age
also does not determine the time a patient experiences tumour progression, as this
event is determined by change in gene expression, but did, however, have a strong
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effect on the overall survival of GBM patient (p = 5.19 x 10−4). Most importantly,
the results also show that our eight-miRNA signature was an independent predictor
of time to progression in GBM.
4.3.3.5 Only three miRNAs in the signature have been reported previ-
ously
Three of the signature miRNAs has been reported in a previous study as risk-
associated and correlating with overall survival in GBM (Srinivasan et al. 2011).
These miRNAs were hsa-miR-193-3p, hsa-miR-146b-5p, and hsa-miR-221. We also
found that these miRNAs were correlated with progression-free survival. hsa-miR-
193-3p was shown promote 5-fluorouracil resistance in hepatocellular carcinoma
through the repression of the SRFSF2, a postive regulator of proapoptotic caspase
2 (Ma et al., 2012). hsa-miR-146-5p was shown to down-regulate the expression of
BRCA1 in triple negative sporadic breast cancers (Garcia et al., 2011). BRCA1 is a
known tumour suppressor in breast cancer (Henderson, 2012; Hu et al., 2009). hsa-
miR-146-5p was positively correlated with survival in large B-cell lymphoma treated
with cyclophophamide, doxrubicin, vincristine, and prednisone (Wu et al., 2014b),
which is not agreement with our result. This miRNA possibly has different func-
tions in large B-cell lymphoma and GBM. We found hsa-miR-146-5p to be linked
to miRNA in GBM and to be negatively correlated with survival. hsa-miRNA-221
was also reported down-regulated in GBM by Srinivasan et al. 2011. Exogenous
overexpression of hsa-miR-221 in hepatocellular carcinoma SNU-398 cells revealed
that the miRNA targeted multiple cancer pathways. RB1, WEE1 (cell cycle in-
hibitors), APAF1 (pro-apoptotic), ANXA1, and CTCF were validated as targets of
the miRNA (Lupini et al., 2013). The risk association of hsa-miR-221 in our study
is also in agreement with the study carried out by Tao et al. (2014), which found
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that high levels of the miRNA was significantly associated with poor prognosis.
4.3.3.6 Five miRNAs in the signature are identified as novel prognostic
miRNAs in GBM
hsa-miR-132 was shown to be promoter-methylated and down-regulated in pancre-
atic cancer. Expression of hsa-miR-132 negatively regulated the Akt signaling path-
way (Zhang et al., 2011d). hsa-miR-132 was silenced by methylation prostate cancer
(Formosa et al., 2012). hsa-miR-25-3p and hsa-miR-92a-3p are positively correlated
with progression-free survival despite being overexpressed (Table 4.2). Both miR-
NAs belong to the miR-92a family. hsa-mR-25-3p has a known function in the self-
renewal of cancer stem cells (DeSano and Xu, 2009). Glioma stem cells are a small
sub-population in GBM that have been shown to mediate radio- and chemoresis-
tant and have the ability to repopulate tumours (Sakariassen et al., 2007; Mangum
and Nakano, 2012; Mannino and Chalmers, 2011). hsa-miR-25-3p was shown to
have anti-apoptotic activity in ovarian cancer cells by targeting pro-apoptotic such
as BCL2L11, BAX and CASP3 (Zhang et al., 2012d). It promoted proliferation,
migration and invasion and decreased apoptosis in gastric cancer, and RECK was
found to be its target (Zhao et al., 2013b). RECK (reversion-inducing cysteine rich
protein with Kazal motifs) inhibit metastasis by acting as an inhibitor of matrix
metalloproteinases involved in breakdown of the extracellular matrix (Clark et al.,
2007). hsa-miR-25-3p correlated positively with overall survival in lung adenocar-
cinoma (Xu et al., 2014b; Landi et al., 2010), hepatocellular carcinoma (Su et al.,
2014) and colorectal cancer (Li et al., 2014). Studies on hsa-miR-25-3p and its over-
expression in this study show that it is an oncogene. A possible explanation for its
protective role comes from a study done on drug-resistant breast cancer cells (Wang
et al., 2014b), which showed that isoliquiritigenin (ISL) improved chemosensitivity
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by inhibiting hsa-mIR-25-3p expression. Inhibition of this miRNA led to upregula-
tion of ULK1, an early regulator in the autophagy induction phase, which in turn
resulted in the degradation of ABCG2, an ATP-binding cassette (ABC) protein that
contribute to multidrug resistance in cancer (Robey et al., 2007; Natarajan et al.,
2012). We suggest that hsa-miR-25-3p could delay progression in GBM by improving
sensitivity to drugs used for treating the cancer. The role of hsa-miR-92a-3p seems to
be cancer-type dependent. Its down-regulation was shown to be promote aggressive
migration and to correlate negatively with recurrence-free survival in breast cancer
(Nilsson et al., 2012), which is in agreement with our finding of a protective role of
hsa-miR-92a-3p. Its up-regulation was associated with tumour metastasis in colorec-
tal cancer (Zhou et al., 2013) and human esophageal squamous cell carcinoma (Chen
et al., 2011).
4.4 Conclusion
Precision medicine is precisely-tailored individualized medicine being advocated for
the prevention and treatment of genetic diseases. The form of medicine depends on
the identification of molecular targets that can be used by clinicians in diagnosis
and in making informed decision on therapy to administer. Achievements have been
made in this area considering predictive and prognostic tools that are available for
breast cancer treatment. However, not much has been achieved in other cancer types.
No known prognostic or predictive tools based on miRNA expression have
been translated into clinical use. The current prognostic and predictive tools
are based on mRNA expression, most of which were developed for breast cancer.
Examples are MammaPrint, ammostrat, Oncotype DX, and Rotterdam Signature.
We have identified an eight-miRNA signature in the miRNA-mRNA networks
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that can predict progression-free survival of GBM patients, irrespective of the
subtypes to which they belong. Since our signature consists of miRNAs that target
cancer-related signaling pathways, it has a promising potential of being used as
prognostic and predictive signature which can be translated into clinical use for
selecting glioblastoma patients that will benefit from adjuvant chemotherapy and
radiotherapy. Differential expression and the prognostic value of signature miRNAs
also suggest that they are involved in the development and progression of the cancer.
Thus, in addition to their potential utility as a diagnostic, the individual miRNAs
are also attractive candidate targets for the development of subtype-unspecific
therapeutic agents for GBM.
 
 
 
 
Chapter 5
A 35-gene signature
discriminates between rapidly-
and slowly-progressing
Glioblastoma multiforme and
predicts progression-free and
overall survival in known
subtypes of the cancer
Abstract
Background: Gene expression can be employed for the discovery of a gene or multi-
gene signature of prognostic value in cancer. The common approach used is to first se-
lect a manageable subset of genes that are correlated with survival before assessing the
ability of the combined set of selected genes to predict progression-free and/or over-
all survival. In this study, we assessed the prognostic value of a gene set selected by
pathway- and SVM-based methods that discriminated between rapidly- and slowly-
progressing Glioblastoma multiforme (GBM) patients in predicting progression-free
survival (PFS) and overall survival (OS) in GBM.
Methods: Pathway enrichment analysis carried out on genes with varied expression
(Median Absolute Deviation MAD ≥ 0.5) across 529 GBM patients. Genes were
then prioritised from the pathway categories known to be involved in chemoradiore-
141
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sistance. These prioritised genes were then used in feature selection using a modified
Support Vector Machine-Recursive Feature Elimination (SVM-RFE) to select genes
that discriminated between 48 rapidly-progressing (6 ≥ PFS times ≤ 120 days) and
35 slowly-progressing (358 ≥ PFS times ≤ 720 days) GBM patients with the least
cross-validation error rate. Multivariate Cox’s regression coefficients (β’s) were calcu-
lated for each discriminating gene using another set of 118 patients with PFS times.
The β’s and the expression of the discriminating genes were then used to compute
prognostic index (PI) scores for 380 patients with PFS and/or OS times. For each
survival analysis, patients were assigned into high- and low-risk groups based on PI
score. Progression-free survival analysis was carried out on the 118 patients and in
a GBM subtype-specific manner using a combined set of the 118 patients and the
patients used in the feature selection. Overall survival analysis was carried out on the
118 patients with PFS times, on all the 380 patients with OS times and in subtype-
specific manner. The prognostic value of the set of discriminating genes was validated
in an independent study cohort using OS times. A multivariate analysis involving the
prognostic index, age at diagnosis, and MGMT promoter methylation was used to
determine if the prognostic index could predict PFS and OS independently of other
factors.
Results: 35 genes selected from 356 genes from the chemoradioresistance-associate
pathways discriminated between the survival groups with 100 % accuracy. Four of
these genes were significantly correlated with PFS (p < 0.05). Survival analyses
showed that the 35-gene signature could predict accurately PFS and OS irrespective
of the subtypes to which the patients belonged. There were statistically significant
differences in PFS and OS between high- and low-risk groups (p < 0.05) in all the
analyses. The median survival times of the high-risk patients were lower than those
of the low-risk patients, and there was also statistically significant difference between
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high- and low-risk groups in the validation cohort. In the multivariate analysis, only
our prognostic index could predict PFS independently of other factors (p < 0.05;
Hazard ratio (HR) = 3.41 95, % CI = 2.04-5.69). All the factors could predict OS
independently (p < 0.05). 1.60 (95 % CI = 1.18-2.17), 1.03 (95 % CI = 1.02-1.05),
and 1.52 (95 % CI = 1.12-2.50) were the HRs for the prognostic index, age of diag-
nosis and MGMT promoter methylation, respectively.
Conclusion The performance of the signature in predicting survival irrespective of
subtypes demands further studies on its ability to serve as both prognostic and pre-
dictive biomarker for GBM. The signature genes could also be useful therapeutic
targets to improve both progression-free and overall survival of GBM patients.
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5.1 Introduction
5.1.1 Glioblastoma multiple has no prognostic biomarker
Glioblastoma multiforme (GBM) is the most common and highly aggressive brain
tumour. Patients with GBM have very poor prognosis with the median OS time of
14.5 months (Hegi et al., 2005). MGMT promoter methylation is a known predictor
of treatment response in GBM. MGMT encodes O-6-methylguanine-DNA methyl-
transferase, a DNA-repair enzyme that removes alkylating groups at the O6 of gua-
nine residues. GBM patients whose MGMT promoters are hypermethylated are
expected to benefit from temozolomide, an alkylating agent used for treating GBM.
There are however conflicting reports regarding the prognostic value of this biomarker
(Costa et al., 2010; Yin et al., 2014). There are no known standardised prognostic
biomarkers for GBM. Hence, there is a need to search for genes that can serve as
prognostic signature for GBM.
5.1.2 Feature selection methods for survival analysis
Gene expression deregulation is one of the classes of alteration in cancer. There have
been a number of studies targeted at identifying genes or subsets of genes whose
expression can be used alone or in combination with clinic parameters to predict
prognosis and treatment outcome in cancer. The initial step common to most
studies on prognostic gene expression in cancer is to select a set of genes from tens
of thousands of genes measured on a microarray. Feature selection methods used
for gene expression can be organised into three categories: filter methods, wrapper
methods and embedded methods (Saeys et al., 2007).
In filtering methods, relevance scores are calculated for each features and the
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low-scoring ones are eliminated. Two filtering approaches are usually employed
in the selection of features for survival analysis. The most common is the use of
univariate Cox’s proportional hazards model to identify genes that are significantly
correlated with survival in a training set of patients. The genes are then arranged
into order of significance and the top ones are selected for survival analysis on risk
groups (Yoshihara et al., 2010; Naderi et al., 2006). The second approach involves
dichotomizing patients into groups based on survival and selecting genes that are
differentially expressed between the survival groups. The number of genes selected
from this approach are usually very many. Therefore, univariate Cox’s proportional
hazards model analysis is used further to prune the list of genes to a manageable size.
In wrapper methods, feature subsets are first defined (Colman et al., 2010),
which are then searched with an algorithm wrapped around a classification model.
In embedded methods, a classifier is used to search for an optimum subset of
features. An embedded method was used in our study for feature selection.
5.1.3 Support vector machine and feature selection
The Support Vector Machine (SVM) is a supervised machine learning tool used for
classification. It constructs a hyperplane to separate data from two classes. SVMs
have been applied to pattern recognition problems including protein remote homol-
ogy, microarray gene expression classification, recognition of protein-protein interac-
tions, protein function prediction,and peptide identification from mass spectrometry
data (Yang, 2004; Dong et al., 2005; Kumar et al., 2014; Webb-Robertson, 2009).
Modifications of the SVM have been adopted in feature selection, especially in mi-
croarray analysis. Support Vector Machine-Recursive Feature Elimination (SVM-
RFE) proposed by Guyon et al. (2002) computes the weight vector for all features
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from SVM classifier and eliminates the feature with the least weight in a recursive
manner. Since SVM-RFE outputs a list of genes ranked in order of weight contri-
bution in the classification, the number of top ranked genes to be selected is still a
challenge. To overcome this challenge, the SVM-RFE was modified by incorporating
a cross validation step into the SVM classifier to assess the error rate in each recursive
step (Zhang et al., 2013; Meng et al., 2008; Kossenkov et al., 2011). The gene subset
with least cross validation error rate is selected for further studies. Recursive-SVM
(R-SVM) is another SVM-based feature selection algorithm with principle similar to
that of SVM-RFE (Zhang et al., 2006), but different in how the ranking criterion is
computed. R-SVM uses the mean of features in each class of data and the weight of
the feature to compute ranking criterion. Both SVM-RFE and R-SVM are embedded
feature selection methods.
5.1.4 Signaling pathways associated with chemo- and radiotherapy
resistance
Chemo- and radiotherapy are expected to improve survival in cancer patients. The
beneficial effects of treatment are, however, hampered by development of resistance.
For example 50-70 % of patients with ovarian adenocarcinoma will relapse following
surgery with chemoresistant phenotype (Castells et al., 2012). Studies have identified
pathways and processes that drive resistance to chemotherapy and radiotherapy in
cancer. Drug inactivation via metabolism, altered drug target, drug eﬄux, DNA
damage repair, epithelial-mesenchymal transition, and cancer cell heterogeneity are
mechanisms for drug resistance (Housman et al., 2014; Long et al., 2011). Altered
expression of detoxifying agents and NF-κB play a role in resistance to chemo- and
radiotherapy, and altered expression of detoxifying enzymes and PI3K/Akt signaling
pathway are associated with chemoresistance development in cancer (Reuter et al,
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2010; West et al., 2002). Inhibitors of Wnt/β, EGFR/PI3K/PTEN/Akt/mTORC1,
Notch, JAK/STAT, ERK signaling pathways are being considered as drugs for
cancer treatment (Hoelder et al., 2012; Davis et al., 2014; Chong and Janne, 2014).
The aim of this study was to identify a multigene signature that could pre-
dict progression-free and overall survival in glioblastoma multiforme (GBM). We
first performed pathway enrichment analysis on genes with varied expression across
a cohort of GBM patients and selected genes from pathways known to be involved
in resistance to chemotherapy and radiation. We then selected a subset of these
genes that discriminated between rapidly- and slowly-progressing patients with the
least 5 % cross-validation error using modified SVM-RFE. The prognostic value of
the gene subset in predicting progression-free and overall survival was assessed in
the risk groups of GBM patients and of patients in each GBM subtype.
5.2 Methods
5.2.1 Sample Selection
To ensure that treatment did not introduce confounding effect, samples from pa-
tients that received adjuvant chemotherapy and radiation (standard treatment) and
had uncensored days to progression were selected. Figure 3.1 shows sample selection
for the identification of genes with prognostic value. 415 patients received the stan-
dard GBM treatment. 201 patients had PFS times, and 380 had OS times (censored
or uncensored). The samples with PFS times were grouped into three classes. Class
1 (rapidly-progressing) had of 48 patients who had progression between 6 and 120
days after standard treatment, Class 2 (slowly-progressing) had 35 patients who had
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progression between 358 and 720, and the remaining samples (118) were used for in
PFS and OS analysis. The rapidly-progressing and slowly-progressing samples were
used for feature selection. Clinical data for all the patients used in this study were ob-
tained the clinical file (nationwidechildrens.org clinical follow up v1.0 gbm.txt) pro-
vided by the TCGA. PFS times for patients who experienced tumour progression
within the follow-up period were obtained from the file for new tumour events (nation-
widechildrens.org clinical follow up v1.0 nte gbm.txt) also provided by the TCGA.
The GBM subtypes of samples used in this study were obtained from the summary
clinical file provided by Brennan et al., (2013).
5.2.2 Microarray gene expression analysis of the TCGA and the
validation data sets
A gene expression matrix generated for 540 GBM and 10 non-neoplastic samples and
12161 genes in Section 2.2.1 of Chapter 2 was used as the TCGA expression data
set in this study. An independent validation data set (GSE7696) was download from
the NCBI’s Gene Expression Omnibus, a public functional genomics data repository
for array- and sequence-based data (Edgar et al., 2002; Barrett et al., 2013). The
data set had 80 GBM and 4 non-neoplastic brain samples used to identify molecular
profiles specific for treatment resistance to the current standard of care of concomitant
chemoradiotherapy with temozolomide (Murat et al., 2008). The data set was chosen
because it provided treatment information for all the GBM samples. Gene expression
of the samples were profiled on HG-U133 Plus 2 Affymetrix platform. The gene
expression data were normalized and summarized using the same method as was
used for the TGCA data, as detailed in Section 2.2.1 of Chapter 2.
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Select genes with varied
expression across cohort
Variable genes (MAD ≥ 0.5)
Pathway-based
feature selection
Feature selection by
modified SVM-RFE (5-fold
cross validation)
Multivariate Cox
model building
Sample selection
Extract coefficient values
for selected features
Calculate prognostic index
(PI) for each sample using
PFS time and feature
expression value
Generate risk groups
based on PI
Compare survival
between risk groups
Calculate prognostic
index (PI) for each
sample using
overall survival
time and feature
expression value
Generate risk groups
based on PI
Compare survival
between risk groups
Calculate prognostic
index (PI) for samples
in each subtype using
overall survival time
and feature expression
value
Generate risk groups
based on PI
Compare survival
between risk groups
Figure 5.1: Flowchart for Identification of prognostic genes in glioblastoma multi-
forme
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558 had clinical
data
415 received both ajuvant
chemotherapy and radiation
201 samples had
progression-free
survival (PFS) data
380 had overall
survival data
83 samples
for feature
selection
118 samples
for Cox model
building
Group 1
6≤ PFS ≥120
Group 2
358≤ PFS ≥720
95
Proneural
samples
60
Neural
samples
105
Classical
samples
120
Mesenchymal
samples
Figure 5.2: Sample selection for the identification of prognostic genes in glioblastoma
multiforme
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5.2.3 Feature Selection
5.2.3.1 Pathway enrichment analysis
Feature selection was carried out by extracting genes in relevant pathways by
pathway enrichment analysis, followed by Support Vector Machine (SVM)-based
method similar to recursive-SVM (R-SVM) reported by Zhang et al. (2006).
The enrichment analysis was done using a web-based Set Analyzer tool pro-
vided by the Comparative Toxicogenomics Database (CTD) and available at
http://ctdbase.org/help/analyzerHelp.jsp. CTD is a public resource that provides
information about the interaction of environmental chemicals with gene products
and their effect on human disease (Davis et al., 2013). The Set Analyzer takes a set
of genes as input and returns pathways that are enriched with genes from the input
list. A pathway is considered enriched if the proportion of genes annotated to it in
a test is significantly larger than the proportion of all genes annotated to it in the
genome. A p-value or an adjusted p-value for statistical significance is set by a user.
5.2.3.2 Feature selection with Support Vector Machine-Recursive Fea-
ture Elimination (SVM-RFE)
SVM is a supervised learning model that classifies data by fitting the best hyperplane
that separates all the data points of one class from those of the other class. This hy-
perplane is called the maximal margin hyperplane. The maximal margin hyperplane
is the separating hyperplane that is farthest from the data points in the two classes.
The data points that are closest to the separating hyperplane are called support vec-
tors. Given a set of n training observations x1, ..., xn ∈ Rp and associated class labels
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y1, ..., yn ∈ {−1, 1}. The decision function of a linear SVM is given by
sgnf(x) = sgn{(w.x) + b} = sgn
{ n∑
i=1
αiyi(xi.x) + b
}
, (5.1)
where x is the vector of a test point and xi is that of a point in the training set,
w =
n∑
i=1
αiyix is a vector of weights of the features, and b is a bias. α’s and b
are estimated from the training set. Only the support vectors have non-zero αi’s.
Therefore, f(x) is a linear combination of only SVs. The sign of f(x) predicts
the classs to which the test point and its absolute value represents distance from
the hyperplane. The farther the point from the hyperplane, the better the prediction.
SVM-Recursive Feature Elimination (SVM-RFE), proposed by Guyon et al.
(2002), is used in microarray data analysis for feature selection (Guo et al., 2014;
Liang et al., 2011; Dawany et al., 2014). It uses the w2 as the ranking criterion. It
has the following steps:
1. Train an SVM on the training set;
2. Compute the ranking criterion for all features (w2i )
3. Order the feature based on the ranking criterion.
4. Eliminate features with the smallest ranking criterion.
5. Repeat steps 1 to 4 until just one feature is left.
R-SVM modified SVM-RFE by introducing a measure which takes the means of the
features in two classes of the training set into consideration. The measure is given
by
sj = wj(m
+
j −m−j ), (5.2)
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where sj is the contribution factor of feature j, m
+
j is the mean of feature j in the +
class and m−j is the mean of feature j in - class.
In this study, we introduced a 5 % cross-validation step into the SVM-RFE
code, similar to what was done in R-SVM, so that the prediction error rate of the
SVM classifier at each recursive step could be computed. We, however, used the
weight magnitude ranking criterion of SVM-RFE for feature elimination. Similar
approaches were employed in other studies for feature selection from microarray
analysis (Zhang et al., 2013a; Liang et al., 2011) . The workflow of the modified
SVM-RFE used in this study is shown in Figure 5.3.
5.2.3.3 Selection of genes that discriminated between rapidly- and
slowly-progressing GBM patients
Genes with varied expression values across 529 samples (MAD >= 0.5) were used
in pathway enrichment analysis. The aim of pathway enrichment analysis was to
select genes in signaling pathways and genes involved in reactive oxygen species
metabolism, DNA repair, drug transport and apoptosis. The gene expression of the
samples were profiled in batches which could introduce bias into the classification
analysis (Soneson et al., 2014). We therefore assessed the statistical significance of
batch bias as a function of the genes obtained from pathway-based feature selection
using guided Principal Component Analysis (gPCA) from the R package gPCA
(Reese et al., 2013). gPCA is an extension of principal component analysis (PCA),
which computes a test statistic δ and determines whether the statistic is significantly
larger that would be expected by chance. A p-value is estimated using a permutation
distribution created by permuting batch vector 1000 times and determining permuted
δ for each permutation. δ is the ratio of the variance of the first principle compo-
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nent from gPCA to the variance of the first principal component from unguided PCA.
Genes whose expression discriminated between the rapidly-progressing and
slowly-progressing groups were selected using our modified SVM-RFE. The default
parameters for SVM were used except: cost was set to 10, kernel set to linear, and
5-fold CV was used for error determination. A set of genes that gave the least
CV error rate (highest accuracy) were identified by assessing the vectors of indices
and their CV error rates outputted by the modified SVM-RFE. These genes were
combined into a signature, and the prognostic value of the signature was assessed in
survival analysis.
5.2.4 Survival Analysis
The 118 patients (Class 3) with PFS times that were not used in the feature selection
step were used to calculate regression coefficients (β) for the selected genes using
univariate Cox proportional hazards analysis. Details of the Cox model is given in
Section 4.2.2 of Chapter 4. The β’s were computed for the genes using coxph from the
R survival package. Prognostic index was calculated for 415 patients who adjuvant
chemo- and radiotherapy using equation (4.6) obtained in Chapter 4:
PI = β1 ∗ gene1 + β2 + ...+ βg ∗ geneg
where βg is the regression coefficient for gene g, and geneg is the gene expression
for geneg. Patients in the Class C were classified into low- and high-risk groups by
choosing a value between the highest and lowest PI that ensured proper patients
distribution based on PI. Patients with PI scores greater or equal than the chosen
value were assigned to the high-risk group, whereas those with PI scores less than
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the value were assigned to the low-risk group.
Create ranked list
Subset of selected features
Train and test the SVM classifier
(5 % cross-validation Cost = 10
, Kernel=linear)
Extract and record the
cross-validation error rate
Compute the weight vector
Compute the ranking
criterion (w2i )
Find the feature with
the smallest ranking criterion
Update the feature
ranked list
Eliminate the feature with
the smallest ranking criterion
One feature
left?
no
Select the vector of
feature indices with the lowest
CV error rate from ranked list
yes
Use the indices
to obtain gene set
Figure 5.3: Workflow of the modified SVM-RFE
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380 patients with OS times were also classified into low- and high-risk groups the
same. Verhaak et al. (2010) identified four subtypes of GBM, namely Proneural,
Neural, Classical and Mesenchymal, using gene expression data from 200 GBM
samples. Brennan et al. (2013) assigned additional 342 TGCA samples into the
four subtypes using single-sample gene set enrichment analysis. A summarised
clinical file provided by Brennan et al. (2013) was used in our study to assign
patients to GBM subtypes. 95, 60, 105 and 120 of the 380 patients with available
OS times were assigned to Proneural, Neural, Classical and Mesenchymal subtypes,
respectively. 51, 33, 51 and 66 of the 201 patient group with PFS times were
assigned to Proneural, Neural, Classical and Mesenchymal subtypes, respectively.
Patients in each subtype were also classified into low- and high-risk groups.
39 of the patients in the validation data set received adjuvant chemo- and ra-
diotherapy and were not recurrent samples. The prognostic value of the selected
gene signature was validated with these 39 patients. PI was calculated for the
patients using the β’s obtained from the training set and the expression values of
the selected gene set in their samples. They were classified into low- and high-risk
groups in such a manner as to ensure proper patient distribution between the two
groups based PI.
Survival of the low- and high-risk groups were determined for both the TCGA and
validation cohorts using the Kaplan-Meier method. Differences in survival between
the risk groups were estimated statistically by log rank test. Survival between groups
was said to be statistically significant if p < 0.05. Hazard ratios (HR) between risk
groups were determined by Cox proportional hazards regression model.
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5.2.5 Multivariate analysis Cox survival analysis
A multivariate Cox survival model was built using three variables: our prognostic
index, MGMT promoter methylation, and age. MGMT promoter methylation is a
known predictor of treatment response in GBM patients (Hegi et al., 2005). MGMT
encodes O-6-methylguanine-DNA methyltransferase, a DNA-repair enzyme that
removes alkylating groups at the O6 of guanine residues. Epigenetic silencing of
MGMT by methylation makes tumour cells sensitive to alkylating agents such as
Temozolomide used in the treatment of GBM.
Ages of patients at diagnosis were obtained from the clinical file (clinical pa-
tient gbm.txt) provided by TCGA. MGMT promoter methylation status data were
obtained from the clinical file provided by Brennan et al., (2013). The univariate
Cox analysis was first carried out on each variable followed by multivariate Cox
analysis on all the variables. coxph function in R survival package was used for
the analysis. 79 who patients had data for time to progression, MGMT promoter
methylation status, and age. Using the median PI value, the patients were assigned
into low- or high-risk groups. Those with PI values lower than the median were
assigned to low-risk groups, and those with PI to high-risk groups. The MGMT
promoter was methylated in 38 and unmethylated in 41 patients. 269 patients
had data for time to death (censored and uncensored), age and MGMT promoter
methylation status.
134 patients with PI values lower than the median were assigned to the low-
risk group, and 135 with PI higher than the median to high-risk group. The MGMT
promoter was methylated in 135 and unmethylated in 134 patients.
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The low-risk groups and the MGMT methylated promoter groups were used
as references for prognostic index and MGMT promoter methylation status, respec-
tively. All measurements were associated with 95 % confidence intervals (95 % CI)
and statistical tests were considered significant if p(Wald) < 0.05.
5.3 Results and Discussion
Table 5.1: Pathway enrichment of genes with varied ex-
pression across samples (MAD >= 0.5
)
Pathway # of Genes Adjusted p
Cell cycle 62 3.02 x 10−25
MAPK signaling 87 4.11 x 10−19
P53 signaling 39 7.68 x 10−19
WNT signaling 48 1.67 x 10−12
Glutathione metabolism 23 1.83 x 10−7
TGF-β signaling 30 4.68 x 10−7
Insulin signaling 40 1.13 x 10−6
ErbB signaling 29 3.67 x 10−6
Phosphatidylinositol signaling 25 9.13 x 10−5
Mismatch repair 12 1.44 x 10−4
Inositol phosphate metabolism 20 2.71 x 10−4
JAK-STAT signaling 37 3.09 x 10−4
Apoptosis 25 4.95 x 10−4
VEGF signaling 22 3.57 x 10−3
Nucleotide excision repair 15 1.04 x 10−2
ABC transporters 12 2.90 x 10−1
mTOR signaling 14 2.90 x 10−1
Base excision repair 10 4.90 x 10−1
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Figure 5.4: Unguided principal component analysis to identify batch effect in the
TCGA data set as function of genes from chemoradioresistance-associated pathways.
Samples for each batch are denoted by a different colour and symbol
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Figure 5.5: Cross-validation error rates of R-SVM in each recursive step. * Level
is the number of features used for SVM classification in each recursive step. The
parameters for SVM were kernel = linear, Cost (C) = 10, and 5 % cross-validation.
The red star represents the level at which the minimal cross-validation error rate was
achieved.
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Table 5.2: Gene set that discriminated between
rapidly- and slowly-progressing GBM patients
with 100 % accuracy using Support Vector Ma-
chine - Recursive Feature Elimination
Gene Coefficient (β) Hazard Ratio p
ABL1 -0.12151 0.886 0.65
CCNA1 -0.08988 0.914 0.52
CCND1 0.0746 1.077 0.62
CCNE1 -0.49752 0.608 0.032
CDC6 0.23236 1.262 0.41
CDK2 -0.52677 0.591 0.15
CDKN1C -0.02847 0.972 0.9
CDKN2A 0.14146 1.152 0.17
DKK1 0.17593 1.192 0.04
FZD3 0.24335 1.276 0.23
FZD7 0.49336 1.638 0.022
GADD45G 0.28502 1.330 0.2
GHR -0.2292 0.795 0.18
GSTT1 0.04846 1.050 0.59
HSPA1B -0.12444 0.883 0.34
ID4 -0.16797 0.845 0.35
IGFBP3 0.11028 1.117 0.34
INHBB -0.1187 0.888 0.39
IRS2 -0.06648 0.936 0.79
LIFR -0.10086 0.904 0.67
PDGFRA 0.02624 1.027 0.76
PIK3CA 0.14793 1.159 0.42
PLA2G5 -0.01756 0.983 0.90
POLE3 0.06153 1.063 0.84
PPARGC1A 0.41207 1.510 0.045
PRKAR2B 0.0641 1.066 0.66
PYGB -0.4071 0.666 0.16
SFRP1 -0.12156 0.886 0.27
SFRP4 0.14611 1.157 0.27
SH2B2 -0.01987 0.980 0.95
STAG3L4 0.00017 1.000 1
STMN1 0.08373 1.087 0.75
THBS2 -0.13189 0.876 0.33
THBS3 -0.39159 0.676 0.16
VEGFA -0.0268 0.974 0.81
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In this present study, pathway-based and modified SVM-RFE-based methods were
used to select a set of genes that discriminated between rapidly- and slowly-
progressing GBM patients and combined into a signature. The prognostic value
of the signature in predicting PFS and OS was accessed in the risk groups of GBM
patients and validated on data set from an independent study. The independence
of the signature in predicting PFS and OS was assessed by a multivariate Cox’s
proportional hazards analysis.
5.3.1 Genes discriminating between rapidly- and slowly-progressing
GBM patients
GBM is a highly aggressive brain tumour, and the median survival of patients with
GBM is 14.6 months (Stupp et al., 2005). We reasoned that the expression of genes
in pathways associated with chemoradioresistance in cancer was a determinant of
how fast a GBM patient experiences progression after standard treatment. Signaling
pathways (MAPK, JAK/STAT, WNT, NOTCH, Hedgehog, PIK3/AKT), cell cycle,
drug transporters, reactive oxygen species metabolism and DNA repair system
are known to be involved in chemoradioresistance in cancer (Reuter et al., 2010;
Housman et al., 2014; Jiang and Liu, 2008; Niero et al., 2014; Martin et al., 2014).
Pathway enrichment analysis was carried on 3899 genes that had varied ex-
pression (MAD ≥ 0.5) across 529 GBM samples. 18 of the 159 gene sets from the
enrichment analysis were annotated for chemoradioresistance-associated pathways
(Table 5.1). 356 genes were extracted from the pathways and were used in gene
selection by the modified SVM-RFE. Assessment of batch effect with gPCA in
TGCA expression data set from 529 GBM samples as a function of the genes
extracted from pathways showed that the data set did not have significant batch
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effect (p = 0.118). Inspection of the unguided principal component analysis plot
of the first two principal components also showed that no batch effect was present
(Figure 5.4).
We also reasoned that PFS times were more appropriate than OS times in
grouping patients because PFS times were expected to be dependent only on
expression of specific genes. OS times are dependent not only on gene expression
but also on other factors including age and treatment after disease progression.
Our modified SVM-RFE was used to identify genes that discriminated between 48
rapidly-progressing patients (6 ≤ PFS ≥ 120) and 35 slowly-progressing patients
(358 ≤ PFS ≥ 720). The modified SVM-RFE recursively ranked a subset of genes
and removed the one that contributed the least to SVM classifiers until at least one
gene was left. At each recursive step, 5 % c6 ≤ PFS ≥ 120 was performed and
prediction error rate was computed. Figure 5.5 shows the plot of 5 % cross-validation
error rate against number of genes at each recursive step, starting with the 356 genes
extracted from the pathways. The CV error rate decreased with decreasing number
of genes until it reached 35 genes (represented with a red star in Figure 5.1), which
discriminated between rapidly- and slowly-progressing GBM patients with 100 %
accuracy. Further decreases in the number of genes resulted in increasing error rate.
5.3.2 Determination of regression coefficients of selected genes and
computation of prognostic index for patients
The PFS times and expression levels of selected genes in the Class C patients (118)
were used in multivariate Cox regression analysis to compute β’s for the genes. Table
5.2 shows the β’s of the 35 selected genes. 18 of the genes were positively associated
with PFS (β < 0). 17 were negatively associated with PFS (β > 0). Four correlated
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significantly with PFS times (p < 0.05). PI scores were calculated for all patients
who received adjuvant chemotherapy and radiation (380) by substituting β’s and
expression levels of selected genes into the prognostic index formula. The scores were
then used to classify samples into low- and high-risk groups in survival analysis.
5.3.3 35-gene signature predicted progression-free and overall sur-
vival in TCGA and validation dataset
The 35 genes that discriminated between rapidly- and slowly-progressing patients
were combined into a signature and its prognostic value first assessed in Class C
patients. The PI scores of these patients were standardized and used to split the
patients into low- and high-risk groups. The lowest and the highest PI scores were
-2.53 and 3.83, respectively. The value 0.098 split the patients into 56 high-risk
and 62 low-risk patients. Figures 5.6 A and B show the PFS and OS Kaplan-Meier
plots, respectively, for the two prognostic groups. The median PFS time (256 days
95 % CI = 232-299 days) for the low-risk group was higher than that (175 days 95
% CI = 158-204 days) of the high-risk group and there was a statistically significant
difference between PFS of the two groups (p < 0.05). The high-risk group patients
experienced progression three times as fast as the low-risk patients (HR = 3.04).
The median OS time (393 days 95 % CI = 345-454 days) of the low-risk group was
higher than that (635 days 95 % CI = 502-1024 days) of the high-risk group and the
difference in OS between the risk groups was statistically significant (p < 0.05).
279 of the 380 patients who received adjuvant chemo- and radiotherapy died
before the end of the follow-up period. The remaining 101 patients were alive at the
end of follow-up or were lost to follow-up. The 380 patients were split into low- and
high-risk groups using a PI score of 0.35. The lowest and highest PI score were -3.71
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and 3.83, respectively. Figure 5.6 C shows the OS plots for the prognostic groups.
There was a significant statistical difference in OS between the groups (p < 0.05).
The median OS time (548 days 95 %CI = 486-646) of the low-risk group was higher
than that (442 days 95 % CI = 394-476) of the high-risk group.
39 patients in the Murat et al. validation cohort received adjuvant chemotherapy
and radiation. The β’s computed with the TCGA cohort and the expression levels
of the signature genes in the validation cohort were used to calculate PI scores for
the patients in the validation cohort. The patients were split into 27 low- and 12
high-risk patients using a PI score of 2. The highest PI score was 2.43 and the
lowest was -1.46. The median OS of the low-risk group was higher than that of the
high-risk group (p < 0.05).
The results show that the 35-gene signature is a good predictor of progression-free
and overall survival in GBM, since prognostic value in the prediction of overall
survival was validated in an independent cohort. The size of the validated cohort
could be increased and the validation repeated as more independent study cohorts
with treatment information are reported and deposited into the public repositories.
5.3.4 The 35-gene signature predicted progression-free and overall
survival in GBM subtypes
The prognostic value of the signature in predicting PFS and OS in subtypes of GBM
was assessed. All the 201 patients with PFS times were assigned to their subtypes.
51, 51, 33, 66 patients belonged to the Classical, Proneural, Neural, and Mesenchy-
mal subtypes, respectively. Figure 5.7 shows the results of the PFS survival analysis
in the subtypes. There was statistically significant difference in survival between low-
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and high-risk groups in all the subtypes (p < 0.05). In the Classical subtype, the me-
dian PFS times of low- and high-risk groups were 256 and 186 days respectively. In
the Mesenchymal subtype, the median PFS times were 269 and 146 days respectively.
In the Neural subtype, the median PFS times were 358 and 172 days, respectively.
In the Proneural subtype, the median PFS times were 304 and 172 days, respectively.
105 Classical, 95 Proneural, 60 Neural and 120 Mesenchymal subtype patients
were used for subtype-specific OS analysis. Figure 5.8 shows the Kaplan-Meier
OS plots for high- and low-risk groups in each subtype. The low- and high-risk
groups differed significantly in OS in all the subtypes (p < 0.05). In the Classical
subtype, the median OS times of low- and high-risk groups were 544 and 452 days
respectively. In the Mesenchymal subtype, the median OS times were 485 and 394
days respectively. In the Neural subtype, the median OS times were 476 and 435
days, respectively. In the Proneural subtype, the median OS times were 748 and 395
days, respectively.
Reports from previous studies show that the prognostic value of MGMT pro-
moter methylation in GBM patients is controversial. Zhang et al. (2013b) showed
that MGMT promoter methylation was associated with better PFS and OS in
patients with GBM regardless of therapeutic intervention, and associated with longer
OS in GBM patients treated with alkylating agents. Costa et al. (2010) did not
find significant association between MGMT promoter methylation and the outcome
of Portuguese GBM patients treated with temozolomide. Brennan et al. (2013)
however reported that MGMT promoter methylation was only correlated with OS
in the GBM Classical subtypes. The possible explanation for these controversial
reports on the prognostic value of MGMT promoter methylation could be due
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to difference in the GBM subtype distribution which was not considered in most
previous studies. Our 31-gene signature predicted PFS and OS regardless of the
subtype to which a GBM subtype belongs. This suggest our signature could be a
more effective predictor of overall and progression-free survival in GBM.
5.3.5 The 35-gene signature is an independent predictor of PFS and
OS in GBM patients
A multivariate Cox regression model analysis involving the prognostic index, age and
MGMT promoter methylation was carried to assess the independence of the gene
signature to predict PFS and OS. 79 patients had PI scores, and age and MGMT pro-
moter methylation data. 269 patients had PI scores, and age and MGMT promoter
methylation data. The results from the univariate and multivariate analyses on the
three variable are shown in Table 5.3. The univariate Cox’s proportional hazard
analysis showed that prognostic index and age were significantly correlated with PFS
(p < 0.05). Only the prognostic index was significantly correlated with PFS in the
multivariate analysis (p < 0.05). MGMT promoter methylation was not correlated
with PFS in both univariate and multivariate Cox analyses (p > 0.05). Prognostic
index, age and MGMT promoter methylation were significantly correlated with OS
in the univariate and multivariate analyses (p < 0.05).
Tumour progression after treatment depends largely on alteration in cancer-
related pathways and on those pathways involved in resistance to chemotherapy and
radiation. This is supported by findings from the multivariate Cox’s proportional
hazard analysis as only prognostic index was significantly associated with PFS
and was an independent predictor of PFS. Overall survival, on the other hand,
is determined by many factors. Age is one the important factors associated with
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overall survival in cancer. Age at diagnosis is associated with overall survival in
GBM (Scott et al., 2011; Thumma et al., 2012; Bozdag et al., 2013). While the
prognostic value of MGMT promoter methylation in GBM remains controversial,
our findings showed that prognostic index, age and MGMT promoter methylation
are all independent prognostic factors for overall survival.
5.3.6 Several of the signature genes are associated with survival in
other cancers
Most of the studies on identification of protein-coding multigene prognostic signa-
tures in GBM focused on overall survival. Arimappamagan et al. (2013) identified
an independent 14-gene signature that predicted overall outcome in GBM. Tayrac
et al. (2011) identified a 4-gene signature that correlated with OS in high-grade
gliomas. High-grade giomas are either grade III or grade IV based on World Health
Organization (WHO) classification. GBM is a grade IV glioma. The prognostic
signature identified by Xiong et al. (2014) consisted of 16 mRNAs and 1 miRNA.
This signature was significantly correlated with OS in GBM patients. Most studies
that considered progression-free survival assessed the prognostic value of MGMT
promoter methylation (Kim et al., 2012; Shen et a., 2014; Melguizo et al., 2012).
To the best of our knowledge, only one study carried out by Colman et al. (2010)
reported a multigene signature for prediction of progression-free survival in GBM
. This study first assigned samples from 4 separate studies into typical survival
categories (TS; OS times ≤ 2 years) and long-term survival (LTS; OS times ≥
2 years). A signature of 38 differentially expressed genes between TT and LST
groups common to the four studies was correlated with overall survival. The
signature was validated in 68 independent samples and further trimmed down to
9 genes. Both the 38- and 9-gene signatures correlated with PFS and OS. There
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was however no clear separation between the survival groups used. Furthermore,
overall survival in cancer is dependent on many factors, not just gene expression
alone. We used PFS times in the grouping of the patients into rapidly- (PFS
times ≥ 6 and ≤ 120 days) and slowly-progressing (PFS times ≥ 358 and ≤
720 days) classes clearly separated by 238 days. We also selected our first set of
genes from pathways known to be involved in resistance to chemoradiation. Only
IGFBP2 in our signature gene was common to signature gene sets from other studies.
However, many of the genes in our prognostic signature have been reported
in other cancers to be associated with progression-free and/or overall survival.
DKK1, FZD3, FZD7, SFRP1, and SFRP4 are regulators of the Wnt/β pathway.
DKK1 encodes a secreted protein that blocks Wnt/β pathway by binding to the
low-density lipoprotein receptor-related protein-5/6 (LRP5/6) Wnt co-receptor
and preventing the formation of active Wnt-Frizzled-LRP5/6 receptor complexes.
High levels of DKK1 is predictor for unfavourable overall survival and time to
recurrence in intrahepatic cholangiocarcinoma patients (Shi et al., 2013). FZD3 and
FZD7 encode receptors for Wnt proteins. High expression of FZD3 in colorectal
patients was correlated with poor survival (Wong et al., 2013b). SFRP1 and
SFRP4 encode are antagonists of the Wnt/β pathway. Low SFRP1 expression was
associated with poor survival and SFRP1 may serve as an independent predictive
and prognostic factor for prostate cancer (Zheng et al., 2015). SFRP4 increased
the sensitivity of ovarian cancer cell lines to Cisplatin, suggesting it is a predictive
marker of chemoresistance in the cancer (Saran et al., 2012). CCNA1, CCND1,
CCNE1, CDC6, CDK2, CDKN1C and CDKN2A regulate the cell cycle. A high-level
amplification of CCND1 was associated with poor prognosis in women with estrogen
receptor positive breast cancer (Roy et al., 2010). Seiler et al. (2014) found
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CCND1 amplification to be an independent prognostic factor in primary tumours
and metastases and, its high expression to be an independent prognostic factor in
metastasis. CDC6 expression was correlated with overall and recurrence survival
in non-small cell lung cancer patients (Allera-Moreau, 2012 ). CDK2 is frequently
amplified and CDKN2A is frequently deleted in GBM (TCGA, 2008). CDKN2A is a
tumour suppressor that plays a role in cell cycle arrest by stabilizing p53.CDKN2A
promoter methylation was correlated with a poor prognosis of colorectal cancer
patients (Maeda et al., 2003; Xing et al., 2013). CDK2 is known oncogene and
regulator of the cell cycle regulated by CDKN2A. Its regression coefficient (β < 0)
in our study, however, showed that it was positively associated with progression-free
survival. Its overexpression was associated with shorter survival in oral cancer
(Mihara et al., 2001). GADD45G is one of the GADD45G genes implicated in stress
signaling responses to physiological or environmental stressors, resulting in cell cycle
arrest, DNA repair, cell survival and senescence, or apoptosis (Cretu et al., 2009;
Zerbini and Libermann, 2005). GADD45G methylation and protein expression were
independently associated with survival of gastric cardia adenocarcinoma patients
(Guo et al., 2013b) and esophageal squamous cell carcinoma patients (Guo et al.,
2013c).
5.4 Conclusion
Several gene expression prognostic and predictive signatures have been translated
into tools of clinical importance for cancer treatment. ColoPrint, and eXageneBC,
MammaPrint, Mammostrat, and Oncotype DX are used as prognostic tools for
colorectal cancer and breast cancer, respectively. NuvoSelect, Roche AmpliChip
and Rotterdam Signature are used as clinical tools for predicting patient’s re-
sponse to certain drugs and for selecting appropriate chemotherapy. At present,
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there is no gene expression signature for GBM that has been translated into clinic use.
The 35 genes in our signature were selected by pathway-based and machine-
learning based methods. The prognostic value of the signature assessed with
progression-free and overall survival of TCGA patients and validated with overall
survival of patients in an independent study cohort. The performance of the
signature in predicting survival irrespective of subtypes demands further studies on
its ability to serve as both prognostic and predictive biomarker. Our signature can be
considered for development into clinical use as it has both prognostic and predictive
function in adjuvant-linked glioblastoma multiforme patients. The signature genes
could also be useful targets to improve both progression-free and overall survival in
GBM patients.
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Conclusion
6.0.1 Summary of findings
This study identified molecular basis of cognitive disorder commonly found in
glioblastoma patients (GBM). α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic
acid receptors (AMPARs) and N-methyl D-aspartate 2A (NMDA) receptors were
down-regulated, and this may lead to reduced long term potential and worsen long
term depression. These receptors can be targeted for palliative therapies to improve
cognitive functions in GBM patients.
Cancer-related pathways were overrepresented in the network modules. NOTCH,
WNT, JNK, JAK/STAT, MTOR, and TGF-β were identified as novel GBM
pathways in addition to receptor tyrosine kinase receptor, PIK3/AKT, RB1, p53
signaling pathways identified in previous integrative studies. In addition, pyruvate
metabolism, genes involved in lipogenessis (ACACA and ACACB), free-radical
generating enzymes (NOS1 and NOS2) were deregulated. Our findings show
that GBM is a complex cancer and provides new insights that will improve the
understanding of its molecular mechanisms.
176
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Glioblastoma multiforme is the most aggressive and malignant of all brain tu-
mours. RELA, NFKB1, IRF1 and STAT5B were identified as being responsible
for inflammatory responses and cell migration in this study. Further studies would
establish the role of these transcription factors in the aggressiveness of this cancer.
The 8-miRNA and the 35-gene signatures that independently predicted adju-
vant therapy-linked progression-free and overall survival of GBM patients give
insights into signaling pathways responsible for tumour recurrence. Cell cycle
control, DNA damage repair, antioxidant systems, the receptor tyrosine-kinase
pathway and angiogenesis mechanisms have all been identified in this study as key
determinants of time to progression in patients who received adjuvant chemo- and
radiotherapy.
6.0.2 Potential research application of findings
6.0.2.1 Opportunities for drug discovery
The diverse mechanisms elucidated in this study would create opportunity for the
discovery of novel molecularly targeted drugs for treatment of GBM. Expression of
driver genes overexpressed in the network module or the subnetwork could poten-
tially be silenced at the post-transcriptional level using exogenous anti-sense RNAs
accurately delivered to the tumours. Similarly, delivery of exogenous intact tumour
suppressor genes would restore their activity and activated oncogenes could be in-
hibited by novel small molecule inhibitors.
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6.0.2.2 Functional validation of genes and pathways identified in the
study
Novel genes identified in this study create opportunities for the development of func-
tional validation assays to establish the roles of these genes in cancer and to study
the effect of their inhibition and activation on tumour growth. Cancer cell lines can
be developed specifically for these genes for use in molecular biology research.
6.0.3 Clinical applications of findings
We hypothesis that due to our multi-faceted approach, most of the genes important to
GBM have been captured in our study and that this has strong potential to improve
in the diagnosis and treatment of GBM.
6.0.3.1 Precision medicine
Precision medicine is the prevention and treatment strategies that take individual
variability into account. This form of medicine would be helpful to GBM patients
because of the heterogeneous nature of the cancer. The GBM network and subnet-
work can serve as reference to which the mutation profile of a patient is compared for
the prioritisation of altered genes. The would aid accurate diagnosis and informed
decision on the chemotherapy to use on patients.
6.0.3.2 Combinatorial medicine
Combinatorial medicine involves therapeutically targeting as many genomic alter-
ations responsible for a disease in a patient as possible and has strong implications
for overcoming the challenge of tumour recurrence. Our GBM network provides a
starting point for achieving this.
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6.0.3.3 Prognostic signatures can be developed for clinical use
Many predictive and prognostic gene expression signatures for breast cancer have
been translated for clinical use and have received FDA approval due to their demon-
strated utility in tailoring treatment regimes. Our miRNA and mRNA signatures
similarly have the potential of being used as clinical tests for predicting prognosis
and treatment response in GBM, and it is likely that combining the signatures would
further improve their performance and generic applicability.
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ro
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ro
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p
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p
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p
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p
y
th
o
n
,
C
o
r
a
n
R
p
a
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b
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